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Immune-mediated inflammatory diseases (IMID) are a group distinguished by specific pathways 
of immune-dysregulation that lead to inflammation, organ damage and dysfunction, of which 
Rheumatoid Arthritis (RA) and Giant Cell Arteritis (GCA) are two examples. An increased risk of 
cardiovascular disease (CVD) is observed in patients with IMID. Inflammation plays an 
important role in atherosclerosis. The inflammatory process has confounding effects on lipid 
and glucose metabolism, blood pressure and haemostatic factors. RA is a chronic inflammatory 
arthritis and one of the most common systemic autoimmune diseases affecting approximately 
1% of the UK population. In RA, the risk of myocardial infarction (MI) is independent of, and 
incremental to, traditional CVD risk factors. CVD, as a direct result of the IMID process and 
independent of atherosclerosis can be an additional insult and seen in GCA. GCA is associated 
with an increased mortality mainly due to CVD, including aortic syndromes. Aortic involvement 
in GCA may manifest clinically as a syndrome of systemic inflammation without specific 
symptoms, or even be asymptomatic until aortic dissection or rupture supervenes with life-
threatening consequences. 
 
The early identification of disease can benefit patients clinically by initiation of earlier disease 
modifying therapy, potentially reducing morbidity and mortality. Determining disease 
phenotype is important to develop effective screening strategies. This thesis aims to identify 
subclinical cardiovascular (CV) change using cardiovascular magnetic resonance (CMR) in the 
IMIDs of RA and GCA. It is also tested whether therapeutic interventions can modulate 
surrogate markers of CV outcomes in RA. 
 
Using CMR, this thesis demonstrates the presence of CV abnormalities in early RA (ERA) and 
established GCA. Changes in vascular function, myocardial tissue composition and ventricular 
geometry/performance are present in ERA, inferring an increased risk of CVD at the earliest 
stages of the RA disease continuum. There are thoracic aortic structural changes in established, 
treated, GCA. Dilatation of the thoracic aorta is common in GCA, with polymyalgic symptoms a 






This thesis also discusses interventional data that evaluates if early aggressive control of newly 
diagnosed RA can reduce subclinical CV pathology at 1 year from treatment initiation. It is 
explored whether tumour necrosis factor inhibitor (TNFi) offers any additional benefit over and 
above conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) in the burden 
of subclinical CV pathology. Increased arterial stiffness, by measure of aortic distensibility, can 
be modulated and improved after 1 year of disease modifying therapy using a methotrexate 
(MTX) treat-to-target (MTX TTT) regimen or early biological therapy with etanercept (ETN). 
Patients with higher baseline C-reactive protein (CRP) appear to improve arterial stiffness the 
most. 
 
CMR is able to detect subclinical CV change in asymptomatic ERA and established GCA patients 
without known CVD. Surrogate markers of CV events can be modulated in ERA with early 
aggressive RA therapy and CMR can identify silent aortic dilatation, associated with adverse 
outcomes, in GCA. CMR can aid the early and appropriate diagnosis of disease and 
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LVSD  LV systolic dysfunction 
MBF  Myocardial blood flow 
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MESA  Multi-Ethnic study of atherosclerosis 
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MTX  Methotrexate 
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1.1 Immune-mediated inflammatory disease 
Immune-mediated inflammatory diseases (IMID) are a group distinguished by specific pathways 
of immune-dysregulation that lead to inflammation, organ damage and dysfunction[1]. This 
thesis focuses on CV changes in IMID as assessed by CMR. During my time as a Clinical Research 
Fellow in CMR at the University of Leeds, I was primarily involved in projects and collaborations 
involving one IMID, RA; by means of studying ERA in the Coronary Artery Disease Evaluation in 
Rheumatoid Arthritis (CADERA) trial and established RA in the Inflammatory Arthritis 
Continuum (IACON) studies. With interest in heart failure and IMID, further projects and 
collaborations allowed me opportunity to study GCA in the UK GCA Consortium study, systemic 
sclerosis in the ELectrophysiology and CArdiac imaging in SclerodermA (ELCASA) study and 
Systemic Lupus Erythematosus (SLE) in the CONnective tissue and VASculitis (CONVAS) registry. 
They all share a common ground of being IMIDs with links to CV morbidity and mortality. I 
chose to focus my thesis on two IMIDs; principally on RA, with an additional study on GCA. RA is 
one of the most common autoimmune diseases affecting approximately 1% of the UK 
population[2]. A chronic, systemic, inflammatory arthritis with increased mortality largely due 
to premature CVD[3]. GCA is the commonest primary systemic vasculitis affecting older 
people[4]. It is also associated with an increased early mortality mainly due to CVD, including 
aortic syndromes[5]. 
 
1.2 Inflammation and atherosclerosis 
Inflammation plays an important role in atherosclerosis. CRP has been well studied, with its 
presence known about in atherosclerotic lesions. Immune cells and intermediate factors also 
found in atheroma further implicate inflammatory mechanisms[6]. Advances in cell biology 
research allowed testing of specific molecules supporting immune mechanisms for 
atherosclerotic formation[7]. When arterial wall endothelial cells are activated by 
inflammation, they can express adhesion molecules to attract white cells. Monocytes are the 
most abundant and chemokine stimuli allow them to enter the vessel intima. There they 




appearance of foam cells[8]. Inflammation is further accelerated by release of growth factors 
and cytokines.  
 
 
Figure reproduced from Libby et al. Inflammation in atherosclerosis: transition from theory to 
practice. Circ J. 2010 Feb;74(2):213-20[8]. 
 
Plaque rupture causes most cases of fatal myocardial infarction and inflammation regulates the 
fibrous cap rupture and subsequent thrombosis[9]. T-lymphocytes play an important role in this 
step and enter the intima in response to various chemokine signals, ligands and proteins[10]. 
Activated T-lymphocytes further secrete pro-inflammatory cytokines and pro-coagulants[11]. 
Inflammation reduces the strength of plaque fibrous caps by way of interferon-γ, which inhibits 
collagen production by smooth muscle cells[12]. There are inflammatory contributions in 
atherosclerosis from the formation of atherosclerotic plaques, their evolution, and the 
reduction of stability to the final conclusion of rupture and thrombosis. There is much interest 
with the development of drugs to target the inflammatory cascade at various levels. Higher 
high-sensitivity CRP (hsCRP) has been shown to predict CV events[13]. Statins can lower hsCRP 
levels, largely in an LDL independent way[14]. It has been shown that rosuvastatin in healthy 
persons without hyperlipidemia and higher hsCRP reduces the incidence of major 
cardiovascular events[15]. Very recently, presented at the European Society of Cardiology 
meeting in Barcelona and published online in the New England Journal of Medicine, the phase 
III study CANTOS (Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease) 




immunity pathway. This was a randomized, double-blind trial and recruited around 10,000 
patients with prior MI and raised hsCRP. Independent of lipid-lowering, a 150mg dose every 3 
months led to a significantly lower rate of recurrent CV events than placebo[16]. 
 
1.3 Rheumatoid arthritis  
RA is a chronic inflammatory arthritis and one of the most common systemic autoimmune 
diseases affecting approximately 1% of the UK population[2]. It is associated with circulating 
rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA), and if not 
adequately controlled can lead to joint damage with subsequent impairment of function. 
Mortality is increased in RA patients, compared to the general population, with premature CVD 
and heart failure constituting up to 40% of mortality compared to 15% in the general UK 
population[3]. It has been compared to the risk of other established CV risk factors such as type 
2 diabetes mellitus (DM)[17].Figure 1-1, taken from a meta-analysis by Avina-Zubieta et al, 
shows the overall and cause-specific CVD in patients with RA. 
 
It is accepted that CVD risk in RA is independent of, and incremental to, traditional CVD risk 
factors[18] with the likely predominant pathological process being immune dysregulation 
leading to systemic inflammation[19]. The inflammatory process has confounding effects on 
lipid and glucose metabolism, blood pressure and haemostatic factors[20]. Markers of RA 
severity are strongly associated with adverse CV outcomes in RA[21] and reduced time-average 
disease activity is associated with fewer CV events[22]. Arterial stiffness is associated with an 
increased risk of CV events in a range of co-morbidities[23]. In patients with established RA 
without traditional CV risk factors, aortic pulse wave velocity (PWV) is higher than in 
controls[24] and correlates with age, mean arterial pressure and CRP. RA patients have a 
greater carotid intimal-media thickness (CIMT), a direct measure of the status of the vascular 
wall and measure of atherosclerotic and arteriosclerotic processes[25], than controls[26]. These 
findings are consistent with the concept of microvascular pathology and accelerated 
atherosclerosis due to systemic inflammation in RA, which may contribute to the effects of 




Figure 1-1 - Overall and cause-specific cardiovascular disease in patients with Rheumatoid Arthritis 
 
Reproduced from Avina-Zubieta JA, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of 
observational studies. Ann Rheum Dis 2012;71(9):1524-9[27].
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1.4 Giant Cell Arteritis 
GCA is the commonest primary systemic vasculitis affecting older people[4]. In the elderly, GCA 
is even more common than rheumatoid arthritis (incidence in the over-70s is 
53/100,000/year[28, 29] and yet it receives relatively little research attention. For example, in 
the 5 years to September 2010 there had been 432 articles on GCA available on Pubmed, 
compared with 7,910 on rheumatoid arthritis. Polymyalgia rheumatica (PMR), characterised by 
inflammatory limb-girdle pain with early morning stiffness and a systemic inflammatory 
response, demonstrated by elevation in inflammatory markers erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP) and/or plasma viscosity (PV). Approximately 10% of patients 
with PMR will go on to develop late GCA[30] and approximately half of all patients presenting 
with GCA also have symptoms of PMR. Most individuals with GCA also have a systemic 
inflammatory response. Although several different sets of classification criteria exist, there is 
still no universally-agreed set of core outcome measures for clinical characterisation of PMR 
which will be necessary for genetic association studies[31]. Like GCA, patients with PMR may 
experience complications related to long-term steroid treatment. Although GCA and PMR 
appear closely related, it remains unclear whether GCA and PMR are the same disease, or 
separate diseases which may share common pathogenetic features[32]. Major sequelae of GCA 
include: 
 
 • Ischaemic manifestations (usually at onset of disease) 
 • Complications of steroid treatment 
 • Arterial aneurysm 
 
1.5 Causes of GCA 
The cause of GCA remains unknown. There are some data to suggest that hypertension or 
atherosclerosis may predispose to ischaemic features[33, 34]. Social deprivation may also be of 
importance, with a gradient of incidence highest in the affluent South-East of England and 
lower moving further north[28], which contrasts with the general pattern of a higher incidence 
at more northern latitudes within Europe. There may be a complex interplay of genetic, 
constitutional and environmental (e.g. ultraviolet light exposure, diet, psychosocial stress, 




have demonstrated genetic associations, particularly with HLA-DBR1*04, but this finding was 
not universal, not being observed either in an Italian GCA cohort, or in many PMR cohorts[33, 
34]. 
 
1.6 Aortic involvement in GCA 
Classical descriptions focus on involvement of the superficial cranial arteries, but with modern 
imaging techniques it is increasingly recognised that aortic involvement is common and may 
lead to serious complications, such as aortic aneurysm[2]. Aortic involvement in GCA may 
manifest clinically as a syndrome of systemic inflammation without specific symptoms, or even 
be asymptomatic until aortic dissection or rupture supervenes with life-threatening 
consequences[35]. Even if asymptomatic, thoracic aortic aneurysm (TAA) may require 
corrective surgery in up to 40% to prevent such complications of dissection or rupture[36]. GCA 
with large-vessel vasculitis (LVV-GCA), or involvement of the large extracranial arteries has a 
younger, female preponderance and may spare the temporal artery, such that the temporal 
artery biopsy may be negative[37]. It has been suggested that glucocorticoid doses sufficient to 
suppress clinical symptoms of GCA may not be adequate to suppress inflammation in the wall 
of the larger arteries[38]. 
 
GCA is associated with an increased early mortality mainly due to CVD, including aortic 
syndromes, during the first 2 years of diagnosis[5]. GCA patients are older and so the definition 
of 'early mortality' from CVD is not well refined. Aortic imaging may reveal thoracic aortic 
dilatation (TAD), presumed to be a precursor to TAA. Previously-described associations of 
TAA/TAD development in GCA include aortic regurgitation (AR), dyslipidaemia, CAD[35], 
hypertension, higher acute phase markers[39], male sex and smoking[40]. Greater aortic 
uptake of 18F-deoxyglucose (18FDG) tracer on positron emission tomography (PET) imaging is 
associated with greater subsequent aortic diameter[37]. The question whether aortic imaging 
should be routinely carried out in unselected patients with GCA is important. Older patients, 
with increasing frequency of co-morbidity, inherently have greater surgical risk, which should 
be considered before looking for TAD. The timing and frequency of imaging is also uncertain 






Much is unknown about the mechanism of TAD in GCA. Dilatations might occur from direct 
inflammation-related damage to elastin; alternatively dilatation might arise proximal or distal 
to a relatively stiff aortic segment[41]. In the general population, aortic stiffness caused by age-
related loss of aortic elasticity is associated with CV risk. In diseases such as PMR and GCA, 
however, additional stiffening may relate to the inflammatory disease itself and be improved 
with glucocorticoid therapy[42]. 
 
1.7 Screening of thoracic aorta dilatation in GCA 
Various guidelines and recommendations have been proposed for TAA screening and 
monitoring in GCA[43]. Current UK guidelines suggest a chest radiograph every 2 years[44] but 
this is insensitive compared to computed tomography or CMR of the aorta. It has been 
estimated that 5 to 10 GCA patients would need aortic imaging to detect a previously unknown 
TAA/TAD but this was based on small, heterogeneous datasets[40]. Furthermore this did not 
seem to fit with clinical experience: although thoracic contrast computed tomography (CT) is 
now performed for a multitude of indications, aortic aneurysm in patients with GCA seems to 
be rarely discovered incidentally. In large-scale routinely-collected clinical data the frequency of 
any aortic aneurysm diagnosis in patients with GCA was only 1%, compared with 0.7% of those 
without GCA[45]. Because of this, and bearing in mind the costs and burdens of sophisticated 
imaging tests used to screen for asymptomatic pathology, there is still no consensus amongst 





1.8 Cardiovascular disease risk in the asymptomatic rheumatoid 
arthritis patient 
 
1.8.0 Assessment of cardiovascular risk 
CVD risk in RA is independent of, and incremental to, traditional CV risk factors[18]. Although 
the exact mechanisms continue to remain unclear, the predominant pathological process is 
likely to be immune dysregulation leading to systemic inflammation[19]. 
 
 




Figure reproduced from Agca R, et al. Atherosclerotic cardiovascular disease in patients with 
chronic inflammatory joint disorders. Heart 2016;102:790–795[46] 
 
 
The inflammatory process is linked to atherosclerosis and plaque rupture and has synergistic 
effects on lipid and glucose metabolism, blood pressure and haemostatic factors[20]. While it 
appears that long-term inflammation in RA contributes to this increased CV risk, traditional CV 
co-morbidities play an important role. Patients with RA have been shown to have increased 
insulin resistance, abnormal fat distribution, increased cigarette smoking and decreased 













The European League Against Rheumatism (EULAR) has published recommendations for CV risk 
management in patients with RA (Table 1-1). Annual CV risk assessment should be offered to 
RA patients with established cardiac risk score models being adapted for patients with RA by 
introducing a 1.5 multiplication factor if not already included in the model. Previously, in the 
2009 guidelines, the multiplication factor was used when two of the following three criteria are 
met; a) disease duration of more than 10 years, b) RF or ACPA positivity or c) presence of 
certain extra-articular manifestations[48], given that markers of RA severity are associated with 
adverse CV outcomes[21]. In contrast, the 2015/2016 EULAR guideline update states the 
presence of RA-specific criteria are no longer mandatory to the multiplication factor, given 
some evidence of increased CV mortality and atherosclerosis in seropositive patients with 
recent-onset/early inflammatory polyarthritis[21, 49]. 
 
Despite the evidence of increased CVD risk in RA and guidelines attempting to mitigate this risk, 
RA patients may not get a level of scrutiny for CVD risk assessment, as do other traditional CV 
risk factors such as DM. The first population-based, cross-sectional observational study that 
looked at RA co-morbidity and management was published in October 2013 and analysed 3920 
patients over 17 countries from rheumatology clinics. History of CVD was 6% with CV risk 
factors of hypertension, hyperglycaemia and hyperlipidaemia at 11.2%, 3.3% and 8.3% 
respectively[50]. Although prevalence of traditional CV risk factors differed from country to 
country, it confirmed previous studies[51] that management of cardiac disease, risk assessment 
and adherence to available guidelines was variable and suboptimal in 30-50% of RA patients. 
The under-recognition of excess CV risk in RA further exists in primary care[52]. 
 
In a 2014 update of national guidelines, for CV primary prevention strategies, the United 
Kingdom National Institute for Health and Care Excellence (NICE) recommend using the 
QRISK®2 assessment tool to assess the 10 year risk of developing CVD in the general 
population. Previously, NICE has asked primary care physicians to decide on whichever CVD risk 
calculator to use themselves, including the Framingham scoring tool. The QRISK®2 calculator is 
the only calculator that takes into account RA as a separate CVD risk factor. It takes into 
account ethnicity, age, smoking status, sex, systolic blood pressure, total cholesterol, HDL 
cholesterol, BMI, family history, postal code, anti-hypertensive therapy, rheumatoid arthritis, 




populations in England and Wales as it not validated for international populations. The tool is 
used if the patient is not in any of the following groups: established CVD; type I diabetic; have 
chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) 
<60mL/min/1.73m2 and/or a urinary albumin:creatinine ratio (ACR) greater than 3 mg/mmol; 
aged 85 years or older. The assessment is repeated every five years, but earlier if any significant 
medical changes occur in personal or family history. QRISK®2 has been specifically developed by 
doctors and academics for use in the UK. Published in 2007, the original research underpinning 
QRISK® was performed using the electronic health records of 550 general practices using the 
Egton Medical Information Systems (EMIS) clinical computer system. 2 million contributed to 
the database. More recently, the QRISK®3 CVD risk calculator has included further factors than 
QRISK®2. These include further disease and treatment history associated with inflammation, in 
that regular corticosteroid use and Systemic Lupus Erythematosus (SLE) are now part of the 
calculator. Other additions include: CKD, including stage 3; history of migraines; use of atypical 
antipsychotics; history of severe mental illness; history of erectile dysfunction and; systolic 
blood pressure variability. By including history of regular corticosteroid use, IMIDs may be 
included and raise the risk of CVD, but so far it is only RA and SLE that are specifically 
mentioned diseases in the QRISK®3 risk calculator. QRISK®3 will be the standard version of 
QRISK® shipped in software development kits during 2018. 
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 Table 1-1 - The EULAR overarching principles and recommendations for CVD risk management in patients with RA 
 




1.8.1 A summary of the effect of rheumatoid arthritis therapy on the risk of 
cardiovascular disease 
The TTT use of conventional DMARDs is internationally recommended practice[54]. In a 2011 
systematic review and meta-analysis, MTX was associated with 21% lower risk of total CVD and 
18% lower risk of myocardial infarction (MI)[55]. Studies that controlled for underlying disease 
severity and medication use were associated with 36% and 27% lower CVD risk respectively 
compared with studies that did not[55]. Biologic DMARD (bDMARD) treatments are highly 
effective therapy that can be used to achieve remission and have improved outcomes in RA. 
TNFi, the first bDMARDs, have demonstrated particularly high rates of remission induction in 
ERA, with similar or slightly greater efficacy than conventional DMARDs, but with superior 
structural benefits and the ability to achieve drug-free remission[56-62]. There may be benefit 
of bDMARD therapy in reducing CV morbidity and mortality given improvement of surrogate 
markers of CVD[63, 64] but as TNFi treatment is reserved for established, MTX-refractory 
disease, observational studies are inherently limited by a selection bias. A large prospective 
study of 3529 etanercept (ETN) treated patients and 2864 on conventional DMARDs, with 
notable baseline differences, found no evidence of adverse outcome from long-term exposure 
to ETN, such as serious infections, but there was evidence of improved survival and reduced CV 
events[65]. In patients with resistant disease and mean disease duration of 7.1 years given 
infliximab, another TNFi, left ventricular ejection fraction (LVEF) measured by transthoracic 
echocardiography (TTE) increased from 59% before treatment to 63% after, with significant 
reduction in biochemical markers of heart failure[66]. ETN has also been shown to be 
associated with a significant decrease in adverse left ventricle (LV) remodelling with medium-
term treatment[67] supporting experimental studies that tumour necrosis factor (TNF) may 
induce adverse LV remodelling[68]. The CV benefit of TNFi treatment appeared to be strongest 
in RA patients over 65 years old in an observational study of 8656 new users of conventional 
DMARDs versus 11587 on TNFi, with the study showing an overall reduced risk of CV events in 
bDMARDs[69]. 
 
A recent, large extended report by Low et al[70] aimed to review the relationship between 
exposure to TNFi therapy and incidence and severity of MI in patients with RA. Their analysis 
looked at RA patients recruited to the British Society for Rheumatology Biologics Register for RA 




(out of 11,200 patients) and 58 were receiving conventional DMARDs (out of 3,058 patients). 
They found that a lower risk of MI in the TNFi, by means of propensity score decile adjusted 
hazard ratio of TNFi to conventional DMARD of 0.61 (95% confidence interval [CI] 0.41 to 0.89). 
They did not find any significant differences between treatment groups of the severity of the MI 
or the CV mortality over this medium term analysis. 
 
Further well conducted experimental studies and randomized clinical trials are needed to 
determine mechanisms, supporting the inflammatory hypothesis of atherothrombosis or not, 
and investigate true causality of disease activity, CV risk factors, DMARD therapy and CV 
outcomes. Studies at present continue to suggest that a direct treatment of inflammation in RA 






1.9 The rheumatoid arthritis patient with cardiac symptoms 
 
1.9.0 Typicality of ischaemic cardiac symptoms 
RA can be associated with atypical cardiac symptoms. The United Kingdom National Institute 
for Health and Care Excellence (NICE) and European Society of Cardiology (ESC) have published 
guidance that aims to define the typicality of symptoms for angina pectoris. They summarise 
anginal pain as; a) a constricting discomfort in the front of the chest, or in the neck, shoulders, 
jaw, or arms, b) precipitated by physical exertion and c) being relieved by rest or GTN within 
about 5 minutes. All three features present are defined as typical angina with two features 
defined as atypical angina. One or none of the features above are defined as non-anginal chest 
pain[71]. The typicality of the symptoms coupled with age, sex and clinical risk factors give a 
pre-test likelihood of having CAD[72]. 
 
A retrospective cohort, by Maradit-Kremers et al, of 603 age/sex matched patients found that, 
along with the increased risk of developing CVD, RA patients were significantly more likely to 
have unrecognised MI and less likely to have a history of angina prior to a cardiac event[73]. 
Typicality of symptoms prior to cardiac events and/or revascularisation was assessed using 
guidance for diagnosis of angina or case-note documentation of clinical diagnosis. A smaller 
cohort of 43 RA patients already selected to undergo percutaneous intervention (PCI) for 
coronary revascularisation found that typicality and frequency of symptoms, as well as CAD 
distribution, were similar in treatment and outcomes to well-matched non-RA patients[74]. This 
study differed significantly to the Maradit-Kremers et al study, however this may be predicted 
given the smaller cohort and that these patients were all already selected out to undergo PCI. 
 
Atypical cardiac symptoms have been described in other chronic diseases, such as end-stage 
renal failure and DM[75]. Possible explanations include the attribution of cardiac ischaemia to 
musculoskeletal pain due to their RA[73] and differences in pain perception[75]. Inflammatory 
hypotheses state that a higher production of anti-inflammatory cytokines with lower expression 
of CD11b/CD18 adhesion molecules on phagocytes can be present among patients and 
contribute to asymptomatic ischaemia[76]. Atypical symptoms may be a factor in the observed 
increase of unrecognised MI and sudden cardiac deaths in RA. There are observations that RA 




the role of inflammation on plaque destabilisation causing an acute occlusion, without existing 




1.9.1 Differential diagnoses of ischaemia: pericarditis, myocarditis and 
coronary vasculitis 
1.9.1.1 Pericarditis 
Evidence of pericardial inflammation in RA patients with a prevalence of 30-50% in older post-
mortem studies of the 1970s[78]. An autopsy-based study in 2013 found increased prevalence 
of pericarditis in 369 RA patients between 1952 to 1991 (23% versus 8% in non-RA controls) but 
found little difference in reported symptoms or diagnoses of pericarditis during lifetime[79]. 
Within clinical practice, there appears to be a low symptom presentation of typical pericarditis 
compared to post-mortem prevalence. An hospital based study in 1986 found an annual 
incidence of pericarditis of 0.34% in females and 0.44% in males. The diagnosis was by clinical 
examination, ECG signs and using chest radiograph as the radiological test. The study did 
support previous work stating associations of pericarditis with positive RF, rheumatoid nodules, 
pleurisy and that it occurred more frequently in patients over 40 years old[80]. A 2012 
retrospective community based study with diagnosis of pericarditis made by TTE, ECG and 
clinical judgement again only found an incidence of 1.5%[81]. 
 
The clinical significance of RA pericarditis is sparse in the contemporary literature, perhaps as a 
result of improved anti-inflammatory regimens. It is unknown whether pericarditis is causal to 
increased morbidity or reflection of inflammatory burden[82]. Two contemporaneous CMR 
studies found no pericardial abnormalities in 75 patients with RA on non-contrast CMR[83] and 
18 patients using contrast-enhanced CMR [84]. Given the higher sensitivity and specificity of 
CMR to detect pericardial abnormalities over ECG, TTE and CXR, these studies require fewer 







Non-infectious causes of myocarditis are on the whole more uncommon but are an important 
differential diagnosis in RA populations for the substantial morbidity and the potential for 
specific immunosuppressive treatments[85]. Extra-articular features in RA are associated with 
an increased incidence of non-ischemic cardiomyopathy, including myocarditis, estimated to be 
as high as 39%. A significant prevalence of myocarditis at autopsy is not associated with 
symptoms or diagnosis of myocarditis during lifetime[79]. These data were acquired in the 
1980s and, similar to incidence of pericarditis, the decreased rate seen today may be due to the 
increased use of DMARDs[86]. Sub-clinical myocardial abnormalities and myocarditis exists in 
established RA. Established RA patients with higher disease activity scores (DAS) have been 
found to have sub-clinical non-ischaemic myocardial scar/fibrosis patterns on CMR[84]. Tissue 
characterisation techniques of myocardial extra-cellular volume (ECV) by T1 mapping show 
diffuse myocardial fibrosis and inflammation and association with impaired strain and RA 







Figure 1-4 - Correlation Between Myocardial Involvement in RA as Detected by Using T1 
Parameters and LV Systolic and Diastolic Strains 
 
 
ECV, extra-cellular volume; LV, left ventricle; RA, rheumaroid arthritis; s, seconds; SA, short-
axis. Reproduced from Ntusi et al. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid 
Arthritis: Insights From CMR T1 Mapping. JACC Cardiovasc Imaging. 2015 May;8(5):526-36[87].. 
 
1.9.1.3 Coronary vasculitis 
Coronary vasculitis due to RA is a rare manifestation with seldom case reports published. This 
may be because differentiation between it and CAD is difficult, even with coronary 
arteriography, and both can co-exist. Additionally, it may never become clinically apparent 
unless resulting in a MI with frequent cases found in older autopsy series[88, 89]. The 
importance of remembering this differential diagnosis becomes apparent when considering the 
immunosuppressive treatment that is required to potentially reverse a life-threatening 






Cardiac arrhythmia in RA could be due to ischaemia, fibrosis, congestive cardiac failure (CCF) or 
AA Amyloidosis[78]. Antibodies to cardiac conducting tissue have been found to be significantly 
higher in RA patients with right bundle branch block[91] but atrio-ventricular block remains 
rare in RA and hasn’t been shown to respond to anti-inflammatory or immunosuppressive 
treatment[92]. International guidelines for pacemaker implantation should be followed without 
specific considerations named for RA patients in them[93]. Complex ventricular arrhythmias 
and sudden cardiac death have been described with prolonged QT interval in RA[94]. Prolonged 
QT interval has been linked to raised CRP[95] with a recent prospective study finding QT 
prolongation associated with CRP levels in RA patients and that a 50ms increase in corrected QT 
interval associated with a doubling of the hazard for all-cause mortality[96]. A 2012 Danish 
longitudinal cohort study over 15 years found a 40% higher risk of atrial fibrillation (AF) with a 
30% higher risk of stroke in RA patients[97], however these results were not corroborated with 
a 2013 retrospective USA study that adjusted for a number of AF risk factors compared with 
non-RA patients[98]. There may be interplay between inflammation and specific antibodies 
with arrhythmias in RA that are for future study but no specific recommendations or differing 
management can be extrapolated at this time. Awareness of the possibility of increased 






1.10 Myocardial Infarction in rheumatoid arthritis 
 
1.10.0 Diagnosis 
Clinical diagnosis of MI requires observation of a rise in cardiac biomarkers with typical 
electrocardiographic features, a new regional wall-motion abnormality, thrombus identified on 
coronary arteriogram or history of cardiac symptoms attributable to a coronary event[99]. 
Presence of traditional CV risk factors alert the physician to a differing diagnostic threshold and 
suspicion but is the patient with RA being assessed or treated differently? Troponin (Tn) is the 
primary biomarker of myocardial injury and care has to be taken in the interpretation when 
requested in the asymptomatic patient with RA or indeed any patient. An incidental false-
positive level can occur in patients with high RF titres without an acute coronary syndrome 
(ACS) due to molecular mechanisms in certain manufacturer assays. If clinical reassurance is 
required in suspicious cases with raised Tn levels and high RF titres, nonlinear results after 
serial sample dilutions, using an alternative assay or using creatinine kinase (CK) measurement 
may be useful[100]. 
 
1.10.1 Corticosteroid use in myocardial infarction 
Active glucocorticoid use is common in inflammatory conditions and presentation with MI 
whilst undergoing a course is a clinical situation encountered not infrequently. Management 
will be based on the clinical scenario and specific indication for the glucocorticoid prescription. 
Physicians may choose to; (a) stop glucocorticoids if only just initiated and the bleeding risk 
outweighs clinical benefit, (b) continue the current dosing regimen or (c) increase the 
maintenance dose in the short-term to account for a possible impaired/blunted stress response 
during acute MI. Glucocorticoid use is associated with a 68% increased risk of MI in RA with 
dosing, cumulative duration of use and cumulative dosing also being factors to the increased 
risk[101]. A large cohort study with nested case-control analysis presented an adjusted odds 
ratio (OR) for MI with existing corticosteroids use of 1.42 compared to non-users. This 
population included other non-RA indications for corticosteroid use such as asthma and chronic 
obstructive pulmonary disease. The risk was greater with prednisolone-equivalent doses 
greater than 10mg/day[102]. Glucocorticoids could exhibit an immediate as well as long-term 




of MI has been the subject of trials of corticosteroids as adjunctive treatment in MI. A meta-
analysis of 11 trials with 2,646 patients did suggest a possible mortality decrease with 
corticosteroids but the benefit was no longer statistically significant when the analysis was 
limited to randomised control trials. Importantly, there was no conclusive evidence of a 
detrimental effect of corticosteroid adjunctive therapy during acute MI[103]. 
 
1.10.2 Management and outcomes 
Increased mortality in RA following MI is commonly reported[104]. It is unlikely that there will 
ever be RCTs to compare effectiveness of secondary prevention therapy in MI specifically in 
patients with RA, with the evidence base primarily being retrospective/prospective cohorts and 
explorative sub-study analyses. Antecedent medical illnesses or surgical events can be more 
common in patients with RA presenting with MI and, along with atypical/delayed 
presentations, could provide explanations as to why acute reperfusion, especially in the 
thrombolysis era, was reduced when compared to matched-controls[105]. These studies looked 
at the RA population as a whole after hospitalisation following first MI and did not select out 
patients who were revascularised as a distinct group on their own. Differing management could 
also be as a result of the observation that RA patients may be likely to have diffuse, multivessel 
and microvascular disease[106]. A meta-analysis of 11 longitudinal studies between 1955 to 
1995 found that although mortality after MI has reduced it still remained higher when 
compared to the general population using incidence and standardised mortality rates[107]. 
Explanations offered to the higher morbidity and mortality in RA patients following MI include a 
higher risk population, such as in DM[108], with evidence supporting higher overall mortality 
despite the same reported management[109]. In a small population-based cohort in Minnesota 
of 77 patients by McCoy et al, although the same management, secondary prevention and 
short-term outcomes were similar, RA patients still seemed to have worse long-term outcomes 
with respect to mortality and recurrent ischaemia[110]. Figure 1-5 and Figure 1-6, taken from 
Low et al[70], show the differences between RA patients on TNFi therapy and conventional 
DMARDs, and the severity of MI and early to medium mortality. Although, as mentioned above, 
there appears to be a lower CVD risk and incident MI with TNFi use in RA, in pooled 




Figure 1-5 - Severity of MI between RA patients treated with conventional DMARDs and TNFi. 
 
 
Figure 1-6 - Medium term mortality in RA patients following first MI 
 
Both figures taken from Low ASL, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of 
myocardial infarction in patients with rheumatoid arthritis[70]. 
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1.10.3 Secondary prevention measures 
Clinical trials of therapy in RA are challenging because of the relatively small number of hard 
clinical endpoints[111] and the UK Trial of Atorvastatin for the primary prevention of CV Events 
in RA (TRACE RA) had recruited over 3000 patients but was stopped early due to this 
reason[112]. Reduced initiation of secondary prevention measures have been hypothesised as 
a factor in unfavourable outcomes. One such cohort of 66107 patients in Denmark found that, 
of 877 RA patients, the immediate and short-term initiation of aspirin, beta-blockers (BB) and 
statins were significantly lower. Angiotensin converting enzyme inhibitors (ACE-i), angiotensin 
receptor blocker (ARB) and clopidogrel prescriptions showed a trend for under-prescription 
that did not reach significance. The adherence to statin therapy following MI was lower 
compared to the non-RA group[113] with discontinuation of statin therapy possibly leading to 
further increased risk of MI[114]. An explorative analysis from the Incremental Decrease in 
Endpoints through Aggressive Lipid-lowering (IDEAL) trial[115] found similar lipid-lowering 
effects and rate of CV events between RA and non-RA patients following MI with lipid 
reductions comparable between atorvastatin 80mg daily or simvastatin 20-40mg daily. It was 
noted that RA patients began with lower baseline cholesterol levels[116]. Current EULAR 
guidelines[48] for CV risk management in primary prevention in RA, as well as established 





1.11 Heart Failure in rheumatoid arthritis 
 
1.11.0 Left ventricular systolic dysfunction: prevalence, risk and effect of 
RA therapy 
Cardiac dysfunction in RA can exist in several and potentially overlapping sub-groups of 
cardiomyopathy. Dysfunction from ischaemia, with or without previous MI, can occur and 
hypertensive heart disease is a further cause secondary to uncontrolled systemic hypertension. 
Within contemporary classifications of non-ischaemic secondary cardiomyopathy[119], RA is 
considered autoimmune in aetiology causing dilatation and/or impairment or as a result from 
chronic inflammation causing restrictive cardiomyopathy from AA amyloidosis[78, 120]. RA is 
associated with abnormal LV remodelling on TTE with significance continuing compared to 
controls after adjustment for CVD and CV risk[121]. TTE of 226 non-matched RA outpatients 
found a prevalence of 5.3% with LVEF <40% with 1 in 9 having a concurrent abnormal resting 
ECG[122]. Any level of systolic dysfunction by TTE was found in around 18% of a cohort and was 
associated with RF, ACPA levels and duration of disease. No adjustments for CVD risk factors 
were made compared to controls but the RA cohort that had LV systolic dysfunction (LVSD) had 
increased prevalence of existing ischaemic heart disease (IHD), DM or dyslipidaemia[123]. 
 
In contrast to previous TTE studies that showed increased LV mass but not decreased 
LVEF[124], CMR studies give evidence that patients with RA have differing LV remodelling to 
what was previously described. A large study of 75 patients showed reduced LV mass as well as 
LVEF[83]. Patterns of CMR findings in 45 patients post-coronary angiogram with RA and New 
York Heart Association (NYHA) class I/II congestive cardiac failure (CCF) found 4 different 
patterns; myocarditis (33%), dilated cardiomyopathy (33%), IHD (22%) and/or diffuse 
subendocardial fibrosis (11%). Chronic versus acute myocarditis was 18% and 16% respectively 
with endomyocardial biopsy supporting CMR diagnosis. Late-gadolinium enhancement 
positively correlated with CRP, erythrocyte sedimentation rate (ESR) and disease activity[125]. 
 
Typicality of CCF symptoms and likelihood of referral for TTE are reduced in RA patients. This 
may institute a delay to diagnosis/therapy. After adjustment of differences to controls, RA 




at one year[126]. Prescription rates for ACEi and BB have been seen to be lower in RA patients 
with CCF but there is a difficulty in comparing unadjusted treatment options compared to non-
RA for potential confounding indications[126]. An attempt to remove traditional CV risk factors 
and causes for CCF with respect to IHD and hypertension continued to find an excess risk of CCF 
in a population-based inception cohort of 575 matched RA patients[127]. Nicola et al calculated 
that patients with RA have twice the risk of developing CCF compared to non-RA sex and age 
matched controls with this not being explained solely with CVD and CV risk factors[128]. CCF 
may contribute more to excess mortality when compared to IHD/MI alone[129]. Adjusting for 
CV risk factors and IHD, the risk of developing CCF in RA is also associated with positive RF, 
severe extra-articular disease and corticosteroid use[130]. 
 
1.11.1 Acute decompensation of congestive cardiac failure 
Preceding inflammation may have a role in the development or exacerbation of CCF in RA. 
Significantly raised ESR has been found in the preceding 6 months to diagnosis of new-onset 
CCF without correlation of ESR with HTN or DM diagnosis timings[131]. An independent impact 
of RA on CCF that can be further modified by conventional DMARDs has been observed with an 
apparent protective effect of MTX[130]. In a case-control design within a retrospective cohort 
of RA patients, the use of DMARDs was associated with a reduction in the risk of hospitalisation 
for CCF with the use of the COX-II inhibitor rofecoxib associated with an increase[132]. TNF is 
considered as part of the pathophysiology of CCF but trials of TNFi have shown harmful 
deterioration of CCF with higher doses of different agents[133, 134]. These studies did enrol 
more patients with NYHA IV CCF. Current recommendations in RA do not support the use of 
TNFi in NYHA III/IV CCF, with caution being exercised in NYHA I/II CCF and discontinuation if 
there is worsening whilst on treatment[135, 136]. TNFi use in patients over 65 is also associated 
with risk of CCF exacerbation and hospitalisation but without residual confounders being ruled 
out[137]. There have not been adequately powered trials to observe CCF risk when adjusted for 
established CVD and risk factors, TNFi naivety and appropriate used clinical dosing. In 2013, 
attempts to overcome some previous limitations were made in a large US cohort. Solomon et al 
concluded that TNFi use following initial MTX use in TNFi-naive RA patients was not associated 
with an increased risk of CCF admissions compared to conventional DMARDs[138]. Severity of 
RA as well as CCF development/exacerbation isolated to community care was not examined 




with TNFi is more likely to be beneficial with regard to the risk of CCF, especially without 
simultaneous use of corticosteroids or COX-II inhibitors[139]. There continues to be a need for 
RCTs looking into development and/or deterioration of LVSD with exacerbation of CCF with 
TNFi in RA but until then it is hard to contest current avoidance of bDMARDs in LVSD with poor 
NYHA status[140]. 
 
1.11.2 Diastolic dysfunction and B-type natriuretic peptide 
Diastolic dysfunction can result in the clinical syndrome of CCF and has been described in RA 
populations by TTE[141, 142] but with conflicting data. Some studies describe a prevalence of 
31%-47.2%[123, 143, 144] with others giving mixed findings of no significance in prevalence 
when compared to matched controls as a whole[143] or within certain diastolic severities[144]. 
The use of DMARDs does not seem to affect its presence[145] as well as traditional CVD or 
duration of RA, implying that different mechanisms may underlie the pathophysiology in 
contrast to LVSD[146]. B-type natriuretic peptide (BNP) has been implemented as part of the 
diagnostic algorithm in heart failure guidelines in recent years for systolic and diastolic 
dysfunction[147]. BNP is released from the myocardium in response to pressure and/or volume 
loading and is thought to be more of a specific cardiac biomarker[148]. The levels of BNP have 
been found to be raised in RA and related to inflammation but not associated with LV 
abnormalities[149]. The implication of this in diastolic dysfunction has been looked in RA 
populations, where it has been found that BNP is a poor screening tool for LV diastolic 
dysfunction without clinical evidence of CVD[150]. There is difficulty in knowing how to manage 
diastolic heart failure in the cardiology community as opposed to the multiple treatments and 
large evidence base for systolic heart failure. It is not unreasonable to control risk factors and 
fluid management in RA patients, as is the practice in non-RA, until further research helps guide 
future management. 
 
1.11.3 Cardiac amyloidosis 
Secondary AA amyloidosis due to RA is a rarer cause of CCF by restrictive cardiomyopathy. This 
is caused by cardiac deposition of circulatory serum amyloid A protein derived from RA 
inflammation[151]. AA Amyloidosis differs from AL amyloidosis, where early mortality in AL 




death is usually from renal failure or sepsis after a survival of 4-5 years[151, 152]. Retrospective 
autopsy findings have shown a frequency of cardiac amyloid similar to the prevalence of renal 
amyloid. Secondary AA amyloidosis is diagnosed in 37% of patients before death and correlated 
with a longer disease duration and disease activity[153]. Prospective studies have supported 
this retrospective work on subclinical AA amyloidosis in RA using Congo red staining on 
abdominal fat aspiration biopsy finding a prevalence of 21.5% to 29% and having associations 
with longer time to diagnosis, extra-articular disease, proteinuria and lack of MTX use[154, 
155]. The cornerstone of treatment of secondary AA amyloidosis in RA is to control disease 
activity aggressively with DMARDs in an attempt to cease the production of serum amyloid A 
protein deposition created from RA inflammation. ETN has been found to be more effective 





1.12 The rheumatoid arthritis patient undergoing invasive procedures 
 
1.12.0 Peri-operative cardiovascular assessment and risk in non-cardiac 
operations 
Three key areas of perioperative care in rheumatic diseases have been suggested by Veetil et al 
in a 2012 review on the subject; the management of CV risk, immunosuppression and altered 
coagulation states[157]. Altered coagulation states in the form of anti-phospholipid syndromes 
are an entity more pronounced in SLE but the first two areas are of importance in RA. The 
position that a cardiologist, surgeon, anaesthetist and rheumatologist hold in discussion with 
the rest of the multi-disciplinary team is not to simply accept/decline an RA patient for a 
procedure but to offer a peri-procedural risk and if acceptable to attempt augmentation of that 
to be as low as possible. The ESC has produced clear recommendations on perioperative cardiac 
risk and evidence base for management that are endorsed by the European Society of 
Anaesthesiology.[158] The ACC/AHA have produced similar documents[159] and all societies do 
not include any specific risk assessment or recommendations for the patient with RA. It can be 
accepted from various cardiac risk algorithms that if (1) the condition is a life-threatening 
emergency, (2) there are no active cardiac conditions, (3) the surgery is low risk or (4) there is 
good functional capacity, then surgery can usually go ahead. However, when this is not the case 
clinical risk factors are taken into account along with level of risk the surgery itself holds before 
further assessment and surgery is considered. 
 
Despite the increased and widespread use of bDMARDs and conventional DMARDs, 
orthopaedic surgery remains an important intervention to improve quality of life for RA 
patients. Hip, knee and other large joint arthroplasty occur in 24% of RA patients over their 
lifetime with more aggressive disease making this more likely[160]. ESC guidelines place 
arthroplasty as an intermediate-risk procedure at 1% to 5% risk of serious cardiac events[158]. 
As discussed in previous sections, CVD in RA patients has been demonstrated to be sub-clinical 
with risk estimates of clinical disease developing at the same rates as DM[161]. Adding RA as a 
clinical risk factor in peri-operative risk assessment, as suggested by Veetil et al, may change 
existing algorithms by introducing a decision whether to proceed with planned surgery along 




general orthopaedic population the risk of post-operative MI can be around 6.4% if a patient 
has pre-existing CV risk factors[162]. In comparison to arthroplasty in patients with 
osteoarthritis, if RA is the only risk factor in elective surgery there is support that short-term CV 
events are not increased but the risk of repeat/redo surgery is[163]. Given that some patients 
with functional limitations may not be able to exercise to maximal predicted physiological 
stress on treadmill or bike, non-invasive stress testing with pharmacological agents in 
adherence to peri-operative guidelines can be considered. 
 
With respect to immunosuppression, current literature focuses on peri-operative flares of RA 
and infectious complications that are focussed on the surgical site. No data are available for 
cardiac complications with differing immunosuppressive regimens peri-operatively but it is 
important to note that pre-existing CAD has been independently associated with increased 
post-operative infection in RA[164]. Type-II MI, defined as MI secondary to ischaemia due to 
either increased oxygen demand or decreased supply, can be caused by sepsis and tends to 
occur in patients with impaired functional levels[165]. There are no specific guidelines with 
respect to type-II MI but these patients are less likely to receive coronary intervention, 
guideline-directed medical therapy and have increased morbidity and mortality[165]. There is a 
wealth of information on MTX throughout the peri-operative period and multi-national 
guidelines in 2009 recommend their continued use[166]. Further recommendations from 
systematic reviews and meta-analyses state that the use of conventional DMARDs could 
continue only in the absence of other risk factors relating to post-operative complications[167, 
168]. With respect to bDMARDs,  there are conflicting datasets and case-series[169, 170] 
regarding their influence on post-operative infections, and wound healing in particular, but no 
RCT data[171]. From observation, the literature leans towards increased infection and 
discontinuation of the drugs but it is necessary to judge each patient on a case-by-case basis 
with respect to their increased morbidity and potential serious complication if they had a RA 
flare due to drug cessation[157]. Limiting peri-operative corticosteroid exposure is well 
recognised to be an important factor in reducing post-operative complications and patients 
should ideally be on 10mg per day prednisolone equivalent with more than 15mg per day 





1.12.1 Percutaneous coronary intervention 
The modern era of early invasive management with percutaneous coronary intervention (PCI) 
of non ST elevation-ACS (NSTE-ACS) and ST elevation MI (STEMI) could well be in favour of the 
RA patient in comparison to previous decades of thrombolysis and medical therapy. One would 
hypothesise that given the observation of worse outcomes in MI as a whole in patients with RA, 
coupled with the observation of more microvascular disease, that coronary intervention may, 
with coronary artery bypass grafting (CABG) or percutaneous intervention, have increased in-
hospital mortality or peri-procedural complications. Paradoxically, opposite findings have been 
published. Outcomes in US groups, where the likelihood of PCI as a primary treatment option in 
MI is higher, show RA patients have an in-hospital survival advantage compared to non-RA 
patients[104, 172]. A smaller retrospective cohort of 43 RA patients (matched on age, sex and 
revascularisation history) who underwent PCI were analysed with respect to presentation, 
coronary anatomy and treatment. Traditional CV risk factors were similar in both groups. Mode 
of presentation was predominantly as an ACS in both RA and non-RA groups and there were 
similar distributions of multi-vessel CAD. The prescription of standard cardiac medications was 
also similar between the 2 groups apart from higher ARB/ACE-i use in the RA group. In short 
term follow-up, there was no difference in mortality or procedural complications[74]. Larger 
numbers in Taiwan of 240 RA patients, which were not differentiated with respect to severity of 
RA, undergoing non-stenting PCI matched to 1200 non-RA patients again failed to find a 
difference in outcomes with respect to in-hospital, 90-day and 1 year mortality or 
readmission[173]. Cross-sectional analysis into mortality of RA patients after coronary 
revascularisation, by CABG or PCI, further found that there was a survival advantage as well as 
reduced hospitalisation[174]. As always with observational data, it cannot be concluded that RA 
would continue to have a protective effect once patients are in an RCT and, furthermore, LV 
function, coronary anatomy and use of medications were not adjusted for. As all MDTs put 
patients forward for intervention based on a consensus opinion that it would be in the patients’ 
favour, the findings above between intervention in RA and non-RA populations show there are 
grounds for further investigation and, at present, it can be considered there should be little 
trepidation in putting forward patients with RA for PCI with respect to short/medium-term 





1.12.2 Cardiac surgery 
Historically, it is known that cardiac surgery in IMID can present with it difficulties include 
suture detachment, valvular dehiscence, impaired wound healing, friable tissues and 
progression of vascular lesions following surgery[175]. Outcomes and surgical approaches in 
these patients have been looked at emphasising the importance in assessing the systemic 
features of each patient, albeit with small case series and reports[176]. The logistical European 
System for Cardiac Operative Risk Evaluation (EUROSCORE) is a common risk scoring calculator 
used to predict peri-operative complication in cardiac surgery. It does not take inflammatory 
diseases into account although reference is made to patients with DM on insulin. Peri-operative 
inflammation in cardiac surgery patients is a complex process involving humeral and cellular 
mechanisms with cytokines produced during cardiopulmonary bypass[177, 178].  
 
1.12.2.1 Coronary artery bypass grafting 
Given the apparent worse outcomes in MI and increased microvascular disease in RA, with 
increased peri-operative inflammation after cardiac surgery it would not be surprising to 
observe increased complications but some data suggests otherwise. To complement their 
findings, with respect to PCI outcomes in RA patients, Varghese et al found that RA patients 
undergoing CABG had a 31% increase of in-hospital survival advantage with reduced days of 
hospitalisation compared to non-RA patients[174]. A retrospective cohort of 44 patients with 
IMID, that included 35 patients with RA and 35 month mean follow up, described an overall 
survival and freedom from re-intervention at 3 years were 89% and 75% respectively[179]. 
They concluded that CABG is an acceptable treatment modality in IMID with reasonable early to 
mid-term results. In established RA, the use of arterial conduits for CABG have been shown 
histopathologically to have expected and acceptable atherosclerotic changes[180]. There are no 
further large data specific to CABG outcomes specifically in patients with RA and the 
observations are so far mixed. Hypotheses for reduction in some complications following CABG 
in RA patients include the RA therapy immunomodulation that can work against the 
cardiopulmonary bypass inflammatory insult. This hypothesis from Varghese et al seems less 
substantial given improvements also described in their PCI cohort. No further satisfactory 
pathophysiological explanation has been put forward in attempt to corroborate the findings in 




1.12.2.2 Heart valve surgery 
Rheumatoid valvular heart disease (VHD), whether caused by valvulitis, vasculitis or 
nodule/amyloid deposition leaves variable degrees of valvular regurgitation and rarely stenosis. 
Presentations can be of acute regurgitation in the cases of nodule rupture or of clinically overt 
syndromes such as peripheral embolism or Libman-Sacks-like vegetation. A trans-oesophageal 
echocardiography (TOE) study of 34 RA patients found no correlation between VHD and 
duration, clinical subtypes or RA therapy other than it was a common finding compared to 
controls and that valve nodules and thickening are distinctive features[181]. In taking a mixed 
cohort of different subtypes of VHD, a small case series showed short and medium term 
morbidity and mortality of RA patients at 1 month and 1 year post valvular replacement is 
approximately 2–3 times higher than that of non-RA patients[182]. Aortic valve regurgitation in 
RA necessitating valve replacement is uncommon and data over 40 years is limited to case 
reports in patients with variable presentations and without long-term follow up[183-186]. The 
difficulty of procedures are seemingly higher in the patient with aortic incompetence and 
aortitis, with experienced authors wanting to ensure active disease is treated with 
immunosuppressant to make the procedure technically easier, with respect to suturing tissue 
that is less inflamed[187]. Mitral valve pathology described in a retrospective surgical series of 
36 RA patients between 1978 and 2005 found that severe MR had similar mechanisms of 
regurgitation to that of non-RA patients. On having mitral valve repair, they had decreased 
survival and freedom from reoperation at 8 years, but when compared to matched RA patients 
without severe MR they had similar survival at 5 years[188]. The disease itself rather than 
surgical specific issues were thought to contribute to these findings and the conclusion being 
that mitral valve repair is safe and durable with the interesting note that this cohort found no 
clear pathology characteristic of involvement with rheumatoid VHD. The short-term mortality 
and length of stay was shown to be similar to non-RA patients in a series between 2005 and 
2008 and it wasn’t apparent that RA appeared to be an additional risk factor for adverse 
outcome following isolated mitral valve surgery. They did find that conversion to mitral valve 
replacement rather than repair was higher but within the RA subset, hospital mortality rates 
were similar[189]. Given that RA patients may need corticosteroids and NSAID medications for 
their articular disease, it would be presumed unfavourable in the long-term if anticoagulation 
was enforced with metallic valve replacement. As CVD is accelerated in RA, younger patients 




re-intervention 10-15 years later have to be weighed up. RA patients with isolated VHD disease 
selected for surgery appear to have similar survival compared to the RA patient without severe 
VHD and with surgical technique being acceptable and durable - especially in mitral valve 
disease and aortic disease without aortitis. In the longer term, it may be that morbidity and 
mortality is higher but whether this is directly due to having VHD versus progression of systemic 





2 Non-invasive cardiovascular imaging modalities 
 
2.1 Introduction 
Common clinical and research cardiovascular imaging modalities used to assess for CVD are 
ultrasound, TTE, single-photon emission computed tomography (SPECT), positron emission 
tomography (PET), computed tomography (CT) and CMR[190]. TTE is safe and low-cost. It can 
assess cardiac structure and function, providing information on ischaemia when combined with 
stress protocols. Poor acoustic windows may be a problem due to individual body habitus or 
acoustic shadowing from lungs. Reproducibility is a further weakness due to measurement & 
reporting variability. PET is the gold standard for quantifying myocardial blood flow but is 
hindered by high cost and reduced availability. SPECT is commonly used and has been 
established over many years for ischaemia testing but, similar to PET, it cannot assess cardiac 
anatomy and exposes patients to ionising radiation[191]. CMR is a safe, sensitive, reproducible 
and comprehensive non-invasive imaging test to detect CVD with the ability to assess cardiac 
anatomy and function. Utilisation is limited by cost, claustrophobia and the inability to scan 
certain metallic implants. 
 
2.2 Carotid Ultrasound 
Ultrasound may directly demonstrate atherosclerotic plaque in the carotid artery as well as 
measure the intima-media thickness. This common carotid intima-media thickness (CIMT) is a 
surrogate measure of CVD and is well validated. In the general population, for every 0.1mm 
increase in CIMT measurement there is a relative risk of MI of 1.15 and of stroke was 1.18 after 
age and sex adjustment[192]. An absolute CIMT of greater than 0.9cm above the 75th centile 
confers a high risk of CVD [193]. There is a large evidence base supporting use in the general 
population and given the simple, rapid and reproducible measurements (along with the lack of 
ionising radiation) they have been used as endpoints in clinical trials assessing therapies for 
lipid management and hypertension. One of the larger CIMT studies in RA (meta-analysis of 
1384 RA patients) found that compared to controls the overall mean CIMT difference was 
greater in RA by 0.09mm (95% CI 0.07, 0.11mm)[26]. However, there are questions over 




randomised clinical trial endpoints. Furthermore, a targeted ultrasound assessment of CIMT 
negates being  able to assess additional CV manifestations of RA in the heart and larger arteries. 
 
 
Figure 2-1 - Ultrasound examination of the carotid intima media thickness 
 
CIMT = distance between arrows. Panel A: Normal CIMT. Panel B: Increased CIMT. 
Image reproduced from Erkocoglu et al, Carotid intima media thickness in adolescents with 
increased risk for atherosclerosis. Turk J Pediatr. 2013 Sep-Oct;55(5):510-8[194]. 
 
Carotid ultrasound is incorporated into recent guidelines (Table 1-1 - The EULAR overarching 
principles and recommendations for CVD risk management in patients with RA, statement 6) 
when assessing CVD risk in RA patients. This is largely when a risk estimate is at an intermediate 
level with an annual CVD risk of 1-4%. When there are high-risk features with an abnormal 
ultrasound, then the physician may consider initiating primary CVD prevention therapy as per 
RA patients with a >5% annual CVD risk as per modified SCORE risk estimation. If the carotid 
ultrasound suggests low-risk, then the RA patient should continue as per <1% annual CVD risk 






2.3 Transthoracic Echocardiography 
TTE shares much of the technical advantages of carotid ultrasound given they are based on the 
same technology and physics. It is similarly relatively low-cost, widespread in availability and 
free from ionising radiation. The largest CV imaging modality used to assess cardiac structure 
and function in RA is with TTE at present time. Individual studies have shown changes in cardiac 
structure with increased left ventricular mass and function with lower left ventricular ejection 
fraction. Although meta-analysis of TTE studies continued to show the finding of left ventricular 
mass changes, no difference in systolic performance by ejection fraction existed when studies 
were combined[197]. The intra-observer and inter-study variability is less attractive than CIMT 
measurement and CMR[198]. 
 
 
2.4 Cardiac Computed Tomography 
Cardiac computed tomography is commonly utilised for two major clinical assessments. The 
first is to assess for burden of coronary artery calcium and the second is for anatomical 
assessment of the epicardial coronary arteries. Due to the marked X-ray attenuation properties 
of calcium, CT coronary artery calcium scoring (CCS) provides good visualisation of vascular 
calcification and effective ionising radiation dosing for CCS is 1mSv[199]. In the Multi-Ethnic 
study of atherosclerosis (MESA), absolute scores alone were considered sufficient for 
quantification of coronary plaque burden over further stratification to age, sex and 
ethnicity[200]. Guideline recommended CCS Agaston scoring categories and their 





Table 2-1 - Recommended calcium score guidelines 
 
Adapted from Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed 
tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic 




There are very limited research data of the use of CCS in RA. This is likely due to options and 
evidence-base of non-ionising radiation imaging modalities. In 2014, Løgstrup BB et al[202] 
investigated RA disease activity, ACPA status and CCS in 53 treatment-naive ERA (30 women), 
along with left ventricular systolic function by TTE. They found CCS showed no correlation with 
TTE, disease duration or any rheumatologic parameters. The mean CCS calculated from this 
study was 65, and when applied to online MESA calculators would lie on the 30th to 60th 
centile for age, ethnicity and sex. 
 
CT coronary angiography (CTCA) studies in RA are similarly as sparse as studies utilising CCS. 
The typical radiation dose is 1-3mSv for a prospective ECG-gated CTCA (step and shoot and fast 
helical acquisition) and 7-12mSv for a retrospective ECG-gated CTCA with ECG-correlated mA 
pulsing[203] A 2016 study by Hromádka et al[204] prospectively recruited 44 women with RA, 
(of at least 1 year disease duration on biological therapy), to be examined using CTCA and 
compared to biomarker parameters of atherosclerosis and the EULAR guideline recommended 




system. 9% of RA patients had severe coronary stenoses (defined as >70%). High-sensitivity 
troponin I level was the only marker found to be associated with severe coronary stenosis (OR 
6.37; 95% CI 1.53 − 26.48; P = 0.01). The SCORE system had no correlation in predicting severe 
stenoses (P ≥ 0.49) in this asymptomatic cohort without known CVD. High-sensitivity troponin I 
is therefore a biomarker for further study, in larger populations and including males, to 
investigate these preliminary findings further. High sensitivity Troponin I may be used to predict 
possible flow-limiting CAD in RA patients with established RA disease and no known CVD or 
cardiac symptoms. 
 
In a CT imaging study [41], Prieto-Gonzalez et al identified active thoracic aortitis in 65% of in 
newly-diagnosed GCA patients, with TAD already present in 15%. Our rate of TAD of 66%, after 
a mean of 65 months of disease, is similar to their initial large-vessel vasculitis (LVV) prevalence. 
Even after one year of therapy, they found persistent aortic wall thickening in 68%. In a follow-
up study of 54 GCA patients with a median disease-length of 5.4 years[36], 22.2% were 
reported to have TAD/TAA. 
 
2.5 Single-photon emission computed tomography 
Nuclear perfusion imaging with single-photon emission computed tomography (SPECT) imaging 
is widely available and well-established with a body of research and trial outcome data in the 
diagnosis of reversible ischaemia in the evaluation of patients with coronary artery disease. A 
patient-based analysis demonstrates a  pooled sensitivity of 88% and specificity of 61% for the 
diagnosis of obstructive coronary artery disease[205]. There is a paucity of data specifically of 
SPECT study use in RA. Perhaps the largest study utilising SPECT in RA was in a 2004 study that 
evaluated 62 patients, that were consecutively recruited from an outpatients clinic, for the 
presence of ischaemic heart disease and compared to circulating autoantibodies[206]. 
Increased levels of antibodies to cytokeratin 18 were found in the RA patients with ischaemic 
heart disease as defined by positive defects seen by adenosine stressed thallous-210 chloride 
SPECT. Dipyridamole Thallium-201 scintigraphy was carried out in an older study by Momose et 
al in 1995, where 27 of 54 established RA patients without CV symptoms had perfusion defects. 
Higher ESR, CRP and IgM/IgG rheumatoid factor levels were observed in the group with 




autopsy and of 7/12 microvasculitis and microthrombosis was seen without myocardial 
infarction[207].  
 
2.6 Positron Emission Tomography 
PET imaging may be utilised as a tool for the evaluation of myocardial blood flow by the 
detection of emitted positrons from radionuclides/labelled radiotracers. The PET radiotracers 
that are used currently to assess myocardial blood flow are 15Oxygen-water, 13Nitrogen-
ammonia and 82Rubidium[208]. Quantification by 15Oxygen-water in absolute terms (millilitres 
per gram per minute) by PET imaging has been considered the gold standard[209] but this is for 
whole heart coverage and not regional cardiac uptake, as the weakness of  15Oxygen-water is 
that there is free diffusion of the radiotracer between target tissue and the background. This 
does not make it clinically applicable to look for regional differences for ischaemia testing or for 
regional hibernating myocardium assessment. 13Nitrogen-ammonia and 82Rubidium both have 
characteristics of active extraction uptake mechanisms with reasonable half-lives, which allows 
for relative perfusion imaging and, therefore, ischaemia testing. The overall characteristics of 
the radiotracers are given in Table 2-2. Although PET can be used to assess people for 
suspected angina, and is incorporated into international guidelines given further usefulness in 
predicting CV mortality in those with CAD[210], several factors have limited widespread use. 
These include the cost and radiotracer availability. Furthermore, an assessment of cardiac 
structures and regional function cannot be performed with nuclear imaging. There have been 
no studies specifically utilising PET for myocardial blood flow quantification in patients with RA 
but there have been in some mixed IMID populations. PET in patients with IMID without CAD 








Table 2-2 - Basic characteristics of common cardiac PET radiotracers 
 
Taken from Al Badarin et al, Assessment of myocardial blood flow and coronary flow reserve 
with positron emission tomography in ischemic heart disease: current state and future 




PET has been utilised in a few studies in patients with RA by assessment of vascular 
inflammation. Mäki-Petäjä et al, in 2012, used 18fluorodeoxyglucose-PET/CT (FDG-PET/CT) 
imaging in 17 patients with established RA before and after 8 weeks of TNFi therapy[212]. They 
demonstrated that the RA patients had increased aortic uptake of the radiotracer, implying 
aortic inflammation, in comparison with 34 non-RA patients with stable CVD. There was also 
increased arterial stiffness by measure of pulse wave velocity. After 8 weeks of the TNFi 
therapy, there were improvements in tracer uptake that correlated with improved arterial 
stiffness. In 2016, Haavisto et al looked at the 18FDG uptake in the carotid artery in 15 patients 
with recently diagnosed, ERA prior to DMARD therapy[213]. They reported that after 1 month 






2.6.0 Cross-sectional imaging in GCA 
Diagnostic performance of large-vessel vasculitis (LVV) by cross-sectional imaging is well-
described and can be performed with CT and CMR using wall thickness measurements with or 
without the of gadolinium-based contrast agents[214]. The lack of a gold standard creates 
problems in calculating sensitivity and specificity. Hybrid 18F-FDG PET-CT may also be utilised if 
initial cross-sectional imaging is non-diagnostic[215], however, the utility for routine disease 
monitoring in GCA is not yet realised. Normal wall aortic thickness does not rule out active 
inflammation and, conversely, it may take time for increased wall thickness to respond to 
therapy and regress[216]. There is an emerging role for hybrid PET-CT/CMR and CMR with 
gadolinium-based contrast in indeterminate cases of relapse/response. Hybrid PET-CMR may 






2.7 Cardiovascular Magnetic Resonance 
2.7.0 Introduction 
As this thesis presents data on the use of CMR in RA and GCA, I have presented information 
here of greater detail than other imaging modalities described above. Further information into 
specific sequences, settings and analysis methodology is described in the methods sections 
later. CMR is a safe, sensitive, reproducible and comprehensive non-invasive imaging test to 
detect CVD with the ability to assess cardiac anatomy and function. LV mass and function can 
be measured more accurately than with any other imaging method[218]. Vascular function 
assessment using aortic distensibility and pulse-wave velocity can be reliably measured from 
the ascending and descending aorta[219]. Myocardial deformation characteristics using tissue-
tagging or cine image feature tracking provide measurements of regional and global myocardial 
strain as early markers of contractile dysfunction[220, 221]. CMR has been shown to detect 
myocardial ischaemia with greater sensitivity than nuclear perfusion imaging[222] and dynamic 
contrast enhanced methods can be used to estimate myocardial blood flow at rest and during 
hyperaemic stress[223]. Late-gadolinium enhancement (LGE) imaging in CMR is used to detect 
myocardial scar tissue and fibrotic tissue and is recognised as the in-vivo gold standard to do 
so[224]. Secondary AA amyloidosis due to RA is a rarer cause of CCF by restrictive 
cardiomyopathy. The classic LGE pattern on CMR imaging is that of diffuse myocardial fibrosis, 
with subendocardial involvement in non-coronary artery territory patterns, as well LV 
hypertrophy, biatrial enlargement and ventricular impairment. The myocardial fibrosis in 
Amyloidosis may be so involved and diffuse that there is difficulty finding the optimum 
inversion time to ‘null’ the myocardium to observe where normal areas of myocardium are 
compared to LGE[120].  T1 mapping methods using contrast agents are used to measure the 
extent of the extracellular matrix in the heart, which expands in response to inflammation and 
fibrosis[225, 226].  CMR has no harmful effects and all measurements can be combined in a 





2.7.1 A summary of CMR physics 
There are three types of magnetic field used in CMR; 
 
 B0, a static field created by the superconducting solenoid 
 A gradient field, that is switched on/off quickly 
 B1, a radiofrequency (RF) field, resonating hydrogen nuclei in different states with 
pulses. 
 
Hydrogen nuclei in free water/adipose tissue align with B0, with a small net magnetisation (M) 
in one direction. The hydrogen nuclei resonate at 127.74MHz at 3Tesla magnet strength, 
termed the Larmor frequency. This emits a small, clinically ineffective, RF signal governed by a 
number of variables including B0, M, hydrogen nuclei density and body temperature. For 
measureable and useful signal generation, an external RF pulse 'flipping' the hydrogen nuclei is 
applied. Once a pre-determined flip angle has been reached, the RF pulse is switched off and 
equilibrium occurs. This release in energy, or 'free induction delay', is detected as an RF signal 
from the hydrogen nuclei. The echo-time is time from RF pulse to maximum amplitude of echo. 
Those generated by gradient-induced dephasing and rephasing are called gradient echoes. 
Those generated using refocussing RF pulses are spin echoes. T1 relaxation time corresponds to 
longitudinal relaxation following an external RF pulse. Fat has the shortest T1 relaxation time, 
followed by muscle, with fluid being the longest. T2 relaxation time corresponds to transverse 
relaxation and occurs quicker than T1 relaxation. T2 measures the interaction of adjacent 
hydrogen nuclei protons. Denser structures, like muscle, aid interaction and so have shorter T2 
relaxation times compared with fluid. Fat demonstrates intermediate T2 relaxation times. 
There are two major forms of gradient echo; spoiled gradient echo and balanced steady state 
free precession (bSSFP). bSSFP is now predominantly used to create moving cine imaging. bSSFP 
sequences ensure that transverse magnetisation is fully re-phased prior to next RF pulse. This 
allows it to culminate and a steady-state of transverse magnetisation allowing for a more 
powerful signal. The imaging contrasts relies on T2/T1 ratio from the tissue and so fluid and fat 
have a higher ratio and appear bright compared to muscle. This is, therefore, useful in cardiac 
cine imaging as it allows for increased endocardial to blood-pool definition aiding cardiac 
volumetric analysis, which is consistent through the cardiac cycle. Every data sample is stored 




equates to a specific frequency across the field of view and not specific position. The position of 
that frequency from k-space translating to location within the subject is related to the strength 
of when each gradient was applied, from when it was applied to when it was measured for any 
particular point measurement. Fast Fourier transformation mathematically interprets this k-
space data for digital transformation into interpretable imaging. 
 
2.7.2 Cardiac volume analysis 
A continuous stack of gradient echo imaging along an axis of a cardiac chamber with 
subsequent measurement of the multiple end-diastolic and end-systolic areas forms the 
backbone of assessment in CMR. These multiple contoured 2D areas allow for the calculation of 
end-diastolic volume, end-systolic volume and epicardial contours. This is turn allows 
calculation of ejection fraction, stroke volume and mass. The convention for left ventricular 
measurement is a series of short-axis stacks covering the length of the left ventricle from base 
to apex. Methodology for this is explained later in this thesis. Different stacks can also be 
applied, such as transverse stacks onto the right ventricle. As well as length of the ventricle, the 
number of breath-holds required depends on slice thickness and gap. CMR measurement of 
ventricular volumes has excellent reproducibility and is superior to 2D echocardiography[198]. 
87 patients are required to detect a 3% change in left ventricular ejection fraction with 2D 
echocardiography but as few as 11 patients are necessary by CMR. Similarly, to identify a 10g 
change in left ventricular mass by 2D echocardiography 132 subjects would be required in 
contrast to 13 by CMR[198]. Scanning time may be reduced with acceleration techniques. 
These include sensitivity encoding (SENSE), simultaneous acquisition of spatial harmonics 
(SMASH) and generalized auto-calibrating partially parallel acquisitions (GRAPPA). Acceleration 
techniques may worsen signal-to-noise ratio, spatial or temporal resolution[227].  
 
2.7.3 Cardiac strain 
Strain is the amount of myocardial shortening divided by the pre-contraction length and is 
another measure of systolic function in addition to ejection fraction. Strain rate incorporates 
the time taken for the shortening to take place. CMR tissue-tagging sequences allow 
measurement of cardiac strain. The tissue-tagging sequence employs a selective RF saturation 




cardiac cycle[220]. Depending on the orientation the acquisition is made, strain can be 
measured in any direction i.e radial, circumferential or longitudinal. Tissue-tagging sequences 
are also utilised to measure the mechanics of left ventricular twisting motion. Typically, the left 
ventricular base rotates clockwise in early systole and apex rotates anti-clockwise later. This 
motion generates maximal force at end-systole[228]. Twist is defined as apical minus basal 
rotation, (measured in degrees). Torsion is a correction taking into account the different lengths 
and diameters of ventricles and so allowing the comparisons of measurements between 
studies[229]. CMR derived left ventricular strain, twist and torsion have good inter-study 
reproducibility[230]. 
 
2.7.4 Phase-contrast imaging 
Blood flow can be quantitatively timed and flow measured using velocity-encoded gradient 
echo imaging (VENC), or phase-contrast imaging. This sequence measures the phase shift of 
hydrogen nuclei as they pass through the magnetic field. The usual clinical utilities of this are to 
qualitatively assess the path of blood flow through cardiac chambers and vessels and to 
quantitatively assess blood flow at pre-specified regions of interest. The common pathologies 
that this is useful for are, but not limited to, cardiac valvular stenoses, regurgitations and 
assessment of shunts. The sequence is also implemented for measurement of aortic pulse-wave 
velocity (PWV), where the timing between peak flows at two regions of interest in the aorta can 
be measured with known distance between them to calculate blood flow at metres per second. 
PWV is a biomarker for arterial stiffness, clinically assessed by applanation tonometry (AT), and 
there is good intra- and inter-observer variability compared to AT. This is also the case for less 
experienced CMR operators using freely available research tools[231]. For VENC image 
measurements, an imaging plane is selected perpendicular to the path of blood flow. A cine is 
formed by creating VENC images for multiple phases of the cardiac cycle. Time-velocity or time-
flow curved can be calculated by post-processing software once a region of interest has been 





2.7.5 Myocardial tissue characterisation 
2.7.5.1 Late gadolinium enhancement imaging  
Gadolinium-based contrast agents, which shorten T1 relaxation times, are of large molecular 
size and exclusively extra-cellular. The length of time it remains in the blood-pool and differing 
tissue types are variable before renal excretion. These properties are utilised for imaging during 
first-pass perfusion and early/late gadolinium enhancement imaging. When there is abnormal 
myocardial tissue, gadolinium kinetics are altered and so the contrast agent persists in the 
tissue, giving lower T1 values. T1 weighted LGE imaging is acquired using an inversion time 
where 'normal' remote myocardium appears normal/black. This is called nulling. Usually, LGE 
images are acquired at least five minutes following contrast[232]. Abnormal myocardium 
therefore appears brighter/white on LGE imaging. 
 
2.7.5.2 T1 Mapping and extracellular volume fraction  
The presence of normal myocardium is needed for effective LGE imaging, therefore diffuse, 
subtle, global processes can be under appreciated and missed. These processes can be 
categorised as 'normal', artefactual or indeed subjective descriptions of 'haze' could be used. 
LGE imaging limitation in diffuse processes may be improved upon with T1 mapping. T1 
mapping allows a pixel-by-pixel point measurement of the T1 relaxation time. Signal is sampled 
at time-points along the tissue recovery curve following an inversion/saturation pulse. The 
time-points are modelled so that the pixel T1 relaxation time can be estimated[233]. This can 
then be encoded into a colour or grayscale image[234]. There are several T1 mapping 
acquisitions and at time of my studies at the University of Leeds, we used a Modified Look-
Locker Inversion Recovery (MOLLI) sequence for acquisition on our Phillips CMR scanners at 
3T[19]. I will go into the MOLLI sequence in some greater detail but other sequences, some 
specific to other vendors, are in use for T1 relaxation time measurement. These include 
Shortened Modified Look-Locker Inversion recovery (ShMOLLI), Saturation recovery single-shot 
acquisition (SASHA) and Saturation Pulse Prepared Heart Rate Independent Inversion Recovery 
(SAPPHIRE). The initial MOLLI sequence was a 3(3b)3(3b)5 scheme and is what is used in my 
studies. This is described in the methods section later. The nomenclature above describes the 
number of samples of the sequence after an inversion pulse (3, 3 and 5, totalling 11) and the 





Native T1, as in T1 relaxation time without presence of gadolinium contrast agent, is more 
prolonged with increasing water content[235]. An increased native T1 is seen in a variety of 
diseases that include acute myocardial infarction and myocarditis of any aetiology[236]. A 
lower native T1 value can be seen in Fabry's and diseases that cause myocardial iron 
deposition, such as haemochromatosis[237]. The specific nature of gadolinium-based contrast 
agents being extra-cellular can be utilised in T1 mapping to provide an estimated calculation of 
extra-cellular volume (ECV) fraction. This can be calculated by using further acquired T1 maps 
following contrast administration. The formula for this requires T1 values of blood pool and the 
subject's haematocrit value. This is described in greater detail in my methods section. As per 
native T1 maps, ECV maps can be created in colour and gray-scale to display the data, rather 
than just take numerical values, once a defined scale is applied. Raised ECV and T1 have been 
correlated to myocardial tissue fibrosis[16] leading to its use as a surrogate in research and 
clinical studies. The danger of this generalisation is that there are other factors that could 
account for differing extra-cellular space and water content that aren't fibrosis i.e. oedema, 
haemorrhage, fat, infiltration, capillary dilation etc. A current issue with T1 is that it is affected 
by scanner field strength, in-homogeneity and the mapping sequence employed. Therefore, 
there are no strict cut-offs for values applicable between vendors, sites and field strengths. The 
requirement of blood sampling may be negated as there is good correlation with synthetic ECV 
calculation using derived haematocrit values[238]. It is imperative that image acquisition 
between native T1 maps and post-contrast T1 maps is as exact as possible to ensure the same 
myocardium is being assessed. Colour/gray-scale maps cannot be fitted if there is movement, 
differing breath-holds or new artefact. 
 
2.7.5.3 T2 imaging 
T2 imaging was not employed for any of my studies and during 2013 and 2015 we were not 
developing sequences with exploratory measures on my studies. I have presented T2 imaging 
briefly here, for completeness of common techniques to describe tissue characterisation and 
awareness of them. As described briefly in the physics summary, T2 imaging is created from 
spin echo sequences. Two major sequences used in clinical applications are turbo spin-echo and 
short-TI triple inversion recovery prepared fast spin echo (STIR)[239]. A brighter signal on T2 




and acute myocardial infarction and correlates with histological specimens[240]. The technique 
is subjective and hampered with higher intra-observer variability, artefacts from slow moving 
blood at the endocardium (giving a higher intensity signal) and field in-homogeneity. There are 
two main areas of quantification of T2 values, T2* mapping and native T2 mapping. T2* is 
shorter than T2, and is more established in clinical practice[241]. It is most clinically useful in 
assessment of myocardial iron loading and correlates with biopsy specimens and improved 
survival when therapy is based on the measurement[242]. There is active sequence 
development in native T2 mapping for development of pixel-by-pixel T2 values, not unlike T1 
mapping. This may help provide less subjectivity and more quantification of any potential 
pathology[243]. 
 
2.7.6 CMR studies in RA 
The following tables present a summary of all the CMR studies in RA. A Pubmed search was 
performed with the keywords; Cardiac, Cardiovascular, CMR, MRI, Rheumatoid. Some studies 
have solely investigated RA and some studies are a mixture of IMID, where RA was one of the 
diseases investigated. Table 2-3 presents the studies that are solely on RA and Table 2-4 
presents studies with a mixture of diseases. 
 
There have not been any randomised control trials for RA therapy using CMR for any endpoints, 
despite the knowledge that fewer numbers are required to power for CV changes on CMR. All 
the studies presented in Table 2-3 and Table 2-4 present patients with established RA disease 
and have a variety of previous therapies including bDMARDs and conventional DMARDs. They 
are mainly cross-sectional heterogeneous RA populations, with a few retrospective and 
prospective studies, however, none are randomised trials or true case-control studies. 
 
CMR is increasingly used to demonstrate subclinical cardiac involvement in IMID[244, 245]. 
Protocols, however, vary and the amount of data describing the disease phenotype is minimal. 
Studies differ in the CMR imaging endpoints as well as recruitment homogeneity of the clinical 
characteristics of the disease population. A larger study of 75 RA patients demonstrated a 
reduced LV mass compared to 225 matched controls, correlating with ACPA titre and use of 
bDMARDs[83]. Smaller studies have shown subclinical changes in myocardial deformational 




that the cardiac abnormalities due to RA appear to be independent and incremental to those 
due to traditional CV risk factors[246] with disease activity scores proposed to be independent 
risk factors for myocardial involvement[247]. Ntusi et al in 2015, utilised T1 mapping CMR 
techniques to demonstrate evidence of diffuse myocardial fibrosis in patients with established 
RA. 39 established RA patients were assessed compared to matched controls with evidence of 
increased myocardial extra-cellular space fraction. Despite the heterogeneous group of 
established RA with respect to medication use and length of disease, impaired LV strain was 
associated with RA disease activity[87]. The use of LGE has demonstrated different patterns of 
enhancement in patients with CCF and RA[125] with presence of LGE also correlating with 
disease activity and disease duration but not qualitative stress perfusion defects[84]. No 
previous trial studies have combined macrovascular, microvascular and detailed myocardial 
assessment by CMR in RA, such that the full potential of CMR for a comprehensive multi-
parametric and quantitative evaluation of CVD in RA has not yet been realised. 
 
The presence of abnormalities by CMR have a wide prevalence and it would be difficult to 
ascertain a true prevalence of sub-clinical CV change given the differences and wide range of 
disease duration, CV symptoms, age and RA therapy. Looking at the 'purpose' column in both 
tables, the questions the community are asking are not being refined and simply collecting 
further large amounts of CMR data with cross-sectional studies does not advance progress 
sufficiently enough to attempt a clinical change and outcome for RA patients. It is time to focus 




Table 2-3 - Summary findings of CMR studies in RA 
Population Year Type  Purpose CVD disease Number CMR details Main findings Ref. 








Asymptomatic 84 female RA 
20 Controls 
LV volumes DAS28 was significantly higher in the conventional DMARD group than in the 
bDMARD group. 
 
conventional DMARD group showed had higher  (by 18%) LVMI and lower 
EF (by 15%). There were no significant differences in LVMI/EF between the 
control and bDMARD groups. 
 
30% of RA patients in conventional DMARD group showed eccentric 
hypertrophy and 4% showed concentric remodelling. The bDMARD group 
showed normal LV morphology. 
 
The LVMI and EF were both significantly correlated with DAS28 (r = 0.545, p 
< 0.001 and r = 0.333, p < 0.002, respectively). The bDMARD group had a 













CVD or CV risk 
factors 




LGE present in 19 (32%) and T2-weighted imaging in 7 (12%). 
 
Higher odds of LGE with each swollen joint (odds ratio [OR] 1.87, P = 0.008), 
each log unit higher CRP level (OR 3.36, P = 0.047), and each log unit higher 
NT-proBNP (OR 20.61, P = 0.009).  
 
NT-proBNP higher (135%) with T2-weighted imaging than in those without 
T2-weighted imaging or LGE. 
 
Higher LVMI and LV remodelling in those with T2-weighted imaging than in 
those without. 
 






Finland 2016 CS CMR in active RA 
without CVD 
Asymptomatic 60 female RA 
21 controls 




With 1.5T, T1 time 1011ms in 20 patients with RA vs. 976ms in 10 control 
subjects (p=0.045). 
 
With 3T CMR, T1 time 1173ms in 29 RA patients vs. 1053ms in 9 control 
subjects (p=0.002). 
 
Myocardial LGE was detected in 55% of the RA patients. 
 
LV ejection fraction averaged 58% vs. 66% (p<0.001) in the RA (n=60) and 
control groups (n=21). 
 
The end-diastolic volumes of either ventricle were enlarged in RA compared 
to the control group (p<0.05 for both). 
 
[250] 
Japan 2016 PC Tocilizumab 







Radial LV strain 
by feature tracking 
DAS28-ESR lower at 52 weeks than at baseline. 
 
Mean peak Err at baseline was lower than in normal subjects (P = 0.03). 




UK 2015 CS Assess 
myocardial 
fibrosis and 













Focal LGE in 46% of RA patients compared with none of the control 
subjects. Focal myocardial edema 10% vs. 0%, higher native T1 values 
(973ms v 961ms; p=0.03), expansion of ECV (30.3% v 27.9%; p<0.001). 
 
LV volumes, mass, and EF similar between RA patients and control subjects. 
Peak systolic circumferential strain (-16.9 v -18.7; p<0.001) and peak 
diastolic circumferential strain rate (83s(-1) v 112s(-1); p<0.001) impaired in 
RA patients. 
 
Myocardial T1 and ECV correlated myocardial strain and RA disease activity. 
 
[252] 








20 controls controls. 
 
TCZ treatment resulted in decrease in disease activity after 52 weeks of 
treatment, paralleling a significant increase in LVEF (+8.2%) and a 
significant decrease in LVMI (-24.4%). 
 
The percentage change in LVMI correlated strongly with the percentage 
change in disease activity (r = -0.63, p=0.0028). 
 
Japan 2014 CS bDMARD (TCZ 
and IFX) and 








Radial LV strain 
by feature tracking 
24, 7, and 10 received MTX, MTX plus IFX, or TCZ, respectively. DAS28 
was higher in the MTX group than bDMARDs (4.5 v 2.9; p=0.002). 
 
Mean peak Err in the MTX group was significantly lower than in the control 
group (p = 0.014). No significant difference in mean peak Err between the 
bDMARDs and the control group (p = 0.424). Mean peak Err was 
significantly higher in the TCZ group than the MTX group (p = 0.036). 
 
Abnormal peak Err in patients with RA was significantly associated with 
longer disease duration (r = –0.69, p=0.001), and was mildly correlated to 
ESR (r = –0.44, p=0.36). 
 
[254] 
Greece 2013 CS CMR in recent 
diagnosis of CCF 










Acute and chronic 
lesions were 
assessed by T2>2 
with positive LGE 
and T2<2 with 
positive LGE, 
respectively. 
4 patterns detected: 
 
Epi/endomyocardial LGE (myocardial inflammation): 33% 
 
Transmural DE (LGE): 22% (all RF+ve) 
 
Dilated cardiomyopathy: 33% (no inflammation/fibrosis present) 
 
Diffuse subendocardial fibrosis: 11% 
 






Japan 2010 CS CMR in RA No clinical 
diagnosis of 
CVD 
18 RA 1.5T 
Stress perfusion 
LGE 
7 had LGE and 2 perfusion defects 
DAS28 higher if had LGE (4.77 vs. 3.44 without, p=0.011). 
Trend for correlation for CRP and ESR with LGE 
[84] 







Mean LV mass lower in RA (18% difference), along with LVEF, CO, SV. 
 










Table 2-4 - Summary findings of CMR studies in immune-mediated inflammatory disease that have included RA 
Population  Year Type Purpose CVD disease Number CMR details Main findings Ref. 
Greece 2017 CS CMR can detect 
occult lesions at 
CTD diagnosis 
Asymptomatic 12 RA 
66 CTD 
1.5T 
Acute and chronic lesions 
were assessed by T2>2 
with positive LGE and 
T2<2 with positive LGE, 
respectively. 
In 9/12 RA, the T2 ratio was higher compared to normal. Myocarditis 
was identified in 1 RA. Diffuse, subendocardial fibrosis in 1 RA patient. 
Subendocardial myocardial infarction in 2 RA patients. 
[255] 
Israel 2016 CS Evaluate aortic 
stiffness in female 
patients with RA 
Asymptomatic. 
Presence of 








Aortic pulse wave velocity 
Mean PWV higher in comparison to controls (6.2 ± 2.3 vs. 5.4 ± 1.7, p = 
0.04). 
 
Aortic distensibility lower (4.4 ± 4.6 vs. 5.8 ± 4.9 kPa(-1) × 10(-3), p = 
0.04). 
 
PWV and age (r = 0.67, p < 0.001), Framingham risk score (r = 0.61, p < 
0.001), waist to hip ratio (r = 0.45, p < 0.001), systolic blood pressure (r 
= 0.37, p = 0.01), diabetes (r = 0.32, p = 0.001) and dyslipidemia (r = 
0.32, p = 0.001). 
[256] 
Greece 2015 CS Imaging patterns of 
CV lesions in 
patients with CTD 









Positive CMR in 1 RA patient 
 
No correlation between disease duration and/or inflammatory indices 
and cardiac lesions was identified 
[257] 
Greece 2014 CS  CMR in CTD with 








Acute and chronic lesions 
were assessed by T2>2 
with positive LGE and 
T2<2 with positive LGE, 
respectively. 
 














Acute and chronic lesions 
were assessed by T2>2 
with positive LGE and 
T2<2 with positive LGE, 
respectively. 
Abnormal CMR identified in 32% and 15% of patients with typical and 
atypical CV symptoms, respectively. 
 
10/10 RA patients had LGE. 3 diff subendocardial, 4 sub-epicardial, 1 
intra-myocardial, 2 transmural. 
[244] 
 




Transthoracic echocardiography remains the cornerstone of first-line testing. There is utilisation 
of carotid ultrasound in current guidelines for an attempt to assess intermediate risk patients, 
in a similar way that CT coronary calcium score has been used in the general, asymptomatic 
population. However, for symptomatic patients and accurate CV assessment, structural and 
functional non-invasive imaging should be utilised. It is recommended that future trials and 
studies adopt a multi-parametric CMR protocol with defined outcomes. This would help assess 
subclinical myocardial and vascular disease, allow lower patient numbers to be recruited given 
the excellent reproducibility and accuracy, and be able to assess multiple CV pathologies in one 
examination and relate them to future hard clinical endpoints and biochemical parameters. 
 
Table 2-5 - The advantages and disadvantages of non-invasive imaging modalities 
 
Adapted from Mavrogeni et al, Heart involvement in rheumatoid arthritis: multimodality imaging and 
the emerging role of cardiac magnetic resonance. Semin Arthritis Rheum. 2013 Dec;43(3):314-24[190]. 
 
 
Table 2-6 - Summary of characteristics of non-invasive functional imaging modalities 
 
Adapted from Mavrogeni et al, Cardiovascular magnetic resonance in rheumatology: Current status and 





3 Thesis aims and hypotheses 
 
Patients with RA have a variety of clinical presentations with overlapping CV pathology that 
need to be recognised by first-line healthcare professionals, cardiology and rheumatology 
teams. The most notable presentation is the earlier and increased incidence of IHD and CCF. 
There is recent formal adoption of RA into the UK CVD risk calculators with QRISK®2 and the 
update of QRISK®3 in 2018. There is support that the use of contemporary medical and 
interventional therapy in cardiac disease is as valuable in patients with RA compared to those 
without but it is with intrigue and anticipation whether we learn that early use of conventional 
DMARDs and bDMARDs significantly alters the risk of developing premature CVD and altering 
CV mortality. 
 
As with RA, GCA is another IMID distinguished by specific pathways of immune-dysregulation 
that lead to inflammation, organ damage and dysfunction[1]. GCA is the commonest primary 
systemic vasculitis affecting older people[4] and, like RA, is associated with an increased early 
mortality mainly due to CVD. There are inflammatory contributions in atherosclerosis from the 
formation of atherosclerotic plaques, the development, the reduction in their stability to the 
final conclusion of rupture and thrombosis. The additional CV mortality that GCA is associated 
with includes aortic syndromes[5]. 
 
Much of the data summarised in my introduction around RA is in patients with established 
disease on a variety of disease-modifying therapy. What has not been adequately answered in 
the literature is precisely when along the RA disease continuum do CV changes start and when 
can they be measured using standard clinical tools. Furthermore, it may be important to realise 
if CV changes are present at the time of diagnosis, when the inflammatory cascade is already in 
force with clinical joint and systemic effects, if they can be modulated with therapy. 
 
The data surrounding aortic change in GCA is hampered with differences in cross-sectional 
imaging modalities, inclusion criteria in studies and definitions of aortic dilatation. The 
prevalence and scale of effect of aortic dilatation is not well documented in the literature by 






The primary aim of this thesis is to characterise subclinical cardiovascular changes by CMR in 
patients with immune-mediated inflammatory disease, namely RA and GCA. The patient 
populations are refined in attempt to answer specific questions about CV change in their 
disease continuums. Namely: 
 
1. The study of CV structural and functional change by CMR in patients with early RA (ERA) 
that have not begun any disease-modifying therapy, in attempt to see if already present 
at diagnosis or not. 
 
2. The study of CV change, specifically of the thoracic aorta, in GCA patients with 
established disease. To contribute data surrounding prevalence of clinically important 
aortic dilatation and aid relevant screening assessment and monitoring. 
 
Furthermore, with the assessment of CV change in ERA, the thesis has further aims in assessing 
if disease-modifying RA therapy modulates any CV changes seen at baseline CMR assessment. 
The studies aim to provide guidance for rheumatologists and reassurance to the patient group 
whether early biologic treatment in patients with early RA can reduce CVD burden - the leading 




The hypotheses in these studies are that, using multi-parametric CMR; 
 
 Subclinical CV pathology exists in patients with early, treatment-naive RA. These data 
will be presented in chapter 5. I hypothesised that patients with ERA would have 
evidence of subclinical CVD compared to healthy controls. 
 
 Early, aggressive control of RA can reduce this subclinical CV pathology at 1 year from 





 TNFi may offer additional benefit over and above conventional DMARD in burden of 
subclinical CV pathology. These data will also be presented in chapter 6. 
 
 GCA patients would have a higher prevalence of thoracic aorta dilatation, both when 
compared to controls without GCA, and when compared to population-derived CMR 
normal ranges. These data will be presented in chapter 7. 
 
3.3 Statistical considerations 
As per recommendations for good practice within pilot studies[260], 30 healthy controls were 
prospectively recruited. Statistical analysis are performed using IBM SPSS Statistics 22.0 (IBM 
Corp., Armonk, NY). Continuous variables are expressed as mean ±SD with normality of 
distribution determined with Kolmogarov-Smirov testing. Categorical variables are expressed as 
N(%) and non-parametric variables as median[inter-quartile range]. Correlation was assessed 
with Pearson’s correlation co-efficient. Differences between groups were evaluated using 
Students t-test for normally distributed data and the Mann-Whitney or Wilcoxon signed-rank 
test on non-parametric data for independent groups and pairwise comparisons respectively. 
The Chi-squared and Fisher-exact tests were used for comparing categories of data. A two sided 
P<0.05 is considered statistically significant. Multivariate linear regression analysis (MVA) is 
used for variables with statistical significance from univariate analysis (UVA) (p<0.1) and CMR 
measurements are adjusted for age, sex and CV risk factors. CV risk factors are defined as: 
hypertension (history of hypertension or anti-hypertensive agent), dyslipidaemia (history of 
dyslipidaemia or on lipid-lowering medication), ever smoked and family history of premature 
CVD (all y/n categories). 
 
Furthermore, with the GCA study, potential predictors of ascending (AsAo) and descending 
aortic (DsAo) diameter within the GCA patients (age, sex and prior diagnosis of atherosclerotic 
vascular disease) and features at onset of GCA ischaemic manifestations, acute-phase markers 
and polymyalgic features) were explored by linear regression in univariable analysis. These 
variables are defined in a previous publication[261]. Features at onset of GCA that were 




atherosclerotic vascular disease) in multivariable linear regression and residuals were plotted to 
assess model fit. 
 
 
I am aware of the limitations of multiple testing, considering a set of statistical inferences 
simultaneously. The more inferences that are made, the more likely an erroneous inference 
may occur. There are several statistical techniques and simple corrections in attempt to prevent 
this from happening, such as Bonferroni and Holm's method. These techniques require a 
stricter significance threshold for individual comparisons, so as to compensate for the number 
of inferences being made. However, there are limitations with statistical correction techniques 
such as Bonferroni. Type I errors cannot decrease (the main point of Bonferroni) without 
increasing type II errors. Type II errors are no less false than type I errors, therefore Bonferroni 
adjustments do not assure a cautious interpretation of data. Several CMR derived CV 
measurements are closely linked in their production, therefore I will carefully report when this 
is present, so as not inflate any potential significant results. 
 
 
3.4 Chapter summaries 
 
Chapter 4 is the methodology of cardiovascular magnetic resonance assessment of 
cardiovascular changes in early Rheumatoid Arthritis and measurement of the effect of early 
biological therapy. Further study design, including the CMR protocol and image analysis, are 
described in detail here. 
 
The results data on this ERA population are presented in chapter 5 and chapter 6. The data 
presented between chapters 5 and 6 are split with respect to the hypotheses of assessing i) the 
presence of sub-clinical CV pathology in early, treatment-naive RA, and ii) the effects of RA 
therapy. 
 
Chapter 5 presents the results of the first component of the RA study and evaluates the 
presence of CV abnormalities in ERA. The CMR findings of a cohort of ERA patients are 




Chapter 5 reports on the entire cohort at baseline and all completed recruitment and data 
analysis under my full-time supervision in the capacity as Clinical Research Fellow in CMR at the 
University of Leeds from 2013. 
 
Chapter 6 presents the second component of the RA study and evaluates if early aggressive 
control of RA can reduce subclinical CV pathology at 1 year from treatment initiation and 
whether tumour necrosis factor inhibitor (TNFi) offers additional benefit over and above 
conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) in the burden of 
subclinical CV pathology. Chapter 6 reports on the interim follow-up analysis on patients that 
had undertaken their 1 year follow up CMR before September 2015, marking the end time-
point of my full-time supervision in the capacity as Clinical Research Fellow in CMR at the 
University of Leeds. Data analysis was undertaken once all the recruited CADERA patients had 
completed their 1 year CMR in November 2016. 
 
In chapter 7, I sought to characterise thoracic aortic structural change in patients with 
established GCA. There were some differences in the CMR sequence protocol between the RA 
studies of chapters 5 and 6 and the GCA study in chapter 7. This is because assessing aortic 
structural change in GCA was the focus, above-and-beyond detailed myocardial change. The 
differences in CMR sequences are described in detail in a separate methods addition in chapter 
7. 
 
Chapter 8 is a summary of the results chapters presented in 5 to 7 with some comments on 








4 Cardiovascular magnetic resonance assessment of 
cardiovascular changes in early Rheumatoid Arthritis and 




The incidence of CVD in RA is increased compared to the general population. Immune 
dysregulation and systemic inflammation are thought to be associated with this increased risk. 
Early diagnosis with immediate treatment and tight control of RA forms a central treatment 
paradigm. It remains unclear however whether using TNFi to achieve remission confer 
additional beneficial effects over standard therapy, especially on the development of CVD. 
 
4.1.1 Methods 
This prospective CV imaging study from the CADERA (Coronary Artery Disease Evaluation in 
Rheumatoid Arthritis) trial bolts onto an existing single-centre, randomised controlled trial, 
VEDERA (Very Early versus Delayed Etanercept in Rheumatoid Arthritis). VEDERA aims to recruit 
120 patients with early, treatment-naïve RA, randomized to TNFi therapy ETN combined with 
MTX or therapy with MTX +/- additional synthetic DMARDs with escalation to ETN following a 
TTT regimen. Patients recruited undertook a comprehensive multi-parametric CMR assessment 
for a complete CV functional and structural assessment including; cine imaging, rest/stress 
adenosine perfusion, tissue-tagging, aortic distensibility, T1 mapping and late-gadolinium 
imaging. The primary objective is to detect the prevalence and change of CV abnormalities by 
CMR between TNFi and standard therapy over a 12 month period. 
 
4.1.2 Discussion 
This chapter describes the methodology for this CMR study describing CV abnormalities in 
early, treatment-naïve RA patients with assessment of changes at 1 year between early 






RA is one of the most common autoimmune diseases affecting approximately 1% of the UK 
population[2]. A chronic, systemic, inflammatory arthritis, if not adequately controlled, RA can 
lead to significant joint damage and subsequent functional impairment.  Mortality is increased 
compared to the general population largely due to increased frequency of premature CVD, 
which constitutes up to 40% of mortality in RA patients[3] and is as high as that of patients with 
other major CVD risk factors such as Type 2 diabetes mellitus[17]. It is accepted that CVD risk in 
RA is independent of, and incremental to, traditional CVD risk factors[18] with the likely 
predominant pathological process being immune dysregulation leading to systemic 
inflammation[19]; although the exact mechanisms remain unclear. The inflammatory process, 
mediated through pro-inflammatory cytokines such as tumour necrosis factor (TNF), is linked to 
atherosclerosis and plaque rupture and has confounding effects on lipid and glucose 
metabolism, blood pressure and haemostatic factors[20]. Markers of RA severity are strongly 
associated with adverse CV (CV) outcomes in RA[21] and reduced time-average disease activity 
is associated with fewer CV events[22]. Atherosclerosis itself being increasingly viewed as an 
inflammatory-mediated process[262]. 
 
Arterial stiffness is associated with an increased risk of CV events with a range of co-
morbidities[23]. In patients with established RA without traditional CV risk factors, aortic pulse 
wave velocity is higher than in controls[24] and correlates with age, mean arterial pressure and 
CRP. Echocardiography studies have shown that patients with RA have high rates of diastolic 
dysfunction[144], heart failure[128, 129] and heart failure with preserved ejection 
fraction[126]. Positron emission tomography (PET) in patients with rheumatic diseases without 
coronary artery disease (CAD) shows lower myocardial blood flow (MBF) reserve compared to 
controls with an inverse correlation to disease duration[211]. In a meta-analysis of 22 studies, 
RA patients had a greater carotid intimal-media thickness (CIMT), a direct measure of the status 
of the vascular wall and measure of atherosclerotic and arteriosclerotic processes[25], than 
controls[26] with emerging evidence that CIMT is abnormal even in early disease[263]. These 
findings are consistent with the concept of microvascular pathology and accelerated 
atherosclerosis due to systemic inflammation in RA, which may precede and contribute to the 





The assessment of left ventricular (LV) mass and geometry provides incremental prognostic 
information regarding CV outcomes[264]. LV hypertrophy (LVH) and concentric geometry has 
been described in established RA echocardiography studies[121] with diastolic dysfunction seen 
in ERA[265]. CMR studies in established RA have conversely shown that patients have reduced 
LV mass and ejection fraction (EF)[83] with lower LV mass associated with seropositivity and 
the use of biological bDMARDs[266]. Recent CMR studies in established RA have found diffuse 
myocardial fibrosis as measured by expansion of the myocardial extra-cellular volume (ECV) 
using CMR T1 mapping[87]. As well as presence of focal fibrosis on CMR, as imaged by late-
gadolinium enhancement (LGE), ECV expansion is associated with poorer outcomes in patients 
with a range of co-morbidities[267]. Without symptomatic cardiac disease, established RA 
patients with higher disease activity scores have been found to have sub-clinical LGE and non-
ischaemic perfusion defect patterns on adenosine stress imaging[84]. 
 
Early diagnosis of RA and immediate intervention with conventional DMARDs in a TTT approach 
with remission the goal of treatment is an internationally recommended, established 
practice[54]. bDMARD treatments, first introduced at the turn of the century, are highly 
effective tools to achieve this and have revolutionised outcomes in RA. TNFi were the first 
bDMARD agents to be introduced. First-line TNFi studies in ERA have demonstrated particularly 
high rates of remission induction, similar or slightly greater than conventional DMARD but with 
superior structural benefits and the ability to achieve drug-free remission[56-62]. TNFi 
treatment has been shown to improve arterial stiffness[63]. In addition, reports have suggested 
wider benefits of bDMARD therapy including reduction in biomarkers associated with CVD[63, 
64]. Recent pilot data have shown that tocilizumab treatment over 1 year significantly 
increased LVEF and decreased LVMI associated with disease activity[266]. 
 
CV clinical trials of TNFi treatments in RA are challenging because under-powering and the small 
number of hard clinical CV mortality endpoints in study populations[111], which also means 
being unable to adjust for important confounders that differentiate between CV events that 
follow other pathophysiological pathways[268]. As TNFi treatment is reserved for patients with 
established, MTX-refractory disease, observational studies are inherently limited by a selection 
bias. Although aggressive treat to target approaches with conventional DMARDs are associated 










4.3.0 Study design 
The CADERA study and experiments bolt on to the VEDERA (Very Early versus Delayed 
Etanercept in Rheumatoid Arthritis) trial, a prospective parallel cohort intervention study of 
patients with ERA, randomly allocated to either first-line TNFi therapy (etanercept, ETN) and 
MTX or optimal synthetic DMARD therapy. VEDERA is an investigator-initiated Research (IIR) 
study based at the Leeds Institute of Rheumatic & Musculoskeletal Medicine and is funded by 
an unrestricted educational grant that is part of an IIR agreement with Pfizer. The aim of 
VEDERA is to assess for the depth of remission (clinical and imaging) and immunological 
normalisation induced by the treatment arms as well as to identify predictors of remission. 
CADERA specifically is reporting on CV changed by CMR assessment. 
 
The patients undergo CMR at baseline (prior to treatment) as well as after 1 year and 2 years of 
treatment. I present the baseline data in chapter 5 and the interim, follow-up results at 1 year 
in chapter 6. Study flow chart is presented in Figure 4-1. 
 
4.3.1 Ethics 
The National Research Ethics Service (NRES) Committee Yorkshire & The Humber – Leeds West 
approved the study protocol and other relevant documentation (Research Ethics Committee 





Figure 4-1 - Study flow diagram 
 
*Etanercept non-responders or intolerance managed at physician’s discretion. #Methotrexate 
for duration of study, addition of other DMARDs at week 8 if not in remission and escalated to 
etanercept at week 24 if not in remission. ~Etanercept discontinued at the primary endpoint 
unless clinically indicated and at physician’s discretion. DAS=disease activity score, 
DMARD=disease modifying anti-rheumatic drug, HRUS=high resolution  ultrasound, LTHT=Leeds 







4.3.2 Enrolment criteria 
Patients eligible for VEDERA were recruited from the Leeds Teaching Hospitals NHS Trust 
Rheumatology service. The recruitment period was between February 2012 until November 
2015. All patients recruited to VEDERA were offered inclusion into the CADERA CMR study. All 
the CMR scans were performed and analysed at Leeds General Infirmary. The study was 
performed in accordance with the Declaration of Helsinki (October 2000), with all patients 
providing informed written consent.  
 
Inclusion criteria: patients diagnosed with RA according to the 2010 ACR/EULAR criteria (Table 
4-1), who have not yet received therapy with DMARDs, have early (symptoms for less than 1 
year) active disease (clinical or imaging evidence of synovitis and DAS28-ESR ≥ 3.2). 
 
Exclusion criteria: previous treatment with DMARDs, known CVD, contraindications to TNFi 
therapy (or severe co-morbidity that would in the clinician’s opinion be associated with 
unacceptable risk of receiving TNFi therapy) and contraindications to CMR, (which include renal 
failure (eGFR<30 ml/min/1.73m2), known allergy to gadolinium-based contrast agents and 
contraindications to adenosine (asthma or high grade heart block)). 
 
As per recommendations for good practice within pilot studies[260], 30 non-RA controls were 
prospectively recruited matched by age/sex to the first 30 ERA patients. Healthy controls were 
sought through existing departmental ethics approval. Interest was received through local 
University of Leeds information bulletins for volunteer recruitment as well as word-of-mouth 









Table 4-1 - The 2010 ACR/EULAR classification criteria for rheumatoid arthritis 
 
JOINT DISTRIBUTION Score 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (large joints not counted) 2 
4-10 small joints (large joints not counted) 3 
>10 joints (at least one small joint) 5 
SEROLOGY  
Negative RF AND negative ACPA 0 
Low positive RF OR low positive ACPA 2 
High positive RF OR high positive ACPA 3 
SYMPTOM DURATION  
<6 weeks 0 
≥6 weeks 1 
ACUTE PHASE REACTANTS  
Normal CRP AND normal ESR 0 
Abnormal CRP OR abnormal ESR 1 
 
A score ≥6 = definite RA. Requires that the patient has at least one joint with definite synovitis 
and that the synovitis is not better explained by another disease. The score may be retrospective 
or prospective. RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibody; CRP, C-reactive 





4.3.3 Outcome measures 
The primary outcome measure for the CADERA trial is aortic distensibility. Aortic distensibility is 
a measure of how much an arterial vessel wall can expand; lower values signify stiffer arteries 
[269]. It is measured and quantified at baseline and at 1 year in each arm of the study. 
Increased arterial stiffness is associated with an increased risk of CV events[23]. It can be 
measured by pulse wave velocity or as distensibility of the aorta. It has shown utility in the 
prediction of CV events in the general population[270].  There are few studies assessing aortic 
distensibility in RA but it appears to be reduced when compared to controls[271, 272]. It has 
previously been shown that aortic distensibility relates to clinical outcome and that TNFi 
improve aortic distensibility[63].  
 
A pilot study was performed in 10 patients with RA (disease duration 20±9.6 years) and 
matched by age and sex to 10 asymptomatic subjects without RA. Aortic distensibility was 
significantly different in RA patients with a mean and standard deviation of 1.83±0.4cm2 versus 
2.6±0.6cm2 in controls. LV volumes and mass were similar between groups and LV strain and 
twist showed trends towards a reduction in RA patients, but without reaching statistical 
significance. Our pilot data therefore suggested CV abnormalities in patients with RA in several 
quantitative CMR parameters with aortic distensibility reaching statistically significant 
difference even in the small sample size. It has previously been shown (with other imaging 
modalities) that aortic distensibility relates to clinical outcome and that TNF alpha blockade 
improves aortic distensibility. From the directly measured aortic area on CMR imaging, AD, 
strain, compliance and stiffness index are further derived and inter-related outcome measures. 
The formulae and image analysis methods are described in this chapter. 
 
Further outcome measures derived directly from CMR image analysis are LV strain, LV twist, 
LV/RV volumes, LV mass and LV myocardial T1 relaxation time. From these directly measured 
outcomes, further data are created including LVEF, LV torsion, LV strain rates, myocardial ECV 
and indexed values to BSA of the above parameters. LGE and qualitative perfusion defects are 
further outcome measures I will be assessing. These outcome measures will be a 





Significant differences (expressed as p<0.05) of CV abnormalities detected by CMR between the 
two treatment arms will be presented and the magnitude of this difference will be expressed as 
a 95% confidence interval. 
 
4.3.4 Sample size calculation 
Powering is based on scaling of effect sizes reported by Ikonomidis et al[64]. We had contacted 
the author and obtained confirmation of the data they presented. Our effect size of 2.46 cm2 
dyne-110-6 represented the smallest detectable difference above measurement error. We 
proposed 2.46 as an effect size in our power calculation (representing 75% of the difference 
between treated and non-treated RA patients of Ikonomidis et al., 2008). 
 
Our pilot and initial patient data  gave a standard deviation of 1.6 from 50 treatment naïve 
patients. The upper limit of a 95% confidence interval for the standard deviation based on 
these data is 2.5 (representing a conservative estimate of the variability in this patient group). 
With a revised standard deviation of 2.5, a 5% significance level in a two-tailed independent 
samples t-test at 90% power, 25 patients would be required per group - biologic therapy versus 
standard conventional therapy - (adjusting for 10% drop-out). 
 
4.3.5 Statistical considerations 
Both treatment arms are compared with primary outcome aortic distensibility from baseline to 
1 year follow up, as well as other outcome measures. As per recommendations for good 
practice within pilot studies[260], 30 non-RA controls were prospectively recruited matched by 
age/sex to the first 30 ERA patients. Statistical analysis are performed using IBM SPSS Statistics 
22.0 (IBM Corp., Armonk, NY). Continuous variables are expressed as mean ±SD with normality 
of distribution determined with Kolmogarov-Smirov testing. Categorical variables are expressed 
as N(%) and non-parametric variables as median[inter-quartile range]. Correlation was assessed 
with Pearson’s correlation co-efficient. Differences between groups were evaluated using 
Students t-test for normally distributed data and the Mann-Whitney or Wilcoxon signed-rank 
test on non-parametric data for independent groups and pairwise comparisons respectively. 
The Chi-squared and Fisher-exact tests were used for comparing categories of data. A two sided 




used for variables with statistical significance from univariate analysis (UVA) (p<0.1) and CMR 
measurements are adjusted for age, sex and CV risk factors. CV risk factors are defined as: 
hypertension (history of hypertension or anti-hypertensive agent), dyslipidaemia (history of 
dyslipidaemia or on lipid-lowering medication), ever smoked and family history of premature 
CVD (all y/n categories). 
 
4.3.6 Missing data 
The numbers of patients with missing data for CMR measurements, and the number of un-
interpretable images, are reported. 
 
4.3.7 CMR investigation details 
Our group has well-established multi-parametric protocols that have been validated in other 
populations[273]. CMR is performed on a dedicated 3T Philips Achieva system equipped with a 
32-channel coil, vectorcardiographic triggering and multi-transmit technology. Patients will be 
asked to avoid caffeine for 24 hours prior to the scan. The CMR protocol (Figure 4-7) lasts 
approximately 60 minutes and comprises: 
 
1. Low resolution survey, reference scans and localisers, Figure 4-2. Following survey and 
reference scans, the heart’s short axis, vertical long axis and horizontal long axis will be defined 
with a series of cine images (balanced steady state free precession acquisition [bSSFP], echo 
time (TE) 1.48ms, repetition time (TR) 3.0ms, flip angle 45o, field of view 320 – 420mm 







Figure 4-2 - Low resolution survey imaging and reference scans 
 
 





2. Baseline T1 mapping. 1 slice will be acquired at the LV short axis using an ECG-triggered 
modified Look-Locker inversion (MOLLI) method, Figure 4-4, to acquire 11 images (3-3-5 
acquisition with 3x R-R interval recovery epochs) in a single end-expiratory breath hold (voxel 






Figure 4-4 - Diagrammatic representation of MOLLI T1 Mapping scheme 
 
A septal region of interest (red contour) will be selected, carefully avoiding blood pool, for T1 
relaxation values. 
 
3. Adenosine stress first-pass myocardial perfusion imaging (spoiled Turbo Gradient Echo, 5x k-t 
Broad-use Linear Acquisition Speed-up Technique (BLAST), 11 training profiles, 
1.31x1.32x10mm³ acquired resolution, pre-pulse delay 100ms, acquisition shot 123ms/slice, 
three short axis slices)[275]. Intravenous adenosine will be administered at 140mcg/kg/min for 
3 minutes under continuous ECG monitoring. Adequate haemodynamic response is assessed by 
either; 
 Heart rate increase by ≥10%; 
 Systolic blood pressure decrease of ≥10mmHg 
 Symptoms attributed to adenosine administration. 
 If there is inadequate haemodynamic response then the dose will be increased to 170 and then 
to 210µg/kg/min for a further 2 minutes until haemodynamic response is achieved. The 
contrast injection will be performed using a dual-bolus technique, by intravenous route in the 
ante-cubital fossa, of 0.1mmol/kg of gadolinium-DTPA (gadopentetate dimeglumine; 
Magnevist, Bayer, Berlin, Germany) for the main bolus preceded by the same volume of a 10% 
dilute contrast agent dose for the pre-bolus, both administered at a rate of 4.0ml/s followed by 





4. Resting wall motion and LV function. Cine image stack covering the entire heart in the LV 
short axis plane at 1 slice per breath-hold in end-expiration and parallel to the mitral valve 
annulus[277, 278] (bSSFP, multiphase, 10-12 contiguous slices, spatial resolution 
2.0x1.63x8mm³, 30 cardiac phases). 
 
5. Tissue tagging for strain analysis and diastology, Figure 4-5. Spatial modulation of 
magnetization (SPAMM) pulse sequence (spatial resolution 1.51×1.57×10mm3, tag separation 7 
mm, ≥18 phases, typical TR/TE 5.8/3.5 ms, flip angle 10°). 
 
Figure 4-5 - Example of a tissue-tagging image. Short-axis of the mid left ventricle. 
 
 
6. Aortic distensibility. Cine images of the ascending aorta (50 phases) at the level of the PA 
bifurcation and the descending aorta, transverse to the vessel according to Lee et al[219]. For 
aortic stiffness, blood pressure and heart rate are recorded immediately prior to the multi-
phase SSFP cine image (24 phases). 
 
7. Resting first-pass myocardial perfusion study. Pulse sequence, slice positioning, and injection 





8. Late gadolinium enhancement (LGE). Performed between 10-15 minutes after step (7). 
Inversion recovery-prepared T1-weighted gradient echo. The optimal inversion time to null 
signal from normal myocardium will be determined using a modified Look-Locker 
approach.[279] Typical parameters: TE 2.0 ms, TR 3.5 ms, flip angle 25o, acquired spatial 
resolution 1.54x1.76x10mm3. Inversion time adjusted according to variable TI scout. Alternate 
heart beat acquisitions by navigator is an option for boor breath holders. Performed in 10-12 
short axis slices with further slices acquired in the vertical and horizontal long axis orientations, 








9. Post contrast T1 mapping 15 minutes following last contrast injection at step (7). Acquisition 
and slice positioning as above in step (2). 
 
T1 mapping, tissue tagging and perfusion imaging are performed in three identical short-axis 
positions. These will be determined using the ‘3-of-5’ approach by acquiring the central 3 slices 






Figure 4-7 - Cardiovascular magnetic resonance protocol 
 





4.3.8 CMR image analysis and reporting 
Image analysis is performed off-line, in a blinded fashion to patient characteristics and 
treatment arm, using commercially available software (cvi42 v4.1.3, Circle Cardiovascular 
Imaging Inc., Calgary, Canada and inTag v1.0, CREATIS lab, Lyon, France) according to 
international standards for reporting of CMR studies. [281] 
 
LV volume and ejection fraction (EF) is calculated from the short axis cine-stack using standard 
criteria to delineate cardiac borders[281]. Regional wall motion in 17 cardiac segments is 
graded visually. 
 
Figure 4-8 - Contouring of the ventricles for volumetric analysis 
 
The yellow contours are of the right ventricle, the red contours are of the left ventricular 





Aortic cross sectional measurements are made by manual planimetry of the endovascular-
blood pool interface, at the times of maximal and minimal distension of the aorta,  
Figure 4-9.  Aortic distensibilty is calculated using non-invasive blood pressure measurements 
taken at the time of image acquisition using the standard formula below and listed in Table 
4-2[282]: 
 
                
      
                     
      
 
 
Figure 4-9 - Measurement of aortic cross sectional area 
 





Table 4-2 - Definitions and formulas of Parameters used in the Assessment of Arterial Stiffness 
 
Parameter Definition Formula 
Aortic Compliance The absolute change in vessel 
diameter (or area) for a given 
change in pressure 
ΔD/ΔP 
Aortic Distensibility The absolute change in vessel 
diameter (or area) for a given 
change in pressure 
ΔD/(ΔPxD) 
Stiffness Index The ratio of the natural logarithm of 




D, diameter; P, pressure; s, systole; d, diastole. Adapted from Oliver, J.J. and D.J. Webb, 
Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler 
Thromb Vasc Biol, 2003. 23(4):p.554-66. 
 
 
Native and post-contrast myocardial T1 will be measured[283]. Care is taken to ensure a 
conservative region of interest and to avoid partial-volume effects from neighboring tissue or 
blood pool. Regions of interest are manually motion corrected as required. The reciprocal of T1 









Strain analysis and LV torsion from the tagging series was derived using the open source 
software Osirix inTag (http://www.osrix-viewer.com) and using the tagged cine series, Figure 
4-10. Endocardial and epicardial contours are drawn by a semi-automated process for each slice. 
Peak circumferential systolic strain and rotation will be calculated for the three short axis slices 
at the level of apex, mid-ventricle and base. LV twist is calculated by subtracting the basal 
rotation from the apical rotation. The method of determining torsion takes the radius and 
length of the heart into account, describing the torsion as the circumferential-longitudinal 
shear angle. This makes the measurement comparable between hearts of different sizes and is 
related to fiber orientation and processes in the myocardium[285, 286]. Basal and apical radius 
is calculated from measuring area by epicardial contours on cine imaging in diastole at the 
same slice location as the tagged images. Base to apex length is determined by subtracting the 









The red region of interest is strain the lateral wall of the left ventricle. The green region of 
interest is strain from the septal wall of the left ventricle. In this example, there is reduced strain 
in the septal wall. 
 
 
Myocardial perfusion is assessed by visual comparison of stress and rest CMR perfusion scans 
(16 segments of the modified 16 segment AHA/ACC model)[287] with scores of 0 (normal), 1 
(equivocal), 2 (non-transmural ischaemia <50%), 3 (non-transmural ischaemia ≥50%), 4 
(transmural ischaemia). 
 
LGE images are analysed visually by 2 experienced observers and any relevant patterns of 
enhancement are described based on a 17-segment model with scores of 0 (no 
hyperenhancement), 1 (1–25% mural thickness), 2 (26–50%), 3 (51–75%), or 4 (>75%) allocated 
to each segment. 
 
4.3.9 Reproducibility 
CMR measurements have been validated in previous reproducibility studies. In our hands, the 
inter- and intra-observer reproducibility for measurement of aortic distensibility by CMR is 
excellent. In a clinical study of 49 volunteers, the intra-observer mean difference for diastolic 
(minimum) aortic volume was 0.009±0.039ml and the mean difference for systolic (maximum) 
aortic volume was 0.0075ml±0.039ml (p=NS). The coefficient of variation (CoV) in the diastolic 
and systolic measurements were 1.4% and 1.1% with an intra-class correlation coefficient (ICC) 
of r=0.998 and r=0.998 respectively[288]. Analysis of tissue tagged CMR images shows an intra-
observer CoV for circumferential strain of 4.3% and 1.2% for LV twist (n=12). Inter-study CoV of 
circumferential strain is 3.7% and 9.6% for LV twist. The ICC shows excellent intra-observer, 
inter-observer, and inter-study reproducibility of circumferential strain ranging from 0.95–0.98. 
The ICC suggested excellent intra-observer and inter-observer interstudy reproducibility (0.97 
and 0.95, respectively) of LV twist and good inter-study reproducibility of LV twist (0.67)[230]. 
In this study, repeated measurements of 12 randomly selected scans, with blinding to the 





4.3.10 Safety and adverse events 
CMR is a standard clinical imaging modality in every day clinical use and risks to the study 
participants are small. Adenosine stress agents carry a small risk of adverse effects including 
transient atrio-ventricular block and bronchospasm. CMR contrast agents carry a low risk of 
allergic reactions (~1:10,000). To avoid the development of nephrogenic systemic fibrosis 
relating to some CMR contrast agents, patients with renal failure and an eGFR of less than 30 
ml/min/1.73m2 will not be recruited. All serious adverse events that occur as a result of the 
CMR will be reported without formal statistical testing being undertaken. 
 
4.3.11 Biomarkers 
As part of exploratory objectives, there is analysis of biomarkers to CMR measurements of CVD. 







Early diagnosis and immediate treatment of new onset, treatment-naive RA is crucial to ensure 
best possible treatment outcomes. Studies demonstrate TNFi agents confer additional 
structural benefit but in particular, may be able to modulate disease progression in a 
proportion of patients. It remains unclear whether use of MTX impedes this potential effect. 
The VEDERA study postulates that first-line TNFi therapy is qualitatively and quantitatively 
superior with better clinical, structural and immunological outcomes when compared with non-
biological DMARDs. This bolt-on study provides a comprehensive CV evaluation of the VEDERA 
population assessing the prevalence and severity of CVD in a treatment-naive patient 
population of new-onset RA with comparison to clinical parameters, such as RA disease 
severity. The study evaluates whether effective RA disease control (remission) can improve CVD 
as assessed by CMR and importantly, whether achieving remission through first-line TNFi offers 
any additional benefit over initial synthetic DMARD-induced remission. The knowledge gained 
from these studies may contribute towards more effective use of targeted therapies for 
patients with RA and improve long-term health-economic benefits. This may be especially 





5 Baseline analysis: Cardiovascular abnormalities exist in 
early rheumatoid arthritis 
 
5.1 Abstract 
5.1.0 Objectives    
Mortality in RA is increased due to increased CVD. CMR can provide assessment of subclinical 
CVD but it is unknown if abnormalities exist in ERA. Our primary objective was to assess arterial 
stiffness, a surrogate marker for increased CVD risk, in ERA. Secondary objectives were to 
determine presence of CV abnormalities. 
 
5.1.1 Methods  
84 ERA patients without history of CVD underwent CMR at 3T. They had RA symptoms <1 year, 
had not received DMARDs and DAS28 ≥3.2. 30 healthy controls were prospectively age/sex 
matched to the first patients recruited. 
 
5.1.2 Results 
Aortic distensibility (AD) was reduced compared to controls (3.35±1.49 versus 4.70±1.95 10-
3mmHg-1, p=0.003) after correction for age/sex and CV risk factors. Descending aortic diameter 
was increased in the ERA group (2.4 ±0.3cm versus 2.6 ±0.4cm, p=0.002). Cardiac structural 
change was evident with lower left ventricular mass/volume ratio (0.56±0.11 versus 
0.6±0.10g/mL, p=0.007) and right ventricular volume (87±17 versus 82±17ml/m2, p=0.036). ERA 
patients had increased myocardial extra-cellular volume fraction (27.4 ±3.5 versus 25.1 ±2.7%, 
p=0.001) and increased early diastolic strain rate (0.67 ± 0.03 versus 0.52 ± 0.15 seconds-1, 
p=0.016). Aortic strain, compliance and stiffness index gave similar results. Higher CRP was 
associated with lower AD (13[29] versus 5[14]mg/L, p=0.027). Increasing CRP was associated 






Abnormalities in vascular function, myocardial tissue composition and ventricular 
geometry/performance are present in ERA, inferring an increased risk of CVD at the earliest 






In established RA, various findings across multiple imaging modalities have supported concepts 
of microvascular pathology and accelerated atherosclerosis due to systemic inflammation[126, 
128, 129, 144]. This may precede and contribute to the effects of coronary artery disease 
(CAD). The current knowledge gap in RA exists in knowing when CV risk increases and when CV 
abnormalities become identifiable. There have been no comprehensive, multi-parametric CMR 
studies of patients with ERA. This is becoming increasingly relevant given strategies of early use 
bDMARDs in attempt to interrupt progression along the RA disease continuum, and thereby the 
additional potential to impact on CV risk in ERA. 
 
5.3 Methods 
This study presents the baseline characteristics of ERA patients recruited to the CADERA trial, as 
described in chapter 4, and compares them to healthy non-RA controls. The methods are 
described in detail in chapter 4. 
 
5.3.0 CMR details 
Image analysis was performed off-line by BE and reproducibility studies were performed in a 
blinded fashion by BE/GF. Abnormal findings were further assessed by AKM and PS, with 
validation subsequently by SP/JPG. Scanning methods, parameters and formulae used are given 
in detail within chapter 4. 
 
5.3.1 Statistical considerations 
In addition to the statistical considerations described in chapters 3 and 4, AD was found to have 
a bimodal shaped distribution within the ERA group. Median AD was 3.21 10-3mmHg-1 falling in 
the trough between these peaks on data exploration. AD was equally dichotomised to a <3.21 








93 ERA patients were invited and 84 ERA patients recruited. 9 were not scanned due to: 
claustrophobia (4); too large body habitus for scanner (2); needlephobia (1); scanner 
malfunction (2), with re-booking falling outside accepted trial timings. Figure 5-1 displays the 
recruitment flow chart. Demographics are presented in Table 5-1. The groups were well-
matched for age and sex (p=0.65 and 0.70 respectively). No study participant had diabetes. 
Smoking was more prevalent in the ERA group (55% versus 30%, p=0.02) but other CV risk 
factors were similar. Rates of CV medication prescription overall and anti-hypertensives were 
similar, however there was increased primary prevention prescription in the healthy non-RA 
control group (anti-platelet and/or statin therapy) (2% versus 13%, p=0.04). 
 







Table 5-1 - Demographic, clinical and RA disease characteristic data 





Age, years 49 ± 13 50 ± 15 0.700 
Female sex; n (%) 57 (68) 19 (63) 0.652 
Weight, kg 73 ± 16 79 ± 17 0.062 
Body mass index, kg/m
2
 25.7 ± 4.5 27.1 ± 5.7 0.149 
Current Smoker; n (%) 17 (20) 4 (13) 0.402 
Ever smoked; n (%) 46 (55) 9 (30) 0.020 
 - Pack Years* 13 ± 13 6 ± 7 0.077 
Hypertension; n (%) 7 (8) 3 (10) 0.721 
Diabetes; n (%) 0 (0) 0 (0) - 
Family history of CVD**; n (%) 2 (2) 2 (7) 0.282 
Hypercholesterolemia; n (%)  3 (4) 2 (7) 0.606 
CV medication; n (%) 9 (11) 6 (20) 0.216 
 - Primary prevention; n (%) 2 (2) 4 (13) 0.041 
 - Anti-hypertensives; n (%) 9 (11) 3 (10) 1.000 
DAS Score, median [IQR] 5.35 [1] - - 
ESR, mm/hr, median [IQR] 30 [33] - - 
CRP, mg/L, median [IQR] 8 [23] - - 
RF; n (%) 61 (73) - - 
ACPA; n (%) 72 (86) - - 
Any seropositivity***; n (%) 76 (91) - - 
 
Data expressed as mean ± standard deviation unless otherwise stated. ACPA, anti-citrullinated 
peptide antibody;  CRP, C-reactive protein; CV, cardiovascular; DAS Score, 3 variable 28 joint 
disease activity score using ESR; ESR, erythrocyte sedimentation rate; IQR, inter-quartile range; 
RA, rheumatoid arthritis; RF, rheumatoid factor;  *Number of cigarettes per day x number of 
years smoked ÷ 20 = pack years; **defined as first degree relative with a history of CVD when 






5.4.1 Arterial stiffness in ERA versus non-RA controls 
There was increased arterial stiffness in ERA with significantly lower AD (3.35 ±1.49 versus 4.70 
±1.95 10-3mmHg-1, p=0.003) after correction for age, sex and presence of CV risk factors (Figure 
5-2, Figure 5-2 and Table 5-2Error! Reference source not found.). Aortic strain, arterial 
compliance and aortic stiffness index gave similar results. Descending thoracic aortic diameter 
was increased in the ERA group (2.4 ±0.3cm versus 2.6 ±0.4cm, p=0.002). On MVA, (Table 5-3), 
increased AD was associated with increasing age (r= -0.686, p<0.001) and male sex (r=0.424, 
p=0.007), presented in Figure 5-3. Despite associations with ESR and CRP on UVA, these did not 
continue to be significant in the regression model (Table 5-3 and Figure 5-3). 
 
 
Figure 5-2 - Aortic distensibility between early RA patients and healthy non-RA controls 
 
 
A; Box and whisker plot of AD between ERA and non-RA controls. B; Transverse images of 





Table 5-2 - Cardiovascular magnetic resonance imaging measurements in all study participants 




Unadjusted P value Adjusted for age, sex and CV risk factors* 






3.35 ± 1.49 
N=83** 
4.70 ± 1.95 0.003 <0.001 1.464 (0.966, 1.961) 
Aortic strain, % 0.17 ± 0.07 0.25 ± 0.09 <0.001 <0.001 0.091 (0.069, 0.113) 
Aortic compliance 12.0 ± 4.3 19.1 ± 7.1 <0.001 <0.001 7.128 (4.939, 9.317) 
Aortic stiffness index, ß 4.1 ± 2.2 2.7 ± 0.84 0.001 <0.001 -1.482 (-2.184, -0.781) 
LV end-diastolic volume indexed, ml/m
2
 80 ± 13 80 ± 11 0.834 0.722 0.891 (-4.054, 5.837) 
LV ejection fraction, % 61 ± 6 62 ± 5 0.308 0.460 0.836 (-1.400, 3.072) 
LV mass indexed, g/m
2
 44 ± 9 49 ± 8 0.004 0.002 5.134 (1.942, 8.326) 
LV mass/volume ratio, g/ml 0.56 ± 0.11 0.62 ± 0.10 0.004 0.007 0.056 (0.016, 0.096) 
RV end-diastolic volume indexed, ml/m
2
 87 ± 17 92 ± 17 0.103 0.036 6.896 (0.471, 13.320) 
RV ejection fraction, % 54 ± 5 54 ± 6 0.790 0.599 -0.609 (-2.902, 1.683) 
Peak systolic strain -0.23 ± 0.03 -0.23 ± 0.02 0.865 0.769 0.001 (-0.008, 0.011) 
Peak systolic strain rate, seconds
-1
 1.14 ± 0.15 1.15 ± 0.12 0.870 0.927 -0.003 (-0.066, 0.060) 
Early diastolic strain rate, seconds
-1
 0.67 ± 0.30 0.52 ± 0.15 0.019 0.016 -0.146 (-0.264, -0.028) 
Late diastolic strain rate, seconds
-1
 1.45 ± 0.34 1.50 ± 0.27 0.430 0.440 0.051 (-0.079, 0.180) 
Peak twist, degrees 15.5 ± 4.0 15.9 ± 4.4 0.646 0.577 0.493 (-1.256, 2.242) 
Torsion, degrees 13.8 ± 3.5 14.9 ± 4.5 0.151 0.151 1.117 (-0.415, 2.648) 
Native T1, ms 1183 ± 41 1202 ± 35 0.026 0.018 20.391 (3.543, 37.239) 
Extra-cellular volume fraction, % 27.4 ± 3.5 25.1 ± 2.7 0.001 0.001 -0.025 (-0.039, -0.011) 
Presence of LGE; n (%) 
8 (11) 
N=76 
1 (3) 0.440 0.117 -0.097 (-0.220, 0.025) 
Descending aortic diameter, cm 2.6 ± 0.4 2.4 ± 0.3 0.002 0.002 0.096 (0.036, 0.156) 
Qualitative stress perfusion defect; n (%) 
0 (0) 
N=71 
0 (0) - - - 
 
Data expressed as mean ± standard deviation unless otherwise stated. CV, cardiovascular; RA, rheumatoid arthritis; CV, cardiovascular; LGE. 
Late-gadolinium enhancement; LV, left ventricular. *CV risk factors defined as: hypertension (history of hypertension or anti-hypertensive 
agent), dyslipidaemia (history of dyslipidaemia or on lipid-lowering medication), ever smoked and family history of premature CVD. **One 






















ACPA, anti-citrullinated peptide antibody;  CRP, C-reactive protein; CVD, cardiovascular disease; DAS Score, 3 variable 28 joint disease activity 
score using ESR; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; *defined as first degree relative with a history of CVD when 60 



























Current Smoker 0.052 
0.190 
(-0.623, 1.002) 








Family history of CVD* -0.110 
-1.070 
(-3.197, 1.058) 




0.386   
































Any seropositivity** 0.104 
0.522 
(-0.584, 1.628) 













5.4.2 Arterial stiffness versus RA disease activity markers and traditional CV 
risk factors 
AD was found to have a bimodal shaped distribution (Figure 5-4). Median AD was 3.21 10-
3mmHg-1 falling in the trough between these peaks on data exploration. AD was equally 
dichotomised to a <3.21 and a ≥3.21 group. These data are shown in Table 5-4. Importantly, 
none of the demographic, clinical and RA disease characteristics had a bimodal distribution. 
Increased CRP was found in the lower AD group (median[IQR] 13[29] versus 5[14]mg/L, 
p=0.027) along with increasing age, male sex, hypertension and smoking. ERA patients with 











Line of best fit overlying the frequency histogram. The dashed central line represents the 




Table 5-4 - Demographic, clinical and RA disease characteristic data between high and low AD groups within ERA 
Characteristic AD < 3.21 
N=42 
AD ≥ 3.21 
N=41 
P Value 
Age, years 57 ± 9 41 ± 12 <0.001 
Female sex; n (%) 20 (48) 36 (88) <0.001 
Weight, kg 77 ± 16 68 ± 14 0.006 
Body mass index, kg/m
2
 26.7 ± 4.4 24.6 ± 4.5 0.038 
Current Smoker; n (%) 8 (19) 9 (22) 0.743 
Ever smoked; n (%) 28 (67) 18 (44) 0.037 
Pack Years* 13 ± 13 15 ± 14 0.847 
Hypertension; n (%) 6 (14) 0 (0) 0.026 
Family history of CVD**; n (%) 2 (5) 0 (0) 0.494 
Hypercholesterolemia; n (%)  2 (5) 1 (3) 1.000 
CV medication; n (%) 6 (14) 2 (5) 0.265 
 - Primary prevention; n (%) 2 (5) 0 (0) 0.494 
 - Anti-hypertensives; n (%) 6 (14) 2 (5) 0.265 
DAS Score, median [IQR] 5.38 [1.60] 5.30 [1.28] 0.689 
ESR, mm/hr, median [IQR] 31 [42] 28 [27] 0.353 
CRP, mg/L, median [IQR] 13 [29] 5 [14] 0.027 
RF; n (%) 28 (67) 32 (78) 0.247 
ACPA; n (%) 33 (79) 38 (93) 0.068 
Any seropositivity***; n (%) 36 (86) 75 (90) 0.265 
 
Data expressed as mean ± standard deviation unless otherwise stated. ACPA, anti-citrullinated peptide antibody;  AD, aortic distensibility; CRP, C-
reactive protein; CV, cardiovascular; DAS Score, 3 variable 28 joint disease activity score using ESR; ERA, early RA; ESR, erythrocyte sedimentation 
rate; IQR, inter-quartile range; RA, rheumatoid arthritis; RF, rheumatoid factor;  *Number of cigarettes per day x number of years smoked ÷ 20 = 
pack years; **defined as first degree relative with a history of CVD when 60 years old or younger if female, and 55 years old or younger if male; 




5.4.3 Arterial stiffness versus other CMR characteristics 
On UVA analysis, a number of CV changes were present between the higher and lower AD 
groups. Lower AD had higher LV mass (47 ±10 versus 42 ±7g/m2, p=0.023) and impaired peak 
systolic strain (-0.22 ±0.03 versus -0.24 ±0.02, p=0.011) and strain-rate. Diastolic strain rate was 
also lower in the low AD group. Once corrected to age, sex and CV risk factors only myocardial 










Table 5-5 - CMR measurements between high and low AD groups within ERA 
CMR measurements 
AD < 3.25 
N=42 




Adjusted for age, sex and CV risk factors 
P value Mean difference (95% CI) 
LV end-diastolic volume indexed, ml/m
2
 78 ± 12 83 ± 14 0.083 0.138 5.262 (-1.731, 12.256) 
LV ejection fraction, % 60 ± 6 62 ± 5 0.098 0.343 1.517 (-1.649, 4.683) 
LV mass indexed, g/m
2
 47 ± 10 42 ± 7 0.023 0.791 -0.578 (-4.894, 3.739) 
LV mass/volume ratio, g/ml 0.60 ± 0.11 0.50 ± 0.08 <0.001 0.154 -0.038 (-0.090, 0.014) 
RV end-diastolic volume indexed, ml/m
2
 84 ± 17 90 ± 15 0.103 0.181 5.769 (-2.743, 14.281) 
RV ejection fraction, % 54 ± 5 54 ± 5 0.642 0.254 -1.724 (-4.708, 1.261) 
Peak systolic strain -0.22 ± 0.03 -0.24 ± 0.02 0.011 0.350 -0.007 (-0.021, 0.008) 
Peak systolic strain rate, seconds
-1
 1.11 ± 0.15 1.17 ± 0.14 0.036 0.404 0.039 (-0.053, 0.131) 
Early diastolic strain rate, seconds
-1
 0.61 ± 0.27 0.72 ± 0.32 0.091 0.724 0.033 (-0.153, 0.219) 
Late diastolic strain rate, seconds
-1
 1.36 ± 0.03 1.54 ± 0.38 0.019 0.704 -0.036 (-0.226, 0.153) 
Peak twist, degrees 16.1 ± 3.9 14.9 ± 4.02 0.166 0.344 -1.134 (-3.509, 1.241) 
Torsion, degrees 14.5 ± 3.6 13.1 ± 3.3 0.085 0.724 -0.344 (-2.276, 1.589) 
Native T1, ms 1169 ± 46 1198 ± 28 0.001 0.049 23.456 (0.075, 46.837) 
Extra-cellular volume fraction, % 26.6 ± 3.2 28.2 ± 3.7 0.038 0.011 0.027 (0.006, 0.048) 






0.719 0.669 0.041 (-0.151, 0.233) 
 
Data expressed as mean ± standard deviation unless otherwise stated. CV, cardiovascular; RA, rheumatoid arthritis; CV, cardiovascular; LGE. 
Late-gadolinium enhancement; LV, left ventricular. *CV risk factors defined as: hypertension (history of hypertension or anti-hypertensive 
agent), dyslipidaemia (history of dyslipidaemia or on lipid-lowering medication), ever smoked and family history of premature CVD. **One 








5.4.4 Cardiac structure and function in ERA 
LV mass was significantly lower in the ERA group, in absolute values and when corrected to 
body surface area (BSA) (44 ±9 versus 49 ±8 g/m2, p=0.002). LV mass/volume ratio takes into 
account the LV end-diastolic volume (EDV) and the difference in LV mass was further shown 
with a lower LV mass/volume ratio (0.56 ±0.11 versus 0.62 ±0.10 g/mL, p=0.007). In the right 
ventricle (RV), the EDV, also indexed to BSA, showed a smaller cavity size in ERA (87 ± 17 versus 
92 ± 17 ml, p=0.036) although remained within normal CMR nomograms. 
 
Systolic performance, assessed by LV and RV ejection fraction, was not significantly different 
between ERA and controls (Table 5-2). LV peak systolic strain and strain-rate were also similar. 
Several measures of diastology were assessed and early diastolic strain rate showed a 
significant difference compared to controls (0.67 ±0.03 versus 0.52 ±0.15 seconds-1, p=0.016). 
 
71 of the 84 ERA patients underwent adenosine stress first-pass myocardial perfusion imaging 
to look for stress-induced hypoperfusion. All patients were offered to undergo this but 13 
declined to have a symptom-inducing measurement performed. Qualitative visual analysis of all 
101 participants who completed the imaging revealed no evidence of reversible ischaemia 
indicative of silent flow-limiting CAD. 
 
Native myocardial T1 relaxation time and extra-cellular volume (ECV) fraction were both 
significantly different between ERA and controls (Table 5-2). There was increased ECV in ERA 
(27.4 ±3.5 versus 25.1 ±2.7%, p=0.001) with colour mapping showing a diffuse process (Figure 
5-6). 8 patients did not have appropriate LGE imaging due to: scanner malfunction; image 
degradation; and patient wanting to cease test due to length of time. Hyperenhancement by 
LGE imaging was seen more in ERA than controls but not to significance (8 (11%) versus 1 (3%), 
p=0.117). The hyperenhancements seen were focal non-ischaemic patterns and distributed as 







Figure 5-6 - Myocardial tissue composition between early RA patients and non-RA controls 
 
A; Box and whisker plot of Native T1 and extra-cellular volume (ECV) fraction between early RA 
and non-RA controls. B; Short-axis left-ventricular ECV maps at the mid-ventricle showing 
diffusely increased ECV in early RA compared to non-RA control. 
 






Figure 5-8 - Late-gadolinium enhancement in ERA patient 
 
Panel A, Mid ventricular short axis LGE image; Panel B, 3-chamber LGE image. 





5.4.5 RA disease activity markers and traditional CV risk factors 
T1, ECV, RVEDV indexed to BSA, LV Mass/LVEDV, Torsion and peak systolic strain were analysed 
in a MVA (Table 5-6, Table 5-7 and Table 5-8). These measurements were significantly different 
compared to control and/or previously described in established RA populations[64, 83, 84, 87]. 
The DAS score did not correlate with any CV abnormalities (Table 5-3, Table 5-4, Table 5-6, 
Table 5-7, Table 5-8 and Figure 5-11). RF and ACPA also did not correlate with any CV 
abnormalities; whether assessed within the whole ERA group or when seropositive only 
subjects were analysed. There was a trend, that didn’t reach statistical significance, for 
increasing ESR and increased ECV (r=0.197, p=0.080) (Figure 5-9 and Table 5-6). Increasing CRP 
did correlate with reduced peak systolic strain (r=0.250, p=0.038, Figure 5-10).  
 
Age was a powerful factor in multiple CV abnormalities (Figure 5-12, Table 5-3, Table 5-6, Table 
5-7 and Table 5-8). Increasing age was associated with lower native T1 (r=-0.374, p=0.002), 
lower AD (r=-0.686, p<0.001), lower RVEDV-i (r=-0.314, p=0.003) and higher LVM/LVEDV 
(r=0.439, p=0.008). Traditional CV risk factors were associated with further CV abnormalities 
and were more powerful than RA disease activity markers after MVA (Table 5-3, Table 5-6, 
Table 5-7 and Table 5-8). Male sex correlated with lower AD (r=0.424, p=0.011) and higher LV 
mass (LVM/LVEDV, r= -0.412, p=0.007). Hypertension was associated with higher LVM/LVEDV 
(r=0.416, p=0.012) and increased LV torsion (r=0.317, p=0.005).  Increased smoking pack years 
was also associated with increased LV torsion (r=0.327, p=0.012). These are shown as box-an-





Figure 5-9 - Scatter plot of erythrocyte sedimentation rate and myocardial extra-cellular volume 
 


































































Current Smoker -0.069 
-3.089 
(-13.166, 6.988) 




Ever smoked -0.047 
-3.826 
(-22.095, 14.442) 




Pack Years -0.214 
-0.685 
(-1.615, 0.244) 











Family history of CVD -0.003 
-0.878 
(-59.284, 57.528) 











Any CV risk factor -0.086 
-7.098 
(-25.552, 11.356) 










































Any seropositivity 0.163 
21.951 
(-8.039, 51.942) 





































































Current Smoker -0.058 
-2.399 
(-11.463, 6.665) 
0.600   -0.084 
-0.022 
(-0.080, 0.036) 
0.447   
Ever smoked -0.063 
-2.089 
(-9.404, 5.225) 
0.571   0.099 
0.021 
(-0.025, 0.068) 
0.370   




















Family history of CVD -0.013 
-1.399 
(-25.324, 22.525) 










0.104   0.131 
0.075 
(-0.050, 0.199) 
0.236   
Any CV risk factor -0.146 
-4.959 
(-12.348, 2.430) 







DAS Score -0.065 
-7.49 
(-3.287, 1.789) 
0.559   0.078 
0.006 
(-0.010, 0.022) 









































Any seropositivity -0.157 
-8.855 
(-21.128, 3.418) 
0.155   -0.150 
-0.054 
(-0.133, 0.024) 




Table 5-8 - Univariate and multivariate analysis of variables with LV Torsion and peak systolic strain 
Characteristic 
Torsion Peak Systolic Strain 

















































Current Smoker -0.134 
-1.158 
(-3.106, 0.791) 
0.240   0.036 
0.002 
(-0.012, 0.017) 
0.750   
Ever smoked 0.086 
0.599 
(-0.977, 2.174) 
0.451   0.037 
0.002 
(-0.010, 0.014) 
0.745   






















0.958   
Family history of CVD -0.075 
-1.657 
(-6.673, 3.360) 

















Any CV risk factor 0.059 
0.419 
(-1.181, 2.018) 
0.604   0.138 
0.007 
(-0.005, 0.019) 
0.226   
DAS Score -0.010 
-0.024 
(-0.560, 0.512) 
0.930   0.153 
0.003 
(-0.001, 0.007) 




0.993   0.114 
0.000 
(0.000, 0.000) 














0.112   -0.011 
-0.001 
(-0.014, 0.013) 










0.515   
Any seropositivity -0.035 
-0.401 
(-3.019, 2.217) 
0.761   -0.108 
-0.009 
(-0.029, 0.010) 






Our Intra-observer and inter-study variability for AD, LV twist and strain are previously 
described[289]. 12 randomly selected studies, blinded to BE/GF, were selected for 
reproducibility of aortic and T1 measures. I wanted to repeat aortic reproducibility in my study 
given the fact it is the primary outcome. We have not published reproducibility of T1 
measurements and so this was also assessed. There was excellent intra-observer variability. The 
intra-observer mean difference for diastolic aortic area was 0.033 ±0.101cm2 and the mean 
difference for systolic aortic area was 0.037 ±0.124cm2 (P=NS). The coefficient of variation (CoV) 
in the diastolic and systolic measurements were 1.7% and 1.9%, with an intra-class correlation 
coefficient (ICC) of r=0.999 and r=0.998, respectively. CoV for T1 measurement was also 






5.5.0 Arterial stiffness 
Increased inflammation has been measured in the carotid artery in ERA[290] using PET-CT and 
several studies have shown increased arterial stiffness in established, heterogeneous RA 
populations[24, 64, 256]. We have not previously known how soon the increased CV risk occurs 
in RA and when CV abnormalities become apparent and measureable. A 2015 systematic 
review showed increased arterial stiffness was present in early-stage disease but this was based 
on small numbers with various definitions of ERA; ranging from <1 year to 6 years[291]. We 
have shown that increased arterial stiffness, a surrogate marker for increased CV risk[23], is 
present at the earliest stages of RA. Increasing age and male sex were strongly associated with 
increased arterial stiffness. The bimodal distribution of AD was not expected and the 
dichotomised grouping of high and low AD found that the major CV risk factors of smoking, 
male sex, raised BMI and hypertension were associated with higher arterial stiffness. Increased 
biochemical evidence of inflammation, by measure of higher CRP, was found in lower AD group. 
The DAS score remained similar, without correlation in a wide range of CV changes, which 
suggests that the joint symptom severity of RA clinically is not important for the presence of CV 
abnormalities in ERA; but the presence of RA, traditional CV risk factors and serum 
inflammatory marker levels are. 
 
5.5.1 Myocardial tissue composition 
A focal and significant area of myocardial tissue change is required before appearance of LGE 
on CMR imaging. Several studies in established RA have shown an increase in LGE[267] and 
positively correlated its presence with CRP/ESR and disease activity[125] but not qualitative 
stress perfusion defects[84]. Although increased compared to controls, we did not find a 
significant difference in LGE. We would not expect to observe a significant amount of LGE in 
ERA, given that cellular insult may require chronicity prior to scarring, but it is interesting to see 
a trend. The expansion of ECV by T1 mapping infers a change in myocardial tissue composition. 
Fibrosis, inflammation and cardiac cell alteration/apoptosis may all increase ECV; with 




ERA, albeit small, was unexpected. If the mechanism for ECV expansion is purely inflammation 
driven, then the higher myocardial water content would increase T1 relaxation. Tissue change 
to alter ECV may be by other undetermined mechanisms in ERA rather than just myocardial 
inflammation. These mechanisms are discussed in greater detail in the discussion section of 
chapter 6. As a new technique gaining ground in a variety of cardiac disease, only two previous 
studies have performed T1 mapping and ECV quantification in RA. Both studies are quite small 
in number. Ntusi et al in 2015 also found ECV expansion in established RA with median disease 
of 7 years and ongoing disease activity[87]. Interestingly, despite a heterogeneous RA 
population of N=39, it was found that DAS correlated well with ECV/T1 and subclinical cardiac 
performance markers. Greulich et al in 2017 studied 20 established RA patients with a range of 
therapies and disease activity and found higher native T1, ECV and T2 values but with no 
correlation to disease activity[292] in contrast to Ntusi et al. In this study, we found no 
correlation between DAS and tissue composition but only a subtle correlation to ESR. It may be 
that chronicity is required before these associations become apparent.  
 
5.5.2 Cardiac structure & function 
Established RA is associated with different LV structural change with recent CMR studies 
showing reduced LV mass, as well as LVEF[83]. We were surprised to see that LV structural 
change was already present in ERA. LV mass was lower compared to controls. Increasing mass 
was, unsurprisingly, associated with increasing age, history of hypertension and male sex. 
Recent smaller ERA studies have shown subclinical impairment of systolic[202] and diastolic 
dysfunction[265]. As expected in such early disease, and in keeping with these smaller studies 
in ERA, we did not find any overt reduction in systolic performance as assessed by LV and RV EF. 
Unlike these TTE studies, our CMR data did not find a reduction in subclinical systolic function 
parameters. Within the ERA group, increasing CRP was associated with reduced LV systolic 
strain, similarly to other CMR studies[87] in established RA. Diastolic dysfunction can also result 
in the clinical syndrome of heart failure and has been described in RA populations by TTE[141, 
142]. Early diastolic strain rate was increased and may imply early relaxation change. Whereas, 
no traditional CV risk factors were associated LV strain, increased LV torsion was associated 




associated with subendocardial fibre/microvascular dysfunction in ERA when these patterns are 
analysed to LV torsion mechanics[229]. 
 
5.6 Limitations 
Invasive coronary arteriography to exclude CAD was not performed or appropriate in 
asymptomatic patients and healthy controls. Stress perfusion imaging was carried out to 
exclude significant silent ischaemia. For the same reason of appropriateness and risk, 
myocardial biopsy was not performed to confirm increased ECV. ECV measured by CMR has 
been validated against histology in other disease processes[293]. Longitudinal tagging, pulse-
wave velocity, atrial volumes, T2-imaging and feature-tracking were not assessed and so could 
not be compared to other CMR studies where they have been employed, as well as previous 
TTE studies where some measurements are methodically similar. This is because the scanning 
protocol to include measurements we have presented was already long in duration and 
recruitment in this well-defined population was paramount to increase uptake into the study 
and limit drop-out for follow-up CMR scans if patients had a negative experience. The analysis 
was not blinded to the presence or absence of RA; however analysis was blinded to treatment 
arm within the CADERA trial as a whole. Reproducibility was performed with randomly selected 
studies that were blinded to the observer and showed excellent CoV and ICC. We did not 
measure serum biomarkers of myocardial injury, including troponins and B-natriuretic peptides, 
in the ERA group or controls. Furthermore, previous medical history was taken from the 
patients’ records rather than re-confirmation of diagnoses of hypercholesterolemia, diabetes 






This is the first CMR study of treatment-naive ERA, and one of the largest CMR studies in RA to 
date. We demonstrate that arterial stiffness is present in ERA. Diffuse myocardial change, by 
measure of ECV and native T1, is present in ERA along with early changes in biventricular 
geometry. This highlights presence of CV abnormalities and infers increased CV risk at the 
earliest stages of the disease process. There are associations with RA activity markers; however 
traditional major risk factors continue to be more powerful. Further investigation will 
determine the natural history, including which effective therapies can modulate these 




6 Interim follow up analysis: Early aggressive control of 
Rheumatoid Arthritis reduces subclinical cardiovascular 




The incidence of CVD in RA is increased compared to the general population. Immune 
dysregulation and systemic inflammation are thought to be associated with this increased 
risk. Early diagnosis with immediate treatment and tight control of RA forms a central 
treatment paradigm. It remains unclear however whether using TNFi to achieve remission 
confer additional beneficial effects over standard therapy, especially on the development of 
CVD. This chapter presents the interim follow up results and analysis of the CADERA 
randomised controlled trial. 
 
6.1.1 Methods 
The methods are described in chapter 4: CMR for the assessment of CV changes in patients 
with ERA and to measure the effect of early biological therapy. Patients included in this 
interim follow-up analysis had undertaken their 1 year follow up CMR before September 
2015, marking the end time-point of my full-time supervision in the capacity as Clinical 
Research Fellow in CMR at the University of Leeds. Data analysis was undertaken once all 
the recruited CADERA patients had completed their 1 year CMR in November 2016. 
 
6.1.2 Results 
51 patients had successfully completed baseline and 1 year CMR studies by September 
2015. Both treatment arms had similar baseline clinical characteristics and CMR 
measurements. There was improved aortic stiffness in both groups, to the point where they 
became similar to non-RA controls at 1 year follow up. Patients who had improved their AD 
the most began with higher baseline CRP and myocardial ECV. LV mass increased in both 




ratio returned to being similar to controls with biological therapy whereas these changes 
were not as apparent in the MTX TTT regimen group. 
 
6.1.3 Conclusion 
CV abnormalities that are present in ERA can be modulated, improved and measured after 1 
year of disease modifying therapy using a MTX TTT regimen or early biological therapy with 
etanercept. Early biological therapy with etanercept, over a MTX TTT regimen, appears to 






6.2.0 Recruitment for interim follow-up analysis 
Patients included in this interim follow-up analysis were all ERA patients recruited into the 
CADERA trial until September 2015. I was a Clinical Research Fellow in CMR at the University 
of Leeds involved in the trial management until September 2015, then returning to a 
Cardiology clinical training programme after my allocated out of programme research time 
ended. Therefore, the interim follow-up analysis was of patients up to this time-point with 
the remaining analysis performed by the current trial team after final patient follow-up in 
November 2016. Un-blinding of patient treatment arm for this interim follow-up analysis did 
not occur until after all the CADERA patients had completed their 1 year follow up scan and 
had completed analysis, so as to not compromise or bias remaining data analysis. 
 
 
6.2.1 CMR protocol and data analysis 
This has been described in detail within Chapter 4. There were no CMR protocol changes 
throughout the study. 
 
 
6.2.2 Statistical considerations 
This has been described in detail within Chapter 3, 4 and 5. There were no changes in 
proposed statistical analysis. Within the follow up groups, further dichotomisation occurred 
in the final analysis to see if there were signals at baseline for patients that had improved 








At time of this interim analysis of the CADERA study, 51 patients had successfully completed 
baseline and 1 year follow up CMR studies between February 2012 and September 2015. 
Taking into account the revised statistical considerations and sample size alterations, for the 
primary outcome of aortic distensibility this interim analysis does surpass the minimum of 
25 patients per group to maintain a 90% power at 5% significance level. 
 
6.3.1 Demographics between treatment arms 
Baseline demographic, clinical and RA disease characteristics are given in Table 6-1. There 
were 25 patients in the group 1 treatment arm (initial biological therapy with etanercept) 
and 26 patients in the group 2 treatment arm (MTX TTT regimen). Age, sex, BMI, BSA and RA 
disease characteristics were not significantly different between the 2 groups. CVD risk 
factors were also similar apart from previous history of smoking, where group 2 had a 
higher percentage of ‘ever smoked’ compared to group 1 (65% versus 28%, p=0.007). 
However, total smoking pack years and current smoking status was not statistically 
different. Overall, the randomisation of the RA patients into the 2 treatment arms has not 







Table 6-1 - Baseline demographic, clinical and RA disease characteristic data 









Age, years 49 ± 13 48 ± 12 49 ± 14 0.808 
Female sex; n (%) 36 (71) 15 (60) 21 (81) 0.104 
Body mass index, kg/m
2
 25.7 ± 4.4 25.7 ± 4.5 25.7 ± 4.4 0.968 
Body surface area, m
2
 1.8 ± 0.2 1.9 ± 0.2 1.8 ± 0.2 0.569 
Current Smoker; n (%) 8 (16) 2 (8) 6 (23) 0.248 
 - Ever smoked; n (%) 24 (47) 7 (28) 17 (65) 0.007 
 - Pack Years* 14 ± 12 9 ± 6 16 ± 13 0.228 
Hypertension; n (%) 3 (6) 1 (4) 2 (8) 1.000 
Family history of CVD**; n (%) 3 (6) 1 (4) 2 (8) 1.000 
Hypercholesterolemia; n (%)  3 (6) 1 (4) 2 (8) 1.000 
DAS Score 5.8 ± 1.7 6.0 ± 2.1 5.6 ± 1.1 0.314 
ESR, mm/hr 36 ± 28 34 ± 27 38 ± 29 0.609 
CRP, mg/L 19 ± 29 21 ± 34 17 ± 23 0.612 
RF; n (%) 38 (75) 16 (64) 22 (85) 0.091 
ACPA; n (%) 43 (84) 19 (76) 24 (92) 0.140 
Any seropositivity***; n (%) 44 (86) 20 (80) 24 (92) 0.248 
 
Data expressed as mean ± standard deviation unless otherwise stated. ACPA, anti-
citrullinated peptide antibody;  CRP, C-reactive protein; CV, cardiovascular; DAS Score, 3 
variable 28 joint disease activity score using CRP; ESR, erythrocyte sedimentation rate; IQR, 
inter-quartile range; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; 
TTT, treat-to-target regimen. *Number of cigarettes per day x number of years smoked ÷ 20 
= pack years; **defined as first degree relative with a history of CVD when 60 years old or 






6.3.2 Baseline CMR measurements between treatment arms 
A baseline comparison was performed between the two treatment arms to see if there were 
any CV changes present between them at randomisation. The complete dataset is presented 
in Table 6-2. Importantly, the primary outcome measure of AD was similar between group 1 
and group 2 (3.2 ±1.8 versus 3.2 ±1.5 10-3mmHg-1, p=0.943). Biventricular structure, function 
and geometry were not different and measures of tissue composition by T1, ECV and LGE 
were also not statistically different. Overall, the randomisation of the RA patients into the 2 
treatment arms hasn’t resulted in statistically different groups with respect to CMR 




Table 6-2 - Baseline CMR measurements between the two treatment arms 







LV end-diastolic volume, ml 150 ± 31 149 ± 36 0.909 
LV end-diastolic volume indexed, ml/m
2
 80 ± 13 81 ± 14 0.909 
LV ejection fraction, % 60 ± 5 60 ± 6 0.722 
LV mass, g 81 ± 20 79 ± 25 0.772 
LV mass indexed, g/m
2
 43 ± 9 42 ± 9 0.754 
LV mass/volume ratio, g/ml 0.54 ± 0.09 0.53 ± 0.12 0.726 
RV end-diastolic volume, ml 163 ± 43 157 ± 43 0.651 
RV end-diastolic volume indexed, ml/m
2
 87 ± 18 85 ± 16 0.709 
RV ejection fraction, % 53 ± 5 55 ± 6 0.163 
Peak systolic strain, apical LV -0.25 ± 0.03 -0.25 ± 0.04 0.672 
Peak systolic strain, mid LV -0.23 ± 0.02 -0.22 ± 0.03 0.646 
Peak systolic strain, basal LV -0.21 ± 0.03 -0.21 ± 0.03 0.997 
Peak systolic strain rate, seconds
-1
 1.11 ± 0.20 1.15 ± 0.10 0.486 
Early diastolic strain rate, seconds
-1
 0.61 ± 0.25 0.58 ± 0.25 0.714 
Late diastolic strain rate, seconds
-1
 1.34 ± 0.33 1.46 ± 0.32 0.257 
Torsion, degrees 13.5 ± 2.4 13.7 ± 3.2 0.881 
Native T1, ms 1176 ± 41 1179 ± 48 0.864 
Extra-cellular volume fraction, % 27.4 ± 4.3 27.7 ± 3.3 0.784 
Presence of LGE; n (%) 2 (9) 3 (12) 1.000 
Aortic strain, % 15.5 ± 7.2 15.9 ± 4.3 0.827 
Aortic compliance 11.4 ± 5.0 11.6 ± 4.3 0.914 





 3.2 ± 1.8 3.2 ± 1.5 0.943 
Qualitative stress perfusion defect; n (%) 0 (0) 0 (0) 1.000 
 
Data expressed as mean ± standard deviation unless otherwise stated. LGE. Late-gadolinium 





6.3.3 Follow up CMR measurements in all patients 
6.3.3.1 Aortic stiffness 
An analysis was performed to assess CMR changes in the entire patient group. All 51 
patients’ CMR measures were compared at baseline and 1 year follow up and the mean 
difference of CMR measurements were calculated. Table 6-3 shows these findings. The 
purpose of this analysis was to see, as a whole, what changes were apparent after strict RA 
disease therapy, whether by MTX TTT regimen or first-line biological therapy. Overall there 
was an increase in AD from baseline to follow up (3.2 ±1.6 to 4.4 ±2.8 10-3mmHg-1, mean 
difference +1.17 10-3mmHg-1, p=0.001). This is presented in Figure 6-1. Additional aortic 
measures of aortic strain and compliance also revealed statistically important 
improvements, with aortic stiffness index showing a trend for improvement without 
statistical significance (mean difference -0.68 ß, p=0.07). 
 
6.3.3.2 LV structure and function 
With respect to LV structure and geometry, LV volumes at follow up did not differ but there 
was a geometric change seen. LV Mass increased by a mean difference of 4g (p=0.005), 
which was also observed when indexed to BSA with a mean increase of 2g/m2 (p=0.01). 
Given the static nature of the LVEDV, and indexed LVEDV, the LV mass/volume ratio also 
increased, as this is a division of mass and volume. This rose by a mean difference of 0.03 
g/ml to 0.57 ±0.10 g/ml (p=0.027). On analysis of tissue composition, despite a reduction in 
ECV by 0.9% and fewer areas of LGE from 10% to 6% presence, these were not statistically 
significant. Native T1 relaxation time was almost identical at follow up, only rising by a mean 
of 3ms (p=0.792). LV function was assessed by ejection fraction and by subclinical measures 
of strain, strain-rate and torsion. LV ejection fraction, peak systolic strain and peak systolic 
strain rate at the mid LV did not differ at follow up. With respect to diastolic measures and 
mechanics, early diastolic strain rate fell from 0.61 ±0.24 to 0.50 ±0.14 seconds-1 (p=0.003) 
and there was a trend for reduction in LV torsion by a mean difference of -0.84 degrees 





6.3.3.3 RV structure and function 
Volumetric analysis revealed similar RVEDV and indexed RVEDV from baseline to follow up, 
however, an increase in RVEF was observed. The RVEF increased by a mean difference of 




Table 6-3 - Baseline and follow up CMR measurements in all ERA patients 






Mean difference P value 
LV end-diastolic volume, ml 149 ± 33 149 ± 33 -0.3 0.881 
LV end-diastolic volume indexed, ml/m
2
 81 ± 13 80 ± 13 -0.6 0.495 
LV ejection fraction, % 60 ± 6 59 ± 6 -0.4 0.637 
LV mass, g 80 ± 23 84 ± 24 4.2 0.005 
LV mass indexed, g/m
2
 43 ± 9 45 ± 10 2.0 0.010 
LV mass/volume ratio, g/ml 0.54 ± 0.10 0.57 ± 0.10 0.027 0.022 
RV end-diastolic volume, ml 160 ± 43 158 ± 39 -1.6 0.542 
RV end-diastolic volume indexed, ml/m
2
 86 ± 17 85 ± 14 -1.3 0.302 
RV ejection fraction, % 54 ± 5 56 ± 5 1.8 0.024 
Peak systolic strain, mid LV -0.23 ± 0.02 -0.23 ± 0.02 -0.000 0.998 
Peak systolic strain rate, seconds
-1
 1.14 ± 0.14 1.15 ± 0.12 0.015 0.480 
Early diastolic strain rate, seconds
-1
 0.61 ± 0.24 0.50 ± 0.14 -0.107 0.003 
Late diastolic strain rate, seconds
-1
 1.40 ± 0.33 1.51 ± 0.35 0.103 0.055 
Torsion, degrees 13.7 ± 2.7 12.9 ± 2.9 -0.838 0.054 
Native T1, ms 1177 ± 44 1180 ± 69 2.7 0.792 
Extra-cellular volume fraction, % 27.5 ± 3.8 26.6 ± 4.2 -0.91 0.220 
Presence of LGE; n (%) 5 (10) 3 (6) - 0.183 
Aortic strain, % 15.7 ± 6.7 20.0 ± 9.2 5.3 <0.001 
Aortic compliance 11.5 ± 4.6 15.5 ± 9.0 4.0 0.001 





 3.2 ± 1.6 4.4 ± 2.8 1.17 0.001 
 
Data expressed as mean ± standard deviation unless otherwise stated. ERA, early rheumatoid arthritis; LGE, Late-gadolinium enhancement; LV, 






Figure 6-1 - Changes in aortic distensibility measured by CMR in all ERA patients. 
 
 
N=51. Overall there was an increase in AD from baseline to follow up (3.2 ±1.6 to 4.4 ±2.8 
10-3mmHg-1, mean difference +1.17 10-3mmHg-1, p=0.001). Blue lines represent ERA patients 
that had a higher AD at 1 year follow up and red lines represent ERA patients that had a 





6.3.4 Aortic stiffness changes between treatment groups 
Table 6-3 has shown that as, an entire group, there has been an improvement in aortic 
stiffness by an increase in AD and other aortic measures. Table 6-5 presents CMR 
measurements at baseline and 1 year follow up in the different treatment arms and Figure 
6-1 displays these data. Both groups have shown an improvement in aortic stiffness using 
the primary outcome measure of AD, as well as using aortic strain, compliance and stiffness 
index. Figure 6-2 and Figure 6-3 graphically displays the individual data points in both 
treatment groups. The absolute mean changes appear similar in both groups with respect to 
AD but the level of statistical significance appears greater in the MTX TTT regimen group 2 
with a p value of 0.003 versus 0.033 (Figure 6-4). Mean differences of CMR measurements 
were analysed and compared between the treatment arms and are shown in Table 6-6. All 
aortic measures had greater changes in group 1, however none were statistically different to 
the mean changes observed in group 2. 
 
Looking at the data points and spread within these figures reveal that the tighter standard 
deviation in group 2 accounts for the more statistically significant p value. There are 3 
outlier patients with the highest AD after 1 year that can be clearly seen in Figure 6-1. The 
AD values were 16.6, 11.8 and 10.8 10-3mmHg-1. These patients with greatest increase in AD 
were re-analysed and found to be reproducible after further blinded measurement. Their 
baseline clinical characteristics  are shown below in Table 6-5. They were all female. There 
does not seem to be any unifying clinical characteristic that was shared between them and 
nothing stood out that was particularly different when compared to the remaining ERA 
population. 
 
The analysis was repeated excluding these outliers and there remained a significant increase 
in AD from baseline to follow up (3.2 ±1.6 to 3.8 ±1.7 10-3mmHg-1, p<0.001). The mean FU 
AD was predictably lower, at 3.8 versus 4.4 10-3mmHg-1 of the entire group. 
 
In summary, both treatment groups had reduced aortic stiffness after 1 year and the 
magnitude of the mean difference was not statistically significant despite greater mean 






Table 6-4 - Clinical characteristics of outlier patients with high AD after 1 year follow up 
 
Characteristic Patient 1 Patient 2 Patient 3 
Age, years 40 32 52 
Body mass index, kg/m
2
 23.7 18.6 40.3 
Current Smoker No No Yes 
 - Ever smoked No No N/A 
 - Pack Years* N/A N/A 18 
Hypertension; n (%) No No No 
Family history of CVD**; n (%) No No No 
Hypercholesterolemia; n (%)  No No No 
DAS Score 5.1 6.9 5.4 
ESR, mm/hr 26 17 15 
CRP, mg/L <5 5 <5 
RF Yes No Yes 
ACPA Yes No Yes 
 
ACPA, anti-citrullinated peptide antibody;  CRP, C-reactive protein; CV, cardiovascular; DAS 
Score, 3 variable 28 joint disease activity score using CRP; ESR, erythrocyte sedimentation 
rate; IQR, inter-quartile range; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid 
factor; TTT, treat-to-target regimen. *Number of cigarettes per day x number of years 
smoked ÷ 20 = pack years; **defined as first degree relative with a history of CVD when 60 







Table 6-5 - Baseline and follow up CMR measurements in each treatment group 























LV end-diastolic volume, ml 150 ± 31 147 ± 31 0.340 149 ± 36 151 ± 35 0.138 
LV end-diastolic volume indexed, ml/m
2
 80 ± 13 78 ± 12 0.138 81 ± 14 82 ± 14 0.218 
LV ejection fraction, % 60 ± 5 59 ± 6 0.240 60 ± 6 60 ± 6 0.640 
LV mass, g 81 ± 20 85 ± 23 0.036 79 ± 25 84 ± 26 0.056 
LV mass indexed, g/m
2
 43 ± 9 45 ± 10 0.077 42 ± 9 45 ± 10 0.065 
LV mass/volume ratio, g/ml 0.54 ± 0.09 0.58 ± 0.09 0.025 0.53 ± 0.12 0.55 ± 10 0.296 
RV end-diastolic volume, ml 163 ± 43 161 ± 38 0.734 157 ± 43 156 ± 41 0.531 
RV end-diastolic volume indexed, ml/m
2
 87 ± 18 85 ± 15 0.519 85 ± 16 84 ± 14 0.391 
RV ejection fraction, % 53 ± 5 55 ± 5 0.079 55 ± 6 56 ± 4 0.164 
Peak systolic strain, mid LV -0.23 ± 0.02 -0.22 ± 0.03 0.366 -0.22 ± 0.03 -0.23 ± 0.02 0.305 
Peak systolic strain rate, seconds
-1
 1.11 ± 0.20 1.17 ± 0.15 0.262 1.15 ± 0.10 1.15 ± 0.10 0.685 
Early diastolic strain rate, seconds
-1
 0.61 ± 0.25 0.50 ± 0.14 0.007 0.58 ± 0.25 0.50 ± 0.14 0.128 
Late diastolic strain rate, seconds
-1
 1.34 ± 0.33 1.51 ± 0.40 0.044 1.46 ± 0.32 1.50 ± 0.31 0.536 
Torsion, degrees 13.5 ± 2.4 12.8 ± 3.0 0.125 13.7 ± 3.2 13.0 ± 2.9 0.259 
Native T1, ms 1176 ± 41 1165 ± 74 0.431 1179 ± 48 1195 ± 67 0.272 
Extra-cellular volume fraction, % 27.4 ± 4.3 27.0 ± 5.1 0.783 27.7 ± 3.3 26.2 ± 3.2 0.065 
Presence of LGE; n (%) 2 (9) 1 (9) 0.162 3 (12) 2 (8) 0.574 
Aortic strain, % 15.5 ± 7.2 20.4 ± 10.9 0.005 15.9 ± 4.3 19.6 ± 7.4 <0.001 
Aortic compliance 11.4 ± 5.0 15.6 ± 10.6 0.036 11.6 ± 4.3 15.4 ± 7.4 0.010 





 3.2 ± 1.8 4.4 ± 3.4 0.033 3.2 ± 1.5 4.4 ± 2.2 0.003 
 
Data expressed as mean ± standard deviation unless otherwise stated. ERA, early rheumatoid arthritis; LGE, Late-gadolinium enhancement; LV, 





Figure 6-2 - Changes in aortic distensibility in early biological therapy group. 
 
 
N=25. There was an increase in AD from baseline to follow up (3.2 ±1.8 to 4.4 ±3.4 10-
3mmHg-1, p=0.033). Blue lines represent ERA patients that had a higher AD at 1 year follow 








Figure 6-3 - Changes in aortic distensibility  in methotrexate treat-to-target regimen group. 
 
 
N=26. There was an increase in AD from baseline to follow up (3.2 ±1.5 to 4.4 ±2.2 10-
3mmHg-1, p=0.003). Blue lines represent ERA patients that had a higher AD at 1 year follow 






Table 6-6 - Comparison of mean difference in CMR measurement from baseline to follow up 







Days between baseline and follow-up CMR 343 ± 30 352 ± 23 0.724 
LV end-diastolic volume, ml -3 ± 15 2 ± 8 0.123 
LV end-diastolic volume indexed, ml/m
2
 -2 ± 7 1 ± 4 0.056 
LV ejection fraction, % -1 ± 5 1 ± 5 0.248 
LV mass, g 4 ± 9 4 ± 11 0.833 
LV mass indexed, g/m
2
 2 ± 5 2 ± 6 0.478 
LV mass/volume ratio, g/ml 0.03 ± 0.07 0.02 ± 0.09 0.726 
RV end-diastolic volume, ml -2 ± 23 -2 ± 13 0.995 
RV end-diastolic volume indexed, ml/m
2
 -1 ± 11 -1 ± 7 0.958 
RV ejection fraction, % 2 ± 5 2 ± 6 0.848 
Peak systolic strain, mid LV 0.01 ± 0.03 -0.01 ± 0.03 0.171 
Peak systolic strain rate, seconds
-1
 0.04 ± 0.16 -0.01 ± 0.12 0.263 
Early diastolic strain rate, seconds
-1
 -0.13 ± 0.21 -0.08 ± 0.24 0.476 
Late diastolic strain rate, seconds
-1
 0.15 ± 0.35 0.05 ± 0.35 0.316 
Torsion, degrees -1.0 ± 2.9 -0.7 ± 2.8 0.773 
Native T1, ms -11 ± 41 17 ± 73 0.178 
Extra-cellular volume fraction, % -0.3 ± 6.1 -1.5 ± 3.7 0.451 
Aortic strain, % 4.9 ± 8.0 3.7 ± 4.2 0.497 
Aortic compliance 4.2 ± 9.4 3.8 ± 6.9 0.885 





 1.2 ± 2.7 1.1 ± 1.7 0.865 
 
 
Data expressed as mean ± standard deviation unless otherwise stated. LV, left ventricular; 






Figure 6-4 - Change in aortic distensibility from baseline to 1 year follow up 
 
 
Biological therapy group: Increase in AD from baseline to follow up (3.2 ±1.5 to 4.4 ±2.2 10-
3mmHg-1, p=0.003). Methotrexate TTT regimen group: An increase in AD from baseline to 





6.3.5 Aortic stiffness changes between treatment groups and healthy 
controls 
The 30 healthy controls described previous chapters were used to compare aortic stiffness 
in the follow up patients (Control group: mean AD = 4.70 ±1.95 10-3mmHg-1). This is shown 
in Figure 6-5. As expected and presented in chapter 5, both treatment groups had 
significantly lower AD compared to healthy controls. At 1 year follow up, both groups had 
improved aortic stiffness measured by AD. The higher AD in each follow up group was a 
slightly lower absolute value but not significantly different when compared to the healthy 
non-RA controls. After 1 year of either MTX TTT regimen or first-line biological therapy with 
etanercept, aortic stiffness improved to the level where is wasn’t significantly different 
when compared to healthy non-RA controls. Biological therapy group: Control AD versus 
baseline and follow up = 4.7 versus 3.2 and 4.4 10-3mmHg-1, p=0.005 and p=0.710 
respectively. Methotrexate TTT regimen group: Control AD versus baseline and follow up = 








Figure 6-5 - Change in aortic distensibility between treatment groups and non-RA controls 
 
 
Control group: mean AD = 4.70 ±1.95 10-3mmHg-1. Biological therapy group: Control AD 
versus baseline and follow up = 4.7 versus 3.2 and 4.4 10-3mmHg-1, p=0.005 and p=0.710 
respectively. Methotrexate TTT regimen group: Control AD versus baseline and follow up = 







6.3.6 Clinical characteristics between RA patients with increased and non-
increased aortic stiffness at follow up 
RA patients were divided into 2 groups characterised by if there was an increased AD value 
or decreased AD value at follow up. This was performed as an entire cohort, with both 
treatment arms included together. Table 6-7 presents these data. 40 RA patients had 
increased AD and 10 patients did not increase their AD. Of these, there was no significant 
difference if they were in treatment arm 1 or 2. Demographic measures and CVD risk factors 
did not differ between RA patients that had increased their AD versus ones that hadn’t. Of 
the RA disease characteristics, DAS score was similar between increased AD and non-
increased AD (5.8 ±1.8 versus 5.6 ±1.4, p=0.69) and there was no difference in seropositivity 
(35 (88%) versus 8 (80%), p=0.616). Of baseline inflammatory markers, CRP was found to be 






Table 6-7 - Baseline demographic, clinical and RA disease characteristic data between increased and non-increased AD groups 





Biologic Treatment arm; n (%) 21 (53) 4 (40) 0.480 
Age, years 49 ± 13 49 ± 14 0.958 
Female sex; n (%) 27 (68) 8 (80) 0.702 
Body mass index, kg/m
2
 26.4 ± 4.6 23.7 ± 2.3 0.083 
Body surface area, m
2
 1.9 ± 0.2 1.7 ± 0.2 0.058 
Current Smoker; n (%) 6 (15) 2 (20) 0.653 
 - Ever smoked; n (%) 19 (48) 4 (40) 0.736 
 - Pack Years* 12.3 ± 10 24 ± 16 0.076 
Hypertension; n (%) 3 (8) 0 (0) 1.000 
Family history of CVD**; n (%) 1 (3) 2 (20) 0.098 
Hypercholesterolemia; n (%)  2 (5) 1 (10) 0.496 
Any CV risk factor; n (%) 22 (55) 5 (50) 1.000 
DAS Score 5.8 ± 1.8 5.6 ± 1.4 0.690 
ESR, mm/hr 36 ± 28 35 ± 31 0.898 
CRP, mg/L 22 ± 31 7 ± 9 0.010 
RF; n (%) 31 (78) 6 (60) 0.420 
ACPA; n (%) 34 (85) 8 (80) 0.653 
Any seropositivity***; n (%) 35 (88) 8 (80) 0.616 
 
Data expressed as mean ± standard deviation unless otherwise stated. ACPA, anti-citrullinated peptide antibody; AD, aortic distensibility; CRP, 
C-reactive protein; CV, cardiovascular; DAS Score, 3 variable 28 joint disease activity score using CRP; ESR, erythrocyte sedimentation rate; IQR, 
inter-quartile range; RA, rheumatoid arthritis; RF, rheumatoid factor; *Number of cigarettes per day x number of years smoked ÷ 20 = pack 
years; **defined as first degree relative with a history of CVD when 60 years old or younger if female, and 55 years old or younger if male; 




6.3.7 CMR characteristics between RA patients with increased and non-
increased aortic stiffness at baseline 
CMR characteristics at baseline and follow up were compared between the increased and 
non-increased AD groups in a similar method to comparison of clinical characteristics. These 
are displayed in Table 6-8 and Table 6-9. The time points between baseline and follow up 
CMR scans were not significantly differing to account for the CV changes seen on CMR, 
which were expected given the strict nature of the trial management. The only CMR 
measurement at baseline that was different was an higher myocardial ECV in the increased 
AD group (28.1 ±4.0% versus 25.4 ±2.2%, p=0.045). Of particular scrutiny, the baseline AD, 
and other aortic measures, between the 2 groups were not significantly different thus giving 
weight that the improvements seen were not small changes in patients with pre-existing 
abnormalities in aortic stiffness. At follow up, there were no additional changes in any CMR 
measurement that were not evident at baseline. Focussing on the ECV change seen at 
baseline, this fell in the increased AD group to 26.4 ±3.5% and rose in the non-increased AD 
group to 27.6 ±6.2% therefore making the p-value non-significant at p=0.403. Table 6-10 
presents the mean differences between the two groups. In addition to ECV, myocardial 
native T1 relaxation time fell in the increased AD group and rose in the non-increased AD 
group (-10.4 ± 65.5 versus 52.5 ± 74.0 ms, p=0.012). Furthermore, and similarly to the data 
in Table 6-9 and Table 6-10, this shows that, apart from myocardial tissue composition, 
there were no statistical differences in cardiac CMR characteristics between the increased 
and non-increased AD groups. 
 
6.3.8 Cardiac structural change between treatment groups 
Table 6-5 and Table 6-6 display results of further CMR measurements at baseline and 1 year 
follow up for both treatment groups. We have already shown that as an entire cohort there 
are structural changes at 1 year (Table 6-3). But unlike aortic stiffness, where both groups 
showed significant change, the other CV CMR changes seem to be driven more by treatment 
arm 1, first-line biological therapy. In group 2, MTX TTT regimen, there were no significant 
differences between baseline and follow up with respect to biventricular volumes, mass and 




85g ±23 (p=0.036). There was a trend to an increase in LV mass in group 2 but not to 
statistical significance. The LV mass/volume ratio was higher at follow up in group 1 (0.54 
±0.1 versus 0.58 ±0.1 g/ml, p=0.025). With respect to tissue composition, in group 1 the 
native T1 relaxation time, ECV and presence of LGE were very similar at baseline and 1 year 
follow up. Surprisingly, despite the change in geometry being more powerful in group 1 it 
was the MTX TTT regimen group that showed a decrease in presence of LGE, reduction in 
ECV and increase in native T1 relaxation time. However, none of these changes were to any 
statistical significance. 
 
6.3.9 Cardiac functional change between treatment groups 
Table 6-5 and Table 6-6 display results of further CMR measurements at baseline and 1 year 
follow up for both treatment groups. We have already shown that as an entire cohort there 
are functional changes at 1 year (Table 6-3). In a similar fashion to the results of structural 
change, functional CV changes seem to be again driven more by treatment arm 1, first-line 
biological therapy. In group 2, MTX TTT regimen, there were no significant differences 
between baseline and follow up with respect to biventricular EF, LV strain, LV strain rates 
and LV torsion. The decreased early diastolic strain rate and increased late diastolic strain 
rate discussed above in the whole cohort is apparent only in treatment arm 1. The increased 
RVEF is not apparent in the individual treatment arms and is only significantly increased 
























Data expressed as mean ± standard deviation unless otherwise stated. LV, left ventricular; RV, right ventricular. 
  







Days between baseline and follow-up CMR 345 ± 26 362 ± 27 0.063 
LV end-diastolic volume, ml 152 ± 33 140 ± 37 0.338 
LV end-diastolic volume indexed, ml/m
2
 81 ± 14 80 ± 12 0.951 
LV ejection fraction, % 60 ± 6 60 ± 5 0.844 
LV mass, g 81 ± 23 77 ± 23 0.609 
LV mass indexed, g/m
2
 43 ± 9 44 ± 8 0.706 
LV  mass/volume  ratio, g/ml 0.54 ± 0.11 0.54 ± 0.05 0.851 
RV end-diastolic volume, ml 162 ± 40 153 ± 53 0.581 
RV end-diastolic volume indexed, ml/m
2
 86 ± 16 87 ± 20 0.798 
RV ejection fraction, % 53 ± 5 56 ± 6 0.101 
Peak systolic strain, mid LV -0.23 ± 0.03 -0.22 ± 0.02 0.816 
Peak systolic strain rate, seconds
-1
 1.13 ± 0.17 1.13 ± 0.11 0.983 
Early diastolic strain rate, seconds
-1
 0.61 ± 0.26 0.56 ± 0.18 0.601 
Late diastolic strain rate, seconds
-1
 1.37 ± 0.32 1.48 ± 0.37 0.348 
Torsion, degrees 14.0 ± 2.6 12.1 ± 2.8 0.052 
Native T1, ms 1182 ± 45 1160 ± 37 0.165 
Extra-cellular volume fraction, % 28.1 ± 4.0 25.4 ± 2.2 0.045 
Aortic strain, % 15.3 ± 6.7 17.3 ± 7.1 0.399 
Aortic compliance 11.1 ± 4.4 13.1 ± 5.3 0.219 

























Data expressed as mean ± standard deviation unless otherwise stated. LV, left ventricular; RV, right ventricular. 
  







LV end-diastolic volume, ml 152 ± 33 137 ± 28 0.206 
LV end-diastolic volume indexed, ml/m
2
 80 ± 14 78 ± 11 0.608 
LV ejection fraction, % 59 ± 6 60 ± 5 0.823 
LV mass, g 85 ± 25 79 ± 24 0.474 
LV mass indexed, g/m
2
 45 ± 10 45 ± 9 0.898 
LV  mass/volume  ratio, g/ml 0.56 ± 0.10 0.57 ± 0.09 0.796 
RV end-diastolic volume, ml 161 ± 38 146 ± 41 0.262 
RV end-diastolic volume indexed, ml/m
2
 85 ± 14 82 ± 16 0.574 
RV ejection fraction, % 55 ± 5 57 ± 6 0.474 
Peak systolic strain, mid LV -0.22 ± 0.03 -0.22 ± 0.03 0.610 
Peak systolic strain rate, seconds
-1
 1.15 ± 0.14 1.14 ± 0.09 0.886 
Early diastolic strain rate, seconds
-1
 0.49 ± 0.13 0.51 ± 0.19 0.813 
Late diastolic strain rate, seconds
-1
 1.49 ± 0.38 1.49 ± 0.31 1.000 
Torsion, degrees 12.9 ± 2.9 11.9 ± 2.8 0.338 
Native T1, ms 1172 ± 70 1213 ± 60 0.096 
Extra-cellular volume fraction, % 26.4 ± 3.5 27.6 ± 6.2 0.403 
Aortic strain, % 21.0 ± 9.2 15.9 ± 8.4 0.118 
Aortic compliance 16.8 ± 9.4 10.2 ± 4.6 0.035 










Table 6-10 - Mean difference of CMR measurements from baseline to follow up between increased and non-increased AD groups 
 







LV end-diastolic volume, ml 0.4 ± 11.5 -2.9 ± 14.8 0.447 
LV end-diastolic volume indexed, ml/m
2
 -0.2 ± 5.5 -2.3 ± 7.9 0.336 
LV ejection fraction, % -0.4 ± 5.5 -0.3 ± 5.0 0.967 
LV mass, g 4.6 ± 10.3 2.5 ± 7.9 0.559 
LV mass indexed, g/m
2
 2.3 ± 5.4 0.7 ± 4.7 0.390 
LV mass/volume ratio, g/ml 0.03 ± 0.08 0.03 ± 0.09 0.943 
RV end-diastolic volume, ml 0.1 ± 17.6 -7.3 ± 20.0 0.268 
RV end-diastolic volume indexed, ml/m
2
 -0.4 ± 8.3 -4.9 ± 10.5 0.158 
RV ejection fraction, % 2.1 ± 5.2 0.3 ± 6.0 0.337 
Peak systolic strain, mid LV -0.001 ± 0.026 0.004 ± 0.029 0.537 
Peak systolic strain rate, seconds
-1
 0.02 ± 0.15 0.01 ± 0.12 0.899 
Early diastolic strain rate, seconds
-1
 -0.13 ± 0.24 -0.05 ± 0.17 0.362 
Late diastolic strain rate, seconds
-1
 0.13 ± 0.37 0.01 ± 0.23 0.331 
Torsion, degrees -1.0 ± 2.8 -0.2 ± 3.2 0.429 
Native T1, ms -10.4 ± 65.5 52.5 ± 74.0 0.012 
Extra-cellular volume fraction, % -1.7 ± 4.5 2.2 ± 6.1 0.026 
 




6.3.10 CMR characteristics compared to non-RA controls 
The 30 healthy controls described previous chapters were used to compare other CMR 
characteristics in the follow up patients. As presented in chapter 5, a number of structural 
and functional changes were observed in ERA when compared to controls. Table 6-11 
presents data of the follow up treatment arms to see, similarly to aortic stiffness described 
previously, whether changes returned to being similar to controls, stayed different or if new 
changes became apparent.  The results table to refer to is Table 5-2. 
 
6.3.10.1 LV mass and LV mass/volume ratio 
With respect to LV mass, both treatment arms had an increase in absolute and indexed 
values that made the means not significantly different when compared to controls (LV mass 
indexed, 45 ± 10 and 45 ± 10 versus 49 ± 8 g/m2, p=0.079 and p=0.095 respectively). LV 
mass/volume ratio, taking into account the LVEDV, showed that the biological therapy 
group had values at 1 year that were not different to controls whereas the MTX TTT regimen 
group continued to show significantly lower LV mass/volume ratio (0.55 ± 0.10 versus 0.62 ± 
0.10 g/ml, p=0.011). Therefore, although both groups increased LV mass at follow up, only 
the biological group returned to a level that was not significant in geometry to controls.  
 
6.3.10.2 Myocardial tissue composition 
Despite some evidence above describing patients with increased AD having a falling ECV and 
rising native T1 relaxation time, there were no observable changes to baseline with respect 
to falling ECV as a whole and both treatment arms remained significantly different with 
higher ECV fractions compared to non-RA controls. 
 
6.3.10.3 Cardiac function measures 
In the previous chapter, only early diastolic strain rate was found to be higher in ERA when 
compared to controls. This measure fell in both treatment arms to values that were not 
significantly different compared to the controls at follow up. However, despite a non-




controls, torsion was found to be lower in both treatment arms when compared to controls. 
For group 1 it was 12.8 ± 3.0 and for group 2 it was 13.0 ± 2.9 versus the control value of 
14.9 ± 4.5 degrees (p=0.048 and p=0.028 respectively). The only new function measure that 
was different at follow up over the baseline data was that the biological treatment arm had 
a lower LVEF value by 1% making it different to controls whereas the MTX TTT regimen 






Table 6-11 - Follow up CMR characteristics between treatment groups and healthy non-RA controls 
 
 
Data expressed as mean ± standard deviation unless otherwise stated. LGE, Late-gadolinium enhancement; LV, left ventricular; MTX, 
methotrexate; RA, rheumatoid arthritis; RV, right ventricular; TTT, treat-to-target regimen. 








P Value Group 2 








LV end-diastolic volume, ml 147 ± 31 154 ± 31 0.400 151 ± 35 154 ± 31 0.822 
LV end-diastolic volume indexed, ml/m
2
 78 ± 12 80 ± 11 0.596 82 ± 14 80 ± 11 0.643 
LV ejection fraction, % 59 ± 6 62 ± 5 0.037 60 ± 6 62 ± 5 0.247 
LV mass, g 85 ± 23 95 ± 19 0.088 84 ± 26 95 ± 19 0.077 
LV mass indexed, g/m
2
 45 ± 10 49 ± 8 0.079 45 ± 10 49 ± 8 0.095 
LV  mass/volume  ratio, g/ml 0.58 ± 0.09 0.62 ± 0.10 0.116 0.55 ± 0.10 0.62 ± 0.10 0.011 
RV end-diastolic volume, ml 161 ± 38 178 ± 42 0.117 156 ± 41 178 ± 42 0.047 
RV end-diastolic volume indexed, ml/m
2
 85 ± 15 92 ± 17 0.111 84 ± 14 92 ± 17 0.060 
RV ejection fraction, % 55 ± 5 54 ± 6 0.536 56 ± 4 54 ± 6 0.049 
Peak systolic strain, mid LV -0.22 ± 0.03 -0.23 ± 0.02 0.492 -0.23 ± 0.02 -0.23 ± 0.02 0.912 
Peak systolic strain rate, seconds
-1
 1.17 ± 0.15 1.15 ± 0.12 0.604 1.15 ± 0.10 1.15 ± 0.12 0.367 
Early diastolic strain rate, seconds
-1
 0.50 ± 0.14 0.52 ± 0.15 0.924 0.50 ± 0.14 0.52 ± 0.15 0.985 
Late diastolic strain rate, seconds
-1
 1.51 ± 0.40 1.50 ± 0.27 0.981 1.50 ± 0.31 1.50 ± 0.27 0.918 
Torsion, degrees 12.8 ± 3.0 14.9 ± 4.5 0.048 13.0 ± 2.9 14.9 ± 4.5 0.028 
Native T1, ms 1165 ± 74 1202 ± 35 0.031 1195 ± 67 1202 ± 35 0.585 
Extra-cellular volume fraction, % 27.0 ± 5.1 25.1 ± 2.7 <0.001 26.2 ± 3.2 25.1 ± 2.7 <0.001 
Presence of LGE; n (%) 1 (4) 1 (3) 1.000 2 (8) 1 (3) 0.592 
Aortic strain, % 20.4 ± 10.9 25.2 ± 8.5 0.076 19.6 ± 7.4 25.2 ± 8.5 0.015 
Aortic compliance 15.6 ± 10.6 19.1 ± 7.1 0.152 15.4 ± 7.4 19.1 ± 7.1 0.058 










Both treatment arms had similar baseline clinical characteristics and CMR measurements. 
There was improved aortic stiffness in both groups, to the point where they became similar 
to non-RA controls at 1 year follow up. Patients who had improved their AD the most began 
with higher CRP baseline values and higher myocardial ECV values. LV mass and indexed LV 
mass increased in both treatment arms but was more pronounced in the biological therapy 
group. Both groups returned to levels that were not significantly different compared to 
controls. LV mass/volume ratio increased, where in group 1 it returned to being not 
different to controls whereas in group 2 it remained lower. EDSR increased and was mainly 
driven by changes in the biological group and LV torsion fell in both treatment arms and 







This chapter presented interim follow-up analysis of the CADERA trial, the first clinical trial 
in ERA using endpoints measured by CMR. Furthermore, this is one of the largest single CMR 
datasets in RA. Although these data are interim, and importantly without follow up clinical 
and biochemical parameters, the primary outcome of AD is powered and can be discussed 
with reasonable confidence. 
 
6.4.0 Arterial stiffness 
The interim analysis of this study, so far, supports that arterial stiffness is already present at 
diagnosis and that early biological therapy or conventional TTT MTX therapy can reduce 
arterial stiffness in treatment-naive ERA. The degree of reduction was to point of 
normalising, as compared to non-RA healthy controls. We have not demonstrated that one 
treatment regimen over another is more effective at reducing arterial stiffness. 
 
Arterial stiffness is associated with an increased risk of CV events with a range of co-
morbidities[23]. Aortic distensibility is a commonly utilised method to measure arterial 
stiffness due to the elastic vasculature hardening as atherosclerosis progresses[294]. In a 
general (non-RA) population, aortic distensibility predicts CV events [270] but there are few 
studies assessing it in RA. In patients with RA without traditional CV risk factors, aortic pulse 
wave velocity is higher than in controls[24] and correlates with age, mean arterial pressure 
and CRP. Increased inflammation has been measured in the carotid artery in ERA[290] using 
PET-CT and several studies have shown increased arterial stiffness in established, 
heterogeneous RA populations[24, 64, 256]. Given the fact it was not shown that either 
treatment arm was superior to one another in improving arterial stiffness, I assessed 
whether there were signals between ERA patients that had improved AD versus those that 
didn't. RA disease characteristics and demographics were similar but the ERA patients that 
appeared to improve their arterial stiffness the most began with higher baseline CRP values, 






Mäki-Petäjä et al, in 2012, used 18fluorodeoxyglucose-PET/CT imaging in 17 patients with 
established RA before and after 8 weeks of TNFi therapy[212]. They demonstrated that the 
RA patients had increased aortic uptake of the radiotracer, implying aortic inflammation, in 
comparison with 34 non-RA patients with stable CVD. There was also increased arterial 
stiffness by measure of pulse wave velocity. After 8 weeks of the TNFi therapy, there were 
improvements in tracer uptake that correlated with improved arterial stiffness. Haavisto et 
al, in 2016, showed the influence of triple DMARD therapy (non-biological) on carotid artery 
inflammation in drug-naive patients with recent onset of RA[213]. They recruited 15 non-
diabetic ERA patients and, using (18)F-FDG-PET/CT, the target-to-background ratio 
decreased by 12.4% (P = 0.01) after 1 month of DMARD triple therapy. Carotid artery 
inflammation in drug-naive ERA patients could be efficiently reduced by 1-month DMARD 
triple therapy. A small prospective study in 2014 examining TNFi therapy in RA, evaluated 
ascending aorta distensibility measured by transthoracic echocardiography in 13 established 
RA patients. They found that TNFi treatment after 12 months significantly improved arterial 
stiffness[295]. 
 
Therefore, in line with previous studies investigating biological therapy or synthetic DMARD 
effects on vascular inflammation/stiffness in RA, these findings are consistent with 
improved aortic stiffness, by measure of lower AD, over 1 year from treatment naivety. We 
have not shown superiority of one regimen over another in altering aortic arterial stiffness 
with this interim data. 
 
Synthetic DMARDs and TNFi therapy have some evidence in their effect on the risk of CVD 
and CV events. MTX use has been associated with a 21% lower risk of total CVD and 18% 
lower risk of MI in systematic reviews and meta-analysis[55]. Studies that controlled for 
underlying disease severity and medication use were associated with 36% and 27% lower 
CVD risk respectively compared with studies that did not[55]. A large prospective study of 
3529 ETN treated patients and 2864 on conventional DMARDs found evidence of reduced 
CV events[65]. The CV benefit of TNFi treatment appeared to be strongest in RA patients 
over 65 years old  in an observational study of 8656 new users of conventional DMARDs 
versus 11587 on TNFi, with the study showing an overall reduced risk of CV events in 




of nearly 2000 RA patients TNFi had a lower hazard ratio for new CVD diagnosis compared 
to MTX[296]. A further meta-analysis showed that TNFi and MTX were associated with 
comparable reductions in risk of CV events[297]. It should be noted, as concluded in a 
systematic review and meta-analysis of TNFi and CV events in RA by Barnabe et al, that 
there is heterogeneity amongst cohort studies and possible publication bias. There are  wide 
confidence intervals in RCTs with CV outcome underpowered and assessed as secondary 
outcomes[298]. Although the mechanisms are unclear, the reduction in CV events and 
incident CVD diagnoses may be as a consequence of reduced inflammation rather than the 
specific actions of therapeutic agents. 
 
6.4.1 Cardiac structure  
Ventricular geometry was assessed between treatment groups and changes were apparent 
between them. We have demonstrated that ERA patients have altered LV remodelling with 
lower mass and mass/volume ratio consistent with previous CMR literature[83]. After 1 
year, early biological therapy with ETN appears to have altered this ventricular geometry 
(increasing LV mass/volume ratio) whereas MTX TTT regimen remained different to controls 
and similar to baseline. This finding of changing LV geometry with immunotherapy has been 
demonstrated in a small pilot study by Kobayashi et al[253]. They found that tocilizumab 
treatment decreased left ventricular mass index, as measured by CMR, after one year of 
therapy. This conflicts with our data where we have seen an increase in LV mass/volume 
ratio after 1 year of therapy. The drug therapies, RA patient types and treatment regimens 
are different but the finding of higher LV mass at baseline compared to controls conflicts 
with this cohort - but also from the previous largest CMR study to date, of 75 RA patients, 
that demonstrated a reduced LV mass in RA compared to 225 matched controls[83]. This 
happens to be data from same group therefore this confliction is hard to reconcile. ETN has 
also been shown to be associated with a significant decrease in adverse left ventricle (LV) 
remodelling with medium-term treatment[67] supporting experimental studies that tumour 
necrosis factor alpha may induce adverse LV remodelling[68]. 
 
We found that myocardial ECV was increased in ERA but this did not reduce in either group 




mapping by CMR has previously demonstrated evidence of increased relaxation times  in 
patients with established RA[87]. This may represent microvascular disease, whether as a 
result of ischaemic heart disease or inflammation from the RA disease process[299]. None 
of our ERA patients had regional areas of hypoperfusion on adenosine stress CMR imaging, 
however there was a weak correlation with rising ESR and ECV expansion. Late gadolinium 
enhancement imaging can measure focal myocardial tissue abnormalities, including focal 
fibrosis, but is limited in assessing diffuse changes. This is because the signal intensity 
between normal and fibrotic myocardium may not be a differentiator. T1 mapping, pre and 
post gadolinium contrast with haematocrit measurement, enables the calculation of extra-
cellular myocardial volume with high spatial resolution. This direct parametric signal 
quantification for each voxel provides superior assessment of myocardium than 
conventional late enhancement techniques[300]. We found decreased pre-contrast T1 
values and higher ECV values in ERA patients, indicating myocardial change at a cellular 
level. Myocardial fibrosis has been linked to lower myocardial strain[301] and we found a 
correlation with increasing CRP with reduced LV systolic strain, similarly to other CMR 
studies[87]. This data further adds to the literature the relationship between myocardial 
changes and impaired myocardial strain parameters. 
 
Fibrosis, inflammation and cardiac cell alteration/apoptosis may all increase ECV. Where our 
data differs from previous experiments in established RA is the finding of lower native T1 in 
ERA. Although this was a small change it was unexpected. If the mechanism for ECV 
expansion is purely inflammation driven, then the higher myocardial water content would 
increase T1 relaxation. Tissue change to alter ECV may be by other undetermined 
mechanisms in ERA rather than just myocardial inflammation. When the tissue composition 
is thought about critically, how can ECV expansion in RA be purely due to increase in water 
content from inflammation if there is a reduction of myocardial mass compared to controls? 
If ECV expansion was only due to myocardial inflammation, then it would reasonable to 
assume increased wall thickening and/or increased LV mass. This is not the case as 
described in these data as well as previous large CMR studies, RA is associated with lower LV 
mass in CMR studies. Another mechanism that could potentially reduce ventricular mass, 
lower T1 relaxation time and increase ECV fraction is by cellular apoptosis. Programmed cell 




processes[302]. Excessive apoptosis is implicated in many diseases, including RA[303]. It is 
also present in IHD[304] and correlates with LV remodelling[305]. Within the mechanisms of 
apoptosis, TNF acts as an apoptotic ligand binding to a 'death receptor' creating a death-
inducing signalling complex[306] and creating an apoptotic cascade, Figure 6-6. In an in vitro 
rat study, TNF-α can induce apoptosis in cardiomyocytes[307] and high concentrations of 
TNF-α increase myocardial injury following ischaemia[308]. This mechanistic hypothesis may 
shed light on the results seen in this analysis. Both MTX and ETN did not change T1 and ECV 
after one year, which one would presume if myocardial composition was purely 
inflammation and oedema driven. However, ETN did alter LV mass/volume ratio and LV 
mass whilst MTX did not, which would imply a TNF-α specific role in change in cardiac 
structure. 
 
A further mechanism that may explain lower of LV mass and LV mass/volume ratio, whilst 
increasing myocardial ECV is the process of physical deconditioning and/or RA cachexia. The 
heart can remodel quickly with respect to increasing or decreasing aerobic activity. For 
example, athletes who train and compete regularly develop changes in cardiac morphology 
and function, most notably an increase in LV mass [309]. This increase in LV mass occurs as 
early as 3-6 months after commencement of endurance training [310] and may be 
accompanied by an increase in LV end-diastolic volume (LVEDV) resulting in a typical 
phenotype of eccentric remodelling[311, 312]. Similar effects are seen when aerobic activity 
is ceased. It is therefore plausible that when an RA patient is untreated, in pain and has 
physical limitation due to joint disease and systemic illness, the general lack of activity may 
reduce the LV mass whilst myocardial ECV expansion occurs. The deconditioning may be 
more powerful with respect to overall LV mass than the small percentage rise in myocardial 
ECV with respect to changing the total volume of myocardium. With its association with 
reduced LV mass, leptin may have a role to play in ‘RA-cachexia’ (loss of body muscle mass 
with an increase in body fat mass)[313], distinct from physical deconditioning[314]. The 
Multi-Ethnic Study of Atherosclerosis CMR project reported higher levels of leptin 
associated with lower LV mass. This was independent of other charactersitics that included 
traditional CV risk factors, CRP and physical activity[315]. Leptin is higher in patients with RA 
and so adds another possible explanation for the change in LV mass. There is suggestion 




improvement following suppression of RA disease activity[313, 316]. There may be 
alternative pathological processes maintaining this state. A limitation of this work is that 
leptin was not studied and there were no objective measurements of physical activity, 






Figure 6-6 - Apoptotic signalling pathway 
 






6.4.2 Cardiac function 
Ventricular function was assessed between treatment groups and some changes were 
apparent between them. Overall, there weren't overt changes in systolic performance by 
measure of ejection fraction and although rising CRP levels at baseline were correlated with 
worsening peak systolic strain, the values were not significantly different compared to 
controls at baseline, follow up or between treatment groups at one year. Recent smaller TTE 
ERA studies have shown subclinical impairment of diastolic dysfunction[265]. Subclinical 
diastolic parameters changed in the ETN group and not the MTX group in that early diastolic 
strain rate fell and late diastolic strain rate increased. Decreased LV torsion was apparent in 
both groups after 1 year and were lower than non-RA controls. The study was not powered 
to look at markers of ventricular function, with them being secondary outcomes, and these 
observations have to be therefore taken with these caveats in mind. Given the fact that we 
are assessing CV changes in ERA and these changes are subtle and sub-clinical, it is not 
surprising we are not seeing overt ventricular dysfunction as studies in asymptomatic, 
established RA without known CVD are only showing sub-clinical CV performance change 
without prevalent overt measures of dysfunction. 
 
6.4.3 Limitations 
Inherently, this is an interim follow-up analysis of trial data but seeing as the primary 
outcome measure of AD was surpassed there is some confidence at least in reporting these 
data. With further numbers of patients analysed between September 2015 and November 
2016, there may be further data points that drive away existing weak statistical outcomes or 
indeed bring in current weaker trends that did not reach statistical significance. 
Furthermore, given the interim nature of this analysis, access to biochemical tests and 
clinical outcomes are not available to analyse and correlate with the CMR measurements. 
Secondary outcomes, that are already not powered, may be heavily influenced by the 
addition of remaining follow up patients. Adenosine stress perfusion is a highly efficient 
method detecting significant flow limiting coronary artery disease however I did not 




disturbance. This was rather due to large amount of data to investigate and the Leeds CMR 
research group will continue this work in the future. Once the trial is analysed at 
completion, it would be of interest to analyse patients in the MTX TTT regimen group for 
amount of escalation to ETN and whether these patients differed in their CMR data 
compared to MTX alone and ETN alone. As per the previous limitations described in earlier 
chapters, invasive coronary arteriography to exclude CAD was not performed or appropriate 
in asymptomatic patients. For the same reason of appropriateness and risk, myocardial 
biopsy was not performed to confirm increased ECV. ECV measured by CMR has been 
validated against histology in other disease processes[293]. Longitudinal tagging, pulse-
wave velocity, atrial volumes, T2-imaging and feature-tracking were not assessed and so 
could not be compared to other CMR studies where they have been employed, as well as 
previous TTE studies where some measurements are methodically similar. This is because 
the scanning protocol to include measurements we have presented was already long in 
duration and recruitment in this well-defined population was paramount to increase uptake 
into the study and limit drop-out for follow-up CMR scans if patients had a negative 
experience. The analysis was not blinded to the presence or absence of RA; however 
analysis was blinded to treatment arm within the study as a whole. Reproducibility was 
performed with randomly selected studies that were blinded to the observer and showed 
excellent CoV and ICC. Previous medical history was taken from the patients’ records rather 
than re-confirmation of diagnoses of hypercholesterolemia, diabetes and hypertension 
using serum tests and 24h ambulatory BP monitoring. 
 
6.5 Conclusion 
Increased arterial stiffness, present in treatment-naive ERA can be modulated, improved 
and measured after 1 year of disease modifying therapy using a MTX TTT regimen or early 
biological therapy with ETN. Patients with baseline higher CRP appear to improve arterial 
stiffness the most. Early biological therapy with ETN, over a MTX TTT regimen, appears to 




7 Dilation of the thoracic aorta and cardiovascular co-






In GCA, aortic inflammation is common but the prevalence of aortic structural damage in 
routine practice remains unclear. We sought to characterise thoracic aortic structural change in 
GCA using CMR. 
 
7.1.1 Methods 
Patients with GCA diagnosed at least 2 years beforehand, from two sites of UK GCA Consortium, 
underwent 3T CMR. Thoracic aortic dimensions were compared to published international 
nomograms. Controls without GCA were recruited for comparison. 
 
7.1.2 Results 
47 GCA patients (mean age 73) and 13 controls (mean age 65) were recruited. Based on 
nomograms, 31/47 (66%) of GCA patients (87% of females; 38% of males) had dilated thoracic 
aortas; all 31 had dilated descending aortas, of these, 9 also had dilated ascending aortas. 
Mean aortic diameter, adjusted for age, sex and CV risk factors, exceeded that of controls. 5/47 
GCA patients had ascending aorta diameter approaching/exceeding surgical intervention 
thresholds. Where the descending aorta was dilated, loss of normal tapering was observed 
rather than saccular/fusiform aneurysm. Polymyalgic symptoms at onset were associated with 
greater aortic diameter. Aortic distensibility was lower in GCA than controls (1.2(±0.9) versus 






Dilatation of the thoracic aorta was common in GCA, with loss of tapering of the descending 
aorta. Polymyalgic symptoms may be a risk factor, but this requires replication. Patients with 
GCA had increased aortic stiffness than controls. Further longitudinal studies are required to 







As with RA, GCA is another IMID distinguished by specific pathways of immune-dysregulation 
that lead to inflammation, organ damage and dysfunction[1]. GCA is the commonest primary 
systemic vasculitis affecting older people[4] and, like RA, is associated with an increased early 
mortality mainly due to CVD. There are inflammatory contributions in atherosclerosis from the 
formation of atherosclerotic plaques, the development, the reduction in their stability to the 
final conclusion of rupture and thrombosis. The additional CV mortality that GCA is associated 
with includes aortic syndromes[5]. 
 
Various guidelines and recommendations have been proposed for TAA screening and 
monitoring in GCA[43]. Current UK guidelines suggest a chest radiograph every 2 years[44] but 
this is insensitive compared to computed tomography or CMR of the aorta. It has been 
estimated that 5 to 10 GCA patients would need aortic imaging to detect a previously unknown 
TAA/TAD but this was based on small, heterogeneous datasets[40]. Furthermore this did not 
seem to fit with clinical experience: although thoracic contrast computed tomography (CT) is 
now performed for a multitude of indications, aortic aneurysm in patients with GCA seems to 
be rarely discovered incidentally. In large-scale routinely-collected clinical data the frequency of 
any aortic aneurysm diagnosis in patients with GCA was only 1%, compared with 0.7% of those 
without GCA[45]. Because of this, and bearing in mind the costs and burdens of sophisticated 
imaging tests used to screen for asymptomatic pathology, there is still no consensus amongst 
clinicians regarding the clinical utility of routine aortic imaging in patients with GCA. 
 
In this study we tested the hypothesis that patients with GCA would have a higher prevalence 
of TAD, both when compared to controls without GCA, and when compared to population-
derived CMR normal ranges. We also tested for association of TAD with putative risk factors for 
TAD in GCA. In exploratory analyses we also examined measures of CV structure and function 








7.3.0 Enrolment criteria 
Consecutive patients previously recruited from Leeds Teaching Hospitals NHS Trust and 
Harrogate and District NHS Foundation Trust sites to the UK GCA Consortium study were invited 
to participate in an aortic imaging study. The UK GCA Consortium study (approved York 
Research Ethics Committee, reference 05/Q1108/28) is an observational study recruiting 
patients with a firm clinical diagnosis of GCA from secondary care. Since temporal artery biopsy 
is an insensitive test, particularly in cases with predominant involvement of the aorta and its 
branches, inclusion was not limited to those with a positive temporal artery biopsy. At the time 
of this study temporal artery ultrasound was not routinely available at these two hospital sites. 
Recognising the uncertainty inherent in clinical diagnosis, all biopsy-positive patients were 
invited first, followed by biopsy-negative patients, until a pre-specified recruitment target of 50 
was achieved. A target of 50 was chosen pragmatically rather than statistically determined. In 
attempt to match age as much as possible to the predictably older GCA cohort, the oldest 
healthy controls were used for comparison from existing studies already undertaken with the 
same CMR sequences from our department. 
 
7.3.1 GCA Consortium project 
As the patients have been approached from their enrolment into the GCA Consortium study, I 
now describe what the project involves and its rationale from the study protocol at the 
University of Leeds. This project was originally powered and directed towards immunogenetic 
characterisation of the FCGR locus within a UK Caucasian cohort. Preliminary data suggest that 
the FCGR locus may exert a strong effect on susceptibility and severity to GCA. Careful clinical 
characterisation of the cohort is required in order to identify potential co-morbidities (e.g. 
vascular disease), drugs (e.g. aspirin) and environmental triggers (e.g. smoking, recent 
infections) that may modify the immunogenetic contribution. Accounting for these gene-
environment interactions will be essential to avoid imprecision and possible bias but again 
requires large numbers of patients. The immunogenetic studies will comprise both whole-
genome and candidate-gene studies (initially investigating the MHC and FCGR loci and 




pathways). Clinical studies, of which this GCA aorta study is one, will focus on factors potentially 
relevant to autoimmunity, inflammation and vascular disease. Since temporal artery biopsy is 
the gold standard for diagnosis, temporal artery biopsy specimens, derived either 
retrospectively (from histopathology archives) or prospectively, will be examined to verify the 
diagnosis and to examine for disease subtypes (e.g. degree of  inflammation and/or of intimal 
hyperplasia). 
 
7.3.2 GCA Consortium eligibility criteria 
 
Inclusion Criteria 
 • Willing to self-identify an ethnic group, such as Caucasian, Asian, Afro-Caribbean. 
 • Have a firm clinical diagnosis of GCA or PMR, or (for patients identified prospectively)  
 GCA or PMR should be more likely than any alternative explanation for the patient’s 
 symptoms. 
 • Able and willing to give informed consent. 
 • Patients are 50 years of age or over, unless both biopsy-proven and a clinically classical 
 case of GCA.   
 
Exclusion Criteria 
 • Patient unwilling or unable to give fully informed consent. 
 • Pacemakers, surgical clips within the head, certain inner ear implants, neuro-electrical 
 stimulators or metal fragments within the eye or head, eGFR <45mL/min/1.73m2 
 
7.3.3 GCA Consortium recruitment details 
Recruitment of the UK cohort of patients will include patients recruited prospectively (at or 
near diagnosis of GCA or PMR) and patients recruited retrospectively from medical records. 
•  Subjects were recruited by the Chief, Principal Investigator or designated Sub-Investigators. 
• Patients were identified from the following sources (i) retrospectively from medical records 





7.3.4 Cardiovascular magnetic resonance protocol 
7.3.4.1 Similarities as compared to RA CMR protocol 
The methodologies and image acquisitions are the same as described in the RA chapters earlier 
in this thesis. The CMR study for the GCA cohort was performed on a dedicated 3T Philips 
Achieva system equipped with a 32-channel coil. Low resolution survey, reference scans and 
localisers determined the cardiac short axis, vertical long axis and horizontal long axis with cine 
imaging (balanced steady state free precession acquisition [bSSFP]). Left ventricle (LV) 
dimensions and function were obtained from cines covering the entire heart in the LV short 
axis[277, 278] (bSSFP, multiphase, contiguous slices, voxel size 1.2x1.2x10mm³, 50 cardiac 
phases). 
 
Arterial stiffness was measured by aortic distensibility (AD). Cines were acquired to measure 
the diameter of the ascending aorta (AsAo) and descending aorta (DsAo) at the level of the 
main pulmonary artery (PA). For aortic area, cine images of the AsAo and DsAo at the level of 
the PA bifurcation were acquired transverse to the vessel[219]. Blood pressure (BP) was 
recorded immediately prior to image acquisition. 
 
Tissue tagging for strain analysis and diastology were generated from the basal, mid and apical 
LV using the ‘3-of-5’ approach[280] (spatial modulation of magnetization (SPAMM) pulse 
sequence, spatial resolution 1.51×1.57×10mm3, tag separation 7 mm, ≥18 phases, typical TR/TE 
5.8/3.5 ms, flip angle 10°). 
 
7.3.4.2 Differences as compared to RA CMR protocol 
Arterial stiffness was also measured by aortic pulse-wave velocity (PWV). Aortic PWV was 
assessed using identical geometry planning to the AD orientations with retrospectively gated, 
through-plane, phase-contrast velocity encoded images (breath-hold, single slice, 10mm thick, 
50 phases, VENC 200cm/s). The addition of VENC imaging was not significant in time given the 
need for sagittal-oblique cine imaging of the thoracic aorta for a thorough dimension 
assessment. Additional arterial stiffness measures were implemented given the focussed 
nature of study of the thoracic aorta. Furthermore, we didn't want to have very low AD in focal 





T1 mapping with gadolinium based contrast agents and adenosine-stress was not performed 
for this study. With the main focus being thoracic aortic assessment, it was not deemed ethical 
for cannulation, further blood sampling and further symptom inducing sequences for 
exploratory objectives. Given the more elderly cohort, fewer numbers and greater distance 
travelled to Leeds, recruitment for the primary outcome was of upmost importance. Therefore, 
a quicker protocol that was less invasive was more ideal. 
 
7.3.5 CMR data analysis 
Image analysis of LV volumes, strain, torsion and AD was performed as per the RA studies 
described earlier in this thesis. The additional data analysis not in the earlier methods was that 
of PWV and thoracic aortic dimensions, described here forth. 
 
The AsAo and DsAo luminal diameters were manually measured from luminal edge-to-edge 
using the sagittal oblique aortic acquisition Figure 7-1. The diameters were indexed to the 
patient's body surface area (BSA) and referenced to extrapolated existing regional aortic size 
CMR nomograms by sex and age[318]. Aortic sizes were determined to be dilated if they were 
greater than 2 standard deviations (SD) above the mean. European guidelines for aortic 
intervention were used to categorise if TAD/TAA were at surgical thresholds[319]. Aortic cross 
sectional measurements were made by manual planimetry of the endovascular-blood pool 
interface, at the times of maximal and minimal distension of the aorta (Figure 7-1). 
 
Aortic PWV was calculated by dividing the distance separating the AsAo and DsAo and the 
transit time needed for the wave to cover this distance (Figure 7-1)[282, 320]_ENREF_19. 
Analysis was performed using in-house software (PMI 0.4) based on IDL 6.4 (ITT Visual 






Figure 7-1 - Aortic image analysis methods by cardiovascular magnetic resonance 
 
 
(A) Sagittal oblique cine image in diastole showing measurement points of the AsAo diameter (A) and proximal 
DsAo (C) at the level of the right PA (B). (B) AsAo (blue) and proximal DsAo (red) cross-sectional area 
measurements made by manual planimetry of the aortic endovascular-blood pool interface at minimal and 
maximal distension. Subsequent phase contrast cines are acquired with this planning. (C) Sagittal oblique cine 
image where the length of the aortic arch is manually measured. (D) Time-Velocity curve of AsAo (blue) and 








7.3.6 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY) 
except for linear regression which was performed in R (version 3.3.3). Continuous variables 
were expressed as mean ± SD. Categorical variables were expressed as N (%). Correlation was 
assessed with Pearson’s correlation coefficient. Each aorta was classified as either non-dilated 
or TAD, as defined above. [318]. Differences between groups were assessed using Student’s t-
test for normally distributed data and the Mann-Whitney or Wilcoxon signed rank test on non-
parametric data for independent groups and pairwise comparisons respectively.  Chi-squared 
and Fisher’s exact tests were used for comparing categorical data. According to convention, for 
the presentation of results a two-sided p<0.05 was considered statistically significant. Since 
aortic size increases with age and differs between sexs[322], adjustment was made for age, sex 
as well as presence of established CVD and CV risk factors. Linear regression was used to 
determine differences between GCA patients and controls when adjusted age, sex, and CVD/CV 
risk factors.  CV risk factors were defined as hypertension (either history of hypertension or 
anti-hypertensive agent), dyslipidaemia (either history of dyslipidaemia or on lipid-lowering 
medication), diabetes, family history of CVD and ever smoked. CVD was defined as an 
established diagnosis of atherosclerotic vascular disease. Potential predictors of ascending 
(AsAo) and descending aortic (DsAo) diameter within the GCA patients (age, sex and prior 
diagnosis of atherosclerotic vascular disease) and features at onset of GCA ischaemic 
manifestations, acute-phase markers and polymyalgic features) were explored by linear 
regression in univariable analysis. These variables are defined in a previous publication[261]. 
Features at onset of GCA that were significant on univariable analysis were then adjusted for 
age, sex and prior diagnosis of atherosclerotic vascular disease) in multivariable linear 








53 GCA patients were invited and 47 completed the CMR protocol for assessment of thoracic 
aortic dimensions. 6 were not scanned due to: claustrophobia (3) and scanner malfunction (3). 
Comparison of characteristics of GCA patients versus controls revealed that the GCA group was 
slightly older and more likely to be ex-smokers (Table 7-1); there was no significant difference 





Table 7-1 - Demographics, cardiovascular risk factors and aortic measurements of Giant Cell Arteritis patients and healthy controls. 
 
GCA 
n = 47 
Controls 
n = 13 
Unadjusted 
P value 
Adjusted for age, sex, CVD and CV risk factors 
Difference of means (95% CI) P Value 
Age, years 73 ± 6 65 ± 5 <0.001 - - 
Female sex; n (%) 33 (70) 8 (62) 0.737 - - 
Body mass index, kg/m2 26.1 ± 3.7 25.6 ± 3.7 0.662 - - 
Cardiovascular risk factors 
Hypertension, n (%) 11 (23) 2 (15) 0.713 - - 
Hyperlipidaemia, n (%) 12 (26) 2 (15) 0.713 - - 
Diabetes mellitus, n (%) 2 (4) 0 (0) 1.000 - - 
Current smoker, n (%) 7 (15) 1 (8) 0.671 - - 
- Ever smoked, n (%) 23 (50) 2 (15) 0.026 - - 
Any established vascular disease, n (%) 2 (4) 0 (0) 1.000 - - 
Aortic measurements 
Ascending aorta, mm 33 ± 6 30 ± 2 0.043 2.913 (-1.716, 7.543) 0.212 
Ascending aorta indexed, mm/m2 19 ± 5 16 ± 2 0.019 1.822 (-1.181, 4.825) 0.228 
Aortic arch, mm 24 ± 3 22 ± 2 0.006 1.578 (-0.274, 3.430) 0.093 
Descending aorta, mm 27 ± 3 21 ± 2 <0.001 5.025 (2.935, 7.114) <0.001 
Descending aorta indexed, mm/m2 15 ± 2 11 ± 1 <0.001 2.914 (1.638, 4.190) <0.001 
Aortic distensibility, 10-3mmHg-1 
1.2 ± 0.9 
n = 46 
3.7 ± 1.4 <0.001 -2.302 (-3.146, -1.458) <0.001 
Aortic Dilatation 
Dilated ascending aorta, n (%) 9 (19) 1 (8) 0.436 - - 
Dilated descending aorta, n (%) 31 (66) 0 (13) <0.001 - - 
Any dilated aorta, n (%) 31 (66) 1 (8) <0.001 - - 
Left ventricular measurements 
End-diastolic volume, ml 
131 ± 26 
n = 45 




Ejection fraction, % 
62 ± 6 
n = 45 
63 ± 5 0.821 -1.044 (-5.707, 3.619) 0.654 
Mass, g 
74 ± 15 
n = 45 
86 ± 22 0.033 -6.887 (-18.174, 4.399) 0.226 
Mass/volume ratio, g/ml 
0.58 ± 0.10 
n = 45 
0.61 ± 0.12 0.400 -0.042 (-0.129, 0.046) 0.347 
Circumferential peak systolic strain 
-0.20 ± 0.04 
n = 40 
-0.23 ± 0.03 
n = 11 
0.024 0.009 (-0.023, 0.042) 0.566 
Torsion, degrees 
16.4 ± 3.6 
n = 40 
13.9 ± 2.7 
n = 11 
0.040 2.583 (-0.251, 5.416) 0.073 
 




7.4.1 Thoracic aortic dimensions compared to controls 
The AsAo, aortic arch and DsAo diameters were all greater in patients with GCA than in 
controls, both in absolute values and when indexed to body surface area (BSA). After adjusting 
for age, sex and CVD, the DsAo diameter was significantly greater in GCA than in controls, both 
in absolute and indexed dimensions, with a mean difference of 5mm (95% CI: 3-7mm). Indexed 
AsAo and DsAo diameters were plotted against established CMR nomograms by age and sex to 
detect TAD. 9/47 of the GCA group had AsAo dilatation and 31/47 had DsAo dilatation (Figure 
7-2). 1/13 of the healthy controls had a minor dilatation of the AsAo. Overall, TAD was 





Figure 7-2 - Indexed thoracic aorta dimensions of GCA patients plotted against CMR reference nomograms 
 
CMR nomograms adapted from Davis et al[318]. Red dashed lines represent 2-SD above mean for females and blue dashed lines represent 2-SD 
above the mean for males. Points above these lines for men (blue) and women (red) were considered to have thoracic aortic dilatation of the 




7.4.2 Thoracic aortic dilatation 
Figure 7-3 gives an example of TAD in the DsAo showing a loss of the normal progressive 
reduction in aortic calibre [323]. Overall, 27/33 (82%) female GCA patients had evidence of 
TAD. Comparing the demographic and GCA disease characteristics between those GCA patients 
with and without TAD, only female sex was more common in the TAD group (Table 7-2). Figure 








All GCA patients 
 
 




n = 16 
Dilated thoracic aorta 
 
n  = 31 
P value 
Age, years 73 ± 6 72 ± 6 74 ± 6 0.257 
Female sex; n (%) 33 (70) 6 (38) 27 (87) 0.001 
Body mass index, kg/m2 26.2 ± 4.2 26.4 ± 2.4 26.0 ± 4.3 0.677 
Disease length, months 65 ± 37 64 ± 29 65 ± 41 0.897 
Number of ACR criteria, median [IQR] 4 [1] 4 [2] 4 [2] 0.480 
Headache, n (%) 44 (94) 13 (81) 31 (100) 0.035 
Temporal artery abnormality, n (%) 33 (70) 13 (81) 20 (65) 0.321 
Abnormal artery biopsy, n (%) 
31 (74) 
n = 42 
13 (93) 
n = 14 
18 (64) 
n = 28 
0.067 
ESR > 50mm/hr, n (%) 
35 (76) 
n = 46 
13 (81) 
n = 16 
22 (73) 
n = 30 
0.549 
C-reactive protein, mg/L 
101 ± 78 
n = 33 
99 ± 43 
n = 13 
106 ± 30 
n = 20 
0.459 
Platelets, 109/L 
417 ± 129 
n = 41 
414 ± 124 
n = 16 
443 ± 147 
n = 25 
0.400 
Plasma viscosity, mPa.s 
 
2.0 ± 0.1 
n = 41 
2.0 ± 0.2 
n = 13 
2.0 ± 0.1 
n = 28 
0.871 
History of PMR, n (%) 23 (50) 9 (56) 14 (47) 0.536 
Symptoms of limb claudication, n (%) 8 (17) 3 (19) 5 (16) 0.821 
Steroid sparing drugs, n (%) 
7 (23) 
n = 30 
4 (33) 
n = 12 
3 (17) 
n = 18 
0.392 
Time taken to reach 7.5mg prednisolone, Weeks 
10 ± 9 
n = 20 
8 ± 2 
n = 6 
11 ± 11 
n = 14 
0.484 
Time taken to reach 5mg prednisolone, Weeks 
18 ± 13 
n = 22 
17 ± 9 
n = 7 
18 ± 15 





Cardiovascular risk factors prior to GCA diagnosis 
Hypertension, n (%) 11 (23) 3 (19) 8 (26) 0.725 
Hyperlipidaemia, n (%) 12 (26) 3 (19) 9 (29) 0.505 
Diabetes mellitus, n (%) 2 (4) 0 (0) 2 (7) 0.545 
Current smoker, n (%) 7 (15) 1 (6) 6 (20) 0.394 
- Ever smoked, n (%) 23 (50) 5 (31) 18 (60) 0.120 
Any established vascular disease, n (%) 2 (4) 0 (0) 2 (7) 0.536 
Cardiovascular magnetic resonance measurements 
Ascending aorta distensibility, 10-3mmHg-1 
0.9 ± 0.7 
n = 46 
0.7 ± 0.3 
 
1.0 ± 0.8 
n = 30  
0.146 
Descending aorta distensibility, 10-3mmHg-1 
1.2 ± 0.9 
n = 46 
1.2 ± 0.8 
 
1.2 ± 0.9 
n = 30 
0.787 
Pulse-Wave Velocity, m/s 
11.7 ± 6.0 
n = 45  
10.1 ± 4 
 
12.6 ± 6.7 
n = 29 
0.177 
LV end-diastolic volume, ml 
131 ± 26 
n = 45 
138 ± 33 
n =15 
128 ± 22 
n = 30 
0.242 
LV ejection fraction, % 
62 ± 6 
n = 45 
63 ± 5 
n = 15 
62 ± 7 
n = 30 
0.447 
LV mass, g 
74 ± 15 
n = 45 
79 ± 20 
n = 15 
72 ± 11 
n = 30 
0.228 
LV mass/volume ratio, g/ml 
0.58 ± 0.10 
n = 45 
0.58 ± 0.11 
n = 15 
0.58 ± 0.10 
n = 30 
0.824 
LV circumferential peak systolic strain 
-0.20 ± 0.04 
n = 40 
-0.22 ± 0.04 
n = 15 
-0.21 ± 0.04 
n = 25 
0.623 
LV torsion, degrees 
16.4 ± 3.6 
n = 40 
15.9 ± 3.9 
n = 15 
16.6 ± 3.6 
n = 24 
0.553 
 
Data expressed as mean ± standard deviation unless otherwise stated. ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; LV, left 






Figure 7-3 - Aortic and cardiac findings in study population 
 
 
A, Dilated ascending aorta in sagittal-oblique cine imaging; B, Dilated ascending aorta in transverse view on black-blood imaging; C, Gothic arch 
shape seen in any aetiology of thoracic aorta dilation; D, Dilated descending aorta without normal tapering off of the aorta; E, Dilated aortic 




7.4.3 Arterial stiffness as assessed by CMR 
AD was measured in GCA patients and controls, and aortic PWV was measured in GCA patients. 
The GCA group had significantly lower AD (1.2 versus 3.7 10-3mmHg-1, p<0.001) indicating 
greater arterial stiffness. Amongst those with GCA, there was no significant difference in either 
AD or PWV between those with and without TAD (Table 7-2). 
 
7.4.4 GCA disease characteristics in thoracic aorta dilatation 
No substantive difference in GCA disease characteristics was noted between those with and 
without TAD when it was categorised as dilated or non-dilated by means of international 
nomograms (Table 7-2). 
 
Univariable analysis of predictors of AsAo and DsAo dimensions (Table 7-3) confirmed that 
aortic diameter was significantly associated with age at the time of the CMR scan, for both 
AsAo and DsAo. Neither age of onset of GCA, nor sex, was significantly associated with aortic 
diameter within the GCA patients. An established diagnosis of atherosclerotic vascular disease 
(cerebrovascular, peripheral vascular disease or CV disease) was significantly associated with 
DsAo but not AsAo dimensions. Regarding disease characteristics of GCA at presentation, 
neither presence of ischaemic manifestations nor laboratory measures of the acute-phase 
response (such as platelet count, CRP or ESR) was associated either with AsAo nor DsAo 
dimensions. However presence of “polymyalgic” symptoms at presentation was significantly 
associated with greater AsAo size. A prior diagnosis of PMR, treated with glucocorticoids, prior 
to GCA diagnosis was not associated with AsAo or DsAo size. 
 
Following adjustment for age, sex and vascular disease in multivariable regression, polymyalgic 
symptoms at the original GCA presentation was still associated with an increased diameter of 
both AsAo and DsAo. For the influence of PMR on the ascending aorta diameter, the regression 
coefficient (95% CI) following adjustment for age, sex and vascular disease was 3.87 (1.28, 
6.45), p=0.004; model adjusted R2: 0.327. For the influence of PMR on the descending aorta 
diameter, the regression coefficient (95% CI) following adjustment for age, sex and vascular 




Table 7-3 - Univariable analysis of ascending and descending aorta dimensions, indexed to body surface area, in patients with giant cell arteritis. 
 Ascending aorta Descending aorta 
Univariable modelling Coefficient (95% CI) p-value Coefficient (95% CI) p-value 
Age at time of CMR scan, per 
year 
0.29 (0.06, 0.51) 0.013 0.143 (0.045, 1.241) 0.005 
Age at GCA diagnosis, per 
year 
0.15 (-0.07, 0.36) 0.180 0.087 (-0.01, 0.18) 0.072 
Male sex -2.50 (-5.47, 0.49) 0.100 -0.36 (-1.74, 1.02) 0.598 
Clinical diagnosis of vascular 
disease prior to GCA 
diagnosis 
0.60 (-6.43, 7.63) 0.864 2.80 (-0.25, 5.85) 0.071 
Ever smoked -1.09 (-3.92, 1.75) 0.444 0.92 (-0.31, 2.14) 0.139 
Presence of hypertension 
diagnosed prior to GCA  
1.17 (-2.14, 4.48) 0.480 0.16 (-1.34, 1.66) 0.831 
Presence of ischaemic 
manifestations of GCA  
-0.34 (-3.37, 2.69) 0.822 0.77 (-0.61, 2.14) 0.267 
CRP prior to glucocorticoid 
treatment of GCA, mg/L 
36.92 (-17.36, 91.21) x10-5 0.176 -9.92 (--34.4, 14.5) x10-5 0.416 
PMR symptoms at GCA 
presentation 
3.26 (0.53, 5.98) 0.020 1.14 (-0.12, 2.40)  0.077 
Previous diagnosis and 
treatment of PMR, before 
GCA onset 
2.25 (0.53, 5.98) 0.196 0.96 (-0.66, 2.57) 0.237 
 




7.4.5 Characteristics of GCA patients with clinically significant ascending 
aorta dilatation or aneurysm 
Current European guidelines state that surgical intervention should be considered for patients 
with ascending TAD/TAA greater than 55mm diameter[319]. There are no specific guidelines for 
TAD/TAA associated with chronic IMID such as GCA. Amongst our 49 GCA patients, five had 
clinically relevant ascending TAD/TAA (Table 7-4). Three had concomitant AR, which has further 
clinical relevance in interventional decision making. All patients continued surveillance imaging. 
Patient 1, who had an AsAo diameter of 56mm with mild LV systolic dysfunction, did not 
undergo aortic intervention due to the concomitant discovery of other life-limiting co-morbidity 





Table 7-4 - Clinical characteristics of the five giant cell arteritis patients with dilated ascending aortas approaching/exceeding international surgical 
intervention thresholds. 
 
 Patient 1 Patient 2 Patient3 Patient 4 Patient 5 
Age and Sex 81F 81F 79F 71M 82F 
Disease length, months 83 108 98 109 84 
Time taken to reach 5mg prednisolone 19 2 n/a 15 44 
Ascending aorta, mm 56 41 51 42 47 
Aortic arch, mm 26 24 20 26 25 
Descending aorta, mm 29 32 25 29 21 
GCA disease characteristics 
ACR Criteria 5 
CRP 52 
Active PMR 
ACR Criteria 4 
ESR 100 
ACR Criteria 5 
Active PMR 
ACR Criteria 3 
CRP 120 
Limb claudication 
ACR Criteria 4 
Active PMR 
Cardiovascular risk and disease None Ex Smoker Hypertensive Smoker 
Hypertensive 
Smoker 









ACR, American College of Rheumatology; CMR, cardiovascular magnetic resonance; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; 





7.4.6 Cardiac structure and function in GCA patients 
Further CMR cardiac measurements showed no substantive difference either in GCA versus 
controls (Table 7-1) or in those with TAD versus those without TAD (Table 7-2). 2/47 (4%) 
patients, without known previous history of IHD, were found to have evidence of prior 
myocardial infarction on CMR. A 78 year old female had evidence of inferior myocardial 
infarction with infero-basal LV aneurysm formation and moderate LV systolic dysfunction with 
LV ejection fraction (EF) of 43% (Figure 7-3). The other patient was a 79 year old female with an 







In this first characterisation of aortic structure and function using CMR in patients with GCA, we 
found TAD to be surprisingly common. 10% of our cohort had clinically relevant ascending 
TAA/TAD requiring referral into cardiology services for assessment. Rather than focal, fusiform 
or saccular aneurysm, the TAD found was characterised by loss of tapering of the descending 
aorta. This may perhaps explain why TAD is not more frequently commented on during routine 
imaging; this could help explain the relatively low absolute frequency of TAA in clinical 
practice[45] compared to studies imaging patients with GCA[40]. 
 
In a CT imaging study [41], Prieto-Gonzalez et al identified active thoracic aortitis in 65% of in 
newly-diagnosed GCA patients, with TAD already present in 15%. Our rate of TAD of 66%, after 
a mean of 65 months of disease, is similar to their initial large-vessel vasculitis (LVV) prevalence. 
Even after one year of therapy, they found persistent aortic wall thickening in 68%. In a follow-
up study of 54 GCA patients with a median disease-length of 5.4 years[36], 22.2% were 
reported to have TAD/TAA. This may have been due to a higher threshold for their definition of 
TAA/TAD (>40mm or with evidence of focal TAA[36]), whereas our definition was indexed to 
BSA and compared to age/sex-matched established CMR nomograms, which is both more 
sensitive and more biologically relevant, given the known correlation of age with aortic 
dimensions in the general population. Aortic diameter increases linearly with age between the 
ages of 30 and 70 and we assumed that this linear increase continued for individuals over 70 
years. Furthermore, in their cohort the initial screening test was a chest radiograph (CXR), and 
only those with abnormal CXR had CT imaging. Even in acute aortic syndrome the sensitivity of 
CXR is only 60%[324]. The proportion of patients categorised as approaching/exceeding 
thresholds for surgical intervention was similar in both studies. 
 
As an additional check of the validity of our results we recruited healthy controls without GCA 
for comparison, which also allowed us to check our CMR measurements against published 
nomograms for ages 30-70 years. We then sought to determine factors associated with TAD in 
the GCA group. Whilst TAD was more common in older patients with GCA, the only GCA disease 
characteristic associated with TAD was polymyalgic symptoms at onset. One could speculate 




of the aorta and its branches, but this finding requires replication before firm conclusions can 
be made. 
 
Much is unknown about the mechanism of TAD in GCA. Aortic dilatation might occur from 
direct inflammation-related damage to elastin; alternatively, dilatation might arise proximal or 
distal to a relatively stiff aortic segment[41]. In the general population, increased aortic 
stiffness caused by age-related loss of aortic elasticity is associated with increased CV risk. In 
diseases such as PMR and GCA, however, additional stiffening may relate to the inflammatory 
disease itself and be improved whilst on glucocorticoid therapy[42]. Diagnostic performance of 
LVV by cross-sectional imaging is well-described and can be performed with CT and CMR using 
wall thickness measurements with or without the of gadolinium-based contrast agents[214]. 
The lack of a gold standard creates problems in calculating sensitivity and specificity. Hybrid 18F-
FDG PET-CT may also be utilised if initial cross-sectional imaging is non-diagnostic[215], 
however, the utility for routine disease monitoring in GCA is not yet realised. Normal wall aortic 
thickness does not rule out active inflammation and, conversely, it may take time for increased 
wall thickness to respond to therapy and regress[216]. There is an emerging role for hybrid PET-
CT/CMR and CMR with gadolinium-based contrast in indeterminate cases of relapse/response. 
Hybrid PET-CMR may aid management of GCA with reduced radiation exposure compared with 
PET-CT[217]. Contrast-enhanced CMR has been shown to be useful when evaluating the 
development of disease activity in primary LVV under biological therapies[325]. Pulse wave 
velocity is a biomarker for arterial stiffness, and can be clinically assessed by applanation 
tonometry. There is good intra- and inter-observer variability of CMR derived PWV compared to 
applanation tonometry and using freely available software tools[231]. We observed a striking 
association of two measures of aortic stiffness (aortic distensibility and pulse wave velocity) 
with GCA compared to healthy controls; this difference persisted following adjustment for age, 
sex, CVD and CV risk factors. However, neither of these measures was associated with presence 
or absence of TAD within the GCA group. We may speculate that aortic stiffness relates to the 
underlying disease process, with damage to the internal elastic lamina and collagen deposition, 
and that over time the haemodynamic effects of this might produce the changes in aortic shape 
that we observed in GCA; a loss of normal tapering of the DsAo, perhaps with later involvement 
of AsAo. As a second possibility, the aortic stiffening might reflect the atherogenic effects of 




occur due to residual confounding (for example, from a history of previous smoking, which was 
more common in GCA than controls) despite statistical adjustment for this. Longitudinal studies 
would be required to further explore these possibilities.  
 
The question remains whether aortic imaging should be routinely carried out in unselected 
patients with GCA; we found that older patients appear more at risk, but older patients also 
have greater surgical risk, which should be considered before looking for TAD. The timing and 
frequency of imaging is also uncertain without further longitudinal studies to determine the 
natural history of these aortic structural changes. We estimate that a focussed CMR protocol 
looking at the thoracic aorta alone in GCA patients would take approximately 15mins of 
scanning time; this CMR protocol offers the opportunity to add further sequences to assess 
aortic valve function and cardiac structure and function which may be relevant to decisions 






CMR offers a safe, sensitive and specific assessment of the heart and aorta in GCA, capable of 
identifying hidden pathology including TAD, AR and previously-unsuspected myocardial 
infarction. Rather than the classical fusiform or saccular aortic aneurysm, we observed a loss of 
tapering of the DsAo. This may explain why few cases of TAA/TAD are discovered incidentally 
on thoracic contrast CT studies conducted for other indications, as it is not something 
specifically looked with indexed measurements taken on routine thoracic imaging. Other than 
age, possibly female sex and polymyalgic symptoms, no clear clinical predictor of TAD within 
the GCA patients was identified. Future longitudinal studies may help to identify the time-







Immune-mediated inflammatory diseases are a group distinguished by specific pathways of 
immune-dysregulation that lead to inflammation, organ damage and dysfunction[1]. 
Cardiovascular disease (CVD) is the second largest cause of mortality in the UK, and an 
accelerated risk of CVD is observed in those with immune-mediated inflammatory diseases. 
Inflammation plays an important role in atherosclerosis. RA is a chronic inflammatory arthritis 
and one of the most common systemic autoimmune diseases affecting approximately 1% of the 
UK population[2]. It has been compared to the risk of other established CV risk factors such as 
type 2 diabetes mellitus [17]. It is accepted that CVD risk in RA is independent of, and 
incremental to, traditional CVD risk factors[18] with the likely predominant pathological process 
being immune dysregulation leading to systemic inflammation[19]. GCA is the commonest 
primary systemic vasculitis affecting older people[4]. In the elderly, GCA is even more common 
than rheumatoid arthritis. Most individuals with GCA also have a systemic inflammatory 
response. Classical descriptions focus on involvement of the superficial cranial arteries, but with 
modern imaging techniques it is increasingly recognised that aortic involvement is common and 
may lead to serious complications, such as aortic aneurysm[2]. Aortic involvement in GCA may 
manifest clinically as a syndrome of systemic inflammation without specific symptoms, or even 
be asymptomatic until aortic dissection or rupture supervenes with life-threatening 
consequences[35]. 
 
Patients with RA have a variety of clinical presentations with overlapping CV pathology that 
need to be recognised by first-line healthcare professionals, cardiology and rheumatology 
teams. The most notable presentation is the earlier and increased incidence of IHD and CCF. 
There is recent formal adoption of RA into the UK CVD risk calculators with QRISK®2 and the 
update of QRISK®3 in 2018. There is support that the use of contemporary medical and 
interventional therapy in cardiac disease is as valuable in patients with RA compared to those 
without but it is with intrigue and anticipation whether we learn that early use of conventional 






CMR provides accurate quantification of subclinical CV change in RA and GCA. The detection of 
subclinical change may have powerful diagnostic and prognostic potential that could integrate 
into clinical practice. 
 
Transthoracic echocardiography remains the cornerstone of first-line cardiac imaging testing for 
a wide range of initial work-up and diagnostic questions. There is utilisation of carotid 
ultrasound in current guidelines for an attempt to assess intermediate risk patients, in a similar 
way that CT coronary calcium score has been used in the general, asymptomatic population. 
However, for symptomatic patients and accurate CV assessment, structural and functional non-
invasive imaging should be utilised. It is recommended that future trials and studies adopt a 
multi-parametric CMR protocol with defined outcomes. This would help assess subclinical 
myocardial and vascular disease, allow lower patient numbers to be recruited given the 
excellent reproducibility and accuracy, and be able to assess multiple CV pathologies in one 
examination and relate them to future hard clinical endpoints and biochemical parameters. 
 
The primary aim of this thesis was to characterise subclinical cardiovascular changes by CMR in 
patients with immune-mediated inflammatory disease, namely RA and GCA. The patient 
populations were refined in attempt to answer specific questions about CV change in their 
disease continuums. Namely: 
 
1. The study of CV structural and functional change by CMR in patients with early RA (ERA) 
that have not begun any disease-modifying therapy, in attempt to see if already present 
at diagnosis or not. 
 
2. The study of CV change, specifically of the thoracic aorta, in GCA patients with 
established disease. To contribute data surrounding prevalence of clinically important 
aortic dilatation and aid relevant screening assessment and monitoring. 
 
Furthermore, with the assessment of CV change in ERA, the thesis has further assessed if 
disease-modifying RA therapy modulates CV changes seen at baseline CMR assessment. In this 




and quantify a wide range of CV changes and the effects of disease modifying therapy. The 
main findings were: 
 
8.1 Chapter 5 summary: assessing subclinical CV change in early RA 
 
I. Arterial stiffness 
A. Lower AD is present in ERA when compared to controls 
B. Increasing age and male sex were strongly associated with AD 
C. A bimodal distribution of AD exists in ERA 
D. Smoking, male sex, raised BMI and hypertension associated with higher AD 
E. Higher CRP was associated with lower AD 
II. Cardiac structure and function 
A. ERA patients had lower LVM and LV mass/volume ratio than controls 
B. Increasing CRP correlated with reducing LV strain 
C. EDSR was different in ERA than controls 
D. LV torsion was associated with smoking, hypertension and male sex 
III. Myocardial tissue composition 
A. Increased ECV is present in ERA compared to controls 
B. A trend correlation of increasing ESR with ECV was seen 
C. Increased LGE in ERA compared to controls but not to significance 
 
8.1.0 Chapter 5 synopsis 
This is the first CMR study of treatment-naive ERA, and one of the largest CMR studies in RA to 
date. We have shown that increased arterial stiffness, a surrogate marker for increased CV 
risk[23], is present at the earliest stages of RA. Choosing the best outcome measure to 
determine CVD risk in RA remains to be determined.  The outcome measure should ideally be a 
true surrogate endpoint[326], predicting future CVD, but few longitudinal trials are available 
and we extract from general population research. In my study, increasing age and male sex 
were strongly associated with increased arterial stiffness. The DAS score remained similar, 
without correlation in a wide range of CV changes, which suggests that the joint symptom 




presence of RA, traditional CV risk factors and serum inflammatory marker levels are. Diffuse 
myocardial change, by measure of ECV and native T1, is present in ERA along with early changes 
in biventricular geometry. This highlights presence of CV abnormalities and infers increased CV 
risk at the earliest stages of the disease process. There are associations with RA activity 
markers; however traditional major risk factors continue to be more powerful. Although 
increased compared to controls, we did not find a significant difference in LGE. We would not 
expect to observe a significant amount of LGE in ERA, given that cellular insult may require 
chronicity prior to scarring, but it is interesting to see a trend. As expected in such early disease, 
and in keeping with these smaller studies in ERA, we did not find any overt reduction in systolic 
performance as assessed by LV and RV EF. Unlike these TTE studies, our CMR data did not find a 
reduction in subclinical systolic function parameters. Within the ERA group, increasing CRP was 
associated with reduced LV systolic strain, similarly to other CMR studies[87] in established RA. 
A non-atherosclerotic process may explain the increased risk of heart failure in those with RA 
unexplained by traditional CV risk factors[127].  Distinguishing between the pathologies may 
also help direct therapy in the management of CVD in RA. 
 
8.2 Chapter 6 summary: effect of RA therapy on subclinical CV change 
 
I.  Arterial stiffness 
A. AD normalised after 1 year therapy with MTX TTT regimen or first line ETN 
B. Higher baseline CRP was associated with more improved AD 
C. Higher baseline ECV was associated with more improved AD 
II. Cardiac structure 
A. First line ETN modulated LV mass/volume ratio whilst MTX TTT regimen did not 
B. Myocardial ECV remained similar in both groups 
III. Cardiac function 
A. No changes in ejection fraction in either treatment group at 1 year 
B. First line ETN affected diastology at 1 year but MTX TTT regimen did not 





8.2.0 Chapter 6 synopsis 
Increased arterial stiffness, present in treatment-naive ERA can be modulated, improved and 
measured after 1 year of disease modifying therapy using a MTX TTT regimen or early biological 
therapy with ETN. Patients with baseline higher CRP appear to improve arterial stiffness the 
most. We have not demonstrated that one treatment regimen over another is more effective at 
reducing arterial stiffness. Synthetic DMARDs and TNFi therapy have some evidence in their 
effect on the risk of CVD and CV events. MTX use has been associated with a 21% lower risk of 
total CVD and 18% lower risk of MI in systematic reviews and meta-analysis[55]. The CV benefit 
of TNFi treatment appeared to be strongest in RA patients over 65 years old  in an 
observational study of 8656 new users of conventional DMARDs versus 11587 on TNFi, with the 
study showing an overall reduced risk of CV events in bDMARDs[69]. A further meta-analysis 
showed that TNFi and MTX were associated with comparable reductions in risk of CV events. 
Although the mechanisms are unclear, the reduction in CV events and incident CVD diagnoses 
may be as a consequence of reduced inflammation rather than the specific actions of 
therapeutic agents. In established RA, disease activity suppressed with any DMARD sub-type 
may reduce CV events and deaths[297, 327]. A recent study of therapy in ERA demonstrated no 
increase in CV mortality in 14,000 patients receiving consistent DMARD treatment between 1 
and 7 years follow-up[328]. The modern approach of prompt management in ERA may be 
improving CV outcomes. In my findings, overall, there weren't overt changes in systolic 
performance by measure of ejection fraction and although rising CRP levels at baseline were 
correlated with worsening peak systolic strain, the values were not significantly different 
compared to controls at baseline, follow up or between treatment groups at one year. Given 
the fact that we are assessing CV changes in ERA and these changes are subtle and sub-clinical, 
it is not surprising we are not seeing overt ventricular dysfunction as studies in asymptomatic, 
established RA without known CVD are only showing sub-clinical CV performance change 
without prevalent overt measures of dysfunction. 
 
8.3 Chapter 7 summary: aortic changes in established GCA 
 
I. TAD is common in GCA 




III. Significant dilatation, nearing surgical thresholds, is prevalent 
IV. TAD was more common in females 
V. PMR symptoms may be a risk factor in TAD 
 
8.3.0 Chapter 7 synopsis 
In this first characterisation of aortic structure and function using CMR in patients with GCA, we 
found TAD to be surprisingly common. 10% of our cohort had clinically relevant ascending 
TAA/TAD requiring referral into cardiology services for assessment. CMR offers a safe, sensitive 
and specific assessment of the heart and aorta in GCA, capable of identifying hidden pathology 
including TAD, AR and previously-unsuspected myocardial infarction. Rather than the classical 
fusiform or saccular aortic aneurysm, we observed a loss of tapering of the DsAo. Other than 
age, possibly female sex and polymyalgic symptoms, no clear clinical predictor of TAD within 
the GCA patients was identified. 
 
8.4 Future work 
A particular point of interest to me is the finding of CV changes in RA present at diagnosis. The 
RA disease continuum is not a discrete event and there may be a  'pre-RA' status phase where 
the pathological process has begun and perhaps even some measurable CV changes. The data 
gathered during these studies have already fed into pilot data and further projects at The 
University of Leeds into this pre-RA population. One method explored, in attempt to gain 
longitudinal data on this, is to collect biomarkers including RF and ACPA in primary care 
patients with joint symptoms that are yet to fulfil RA diagnostic criteria. These patients can be 
invited for CMR study and if they subsequently go on to be diagnosed with RA in the future, 
then a 'pre-RA' cohort can be analysed. These studies may shed light onto alternative processes 
other than direct inflammation or physical reconditioning to the CV changes observed in these 
ERA patients. Multiple CMR outcome measures and testing is observed in this thesis, as well as 
many CMR based IMID studies. The optimal outcome measure to assess for CVD risk in IMID 
remains to be determined. The data from these studies will continue to contribute to  
longitudinal studies at the University of Leeds, such as the IACON registry and will help 
determine which outcome measure (or combination of measures) is most predictive of CVD in 




With its association with reduced LV mass, leptin may have a role to play in ‘RA-cachexia’ 
distinct from physical deconditioning. A limitation of this work is that leptin was not studied 
and there were no objective measurements of physical activity, limitation or fitness. This is 
something that may be explored in future studies of pre-RA, ERA and established RA to further 
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